Urine tests for Down's syndrome screening (Review)

Alldred SK, Guo B, Takwoingi Y, Pennant M, Wisniewski S, Deeks JJ, Neilson JP, Alfirevic Z

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2015, Issue 12

http://www.thecochranelibrary.com

WILEY

TABLE OF CONTENTS

[Diagnostic Test Accuracy Review]

Urine tests for Down's syndrome screening

S Kate Alldred[1], Boliang Guo[2], Yemisi Takwoingi[3], Mary Pennant[4], Susanna Wisniewski[5], Jonathan J Deeks[3], James P Neilson[1], Zarko Alfirevic[1]

[1]Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK. [2]School of Medicine, University of Nottingham, Nottingham, UK. [3]Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, UK. [4]Public Health Directorate, Cambridgeshire County Council, Cambridge, UK. [5]Cochrane Dementia and Cognitive Improvement Group, Oxford University, Oxford, UK

Contact address: S Kate Alldred, Department of Women's and Children's Health, The University of Liverpool, First Floor, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK. katealldred@gmail.com.

Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New, published in Issue 12, 2015.
Review content assessed as up-to-date: 17 December 2013.

Citation: Alldred SK, Guo B, Takwoingi Y, Pennant M, Wisniewski S, Deeks JJ, Neilson JP, Alfirevic Z. Urine tests for Down's syndrome screening. *Cochrane Database of Systematic Reviews* 2015, Issue 12. Art. No.: CD011984. DOI: 10.1002/14651858.CD011984.

ABSTRACT

Background

Down's syndrome occurs when a person has three copies of chromosome 21, or the specific area of chromosome 21 implicated in causing Down's syndrome, rather than two. It is the commonest congenital cause of mental disability and also leads to numerous metabolic and structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals have only mild problems and can lead relatively normal lives. Having a baby with Down's syndrome is likely to have a significant impact on family life. The risk of a Down's syndrome affected pregnancy increases with advancing maternal age.

Noninvasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing. Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test. This includes subsequent choices for further tests they may face, and the implications of both false positive and false negative screening tests (i.e. invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal). The decisions that may be faced by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can be associated with considerable physical and psychological morbidity. No screening test can predict the severity of problems a person with Down's syndrome will have.

Objectives

To estimate and compare the accuracy of first and second trimester urine markers for the detection of Down's syndrome.

Search methods

We carried out a sensitive and comprehensive literature search of MEDLINE (1980 to 25 August 2011), EMBASE (1980 to 25 August 2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), The Database of Abstracts of Reviews of Effectiveness (*The Cochrane Library* 2011, Issue 7), MEDION (25 August 2011), The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine (25 August 2011), The National Research Register (archived 2007), Health Services Research Projects in Progress database (25 August 2011). We studied reference lists and published review articles.

Selection criteria

Studies evaluating tests of maternal urine in women up to 24 weeks of gestation for Down's syndrome, compared with a reference standard, either chromosomal verification or macroscopic postnatal inspection.

Data collection and analysis

We extracted data as test positive or test negative results for Down's and non-Down's pregnancies allowing estimation of detection rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS (Quality Assessment of Diagnostic Accuracy Studies) criteria. We used hierarchical summary ROC (receiver operating characteristic) meta-analytical methods to analyse test performance and compare test accuracy. We performed analysis of studies allowing direct comparison between tests. We investigated the impact of maternal age on test performance in subgroup analyses.

Main results

We included 19 studies involving 18,013 pregnancies (including 527 with Down's syndrome). Studies were generally of high quality, although differential verification was common with invasive testing of only high-risk pregnancies. Twenty-four test combinations were evaluated formed from combinations of the following seven different markers with and without maternal age: AFP (alpha-fetoprotein), ITA (invasive trophoblast antigen), ß-core fragment, free ßhCG (beta human chorionic gonadotrophin), total hCG, oestriol, gonadotropin peptide and various marker ratios. The strategies evaluated included three double tests and seven single tests in combination with maternal age, and one triple test, two double tests and 11 single tests without maternal age. Twelve of the 19 studies only evaluated the performance of a single test strategy while the remaining seven evaluated at least two test strategies. Two marker combinations were evaluated in more than four studies; second trimester ß-core fragment (six studies), and second trimester ß-core fragment with maternal age (five studies).

In direct test comparisons, for a 5% false positive rate (FPR), the diagnostic accuracy of the double marker second trimester ß-core fragment and oestriol with maternal age test combination was significantly better (ratio of diagnostic odds ratio (RDOR): 2.2 (95% confidence interval (CI) 1.1 to 4.5), P = 0.02) (summary sensitivity of 73% (CI 57 to 85) at a cut-point of 5% FPR) than that of the single marker test strategy of second trimester ß-core fragment and maternal age (summary sensitivity of 56% (CI 45 to 66) at a cut-point of 5% FPR), but was not significantly better (RDOR: 1.5 (0.8 to 2.8), P = 0.21) than that of the second trimester ß-core fragment to oestriol ratio and maternal age test strategy (summary sensitivity of 71% (CI 51 to 86) at a cut-point of 5% FPR).

Authors' conclusions

Tests involving second trimester ß-core fragment and oestriol with maternal age are significantly more sensitive than the single marker second trimester ß-core fragment and maternal age, however, there were few studies. There is a paucity of evidence available to support the use of urine testing for Down's syndrome screening in clinical practice where alternatives are available.

PLAIN LANGUAGE SUMMARY

Screening tests for Down's syndrome in first 24 weeks of pregnancy

Background

Down's syndrome (also known as Down's or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental health problems, and disabilities. However, there is wide variation in how Down's affects people. Some individuals are severely affected whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be affected.

Expectant parents are given the choice to be tested for Down's during pregnancy to assist them in making decisions. If a mother is carrying a baby with Down's, then there is the decision about whether to terminate or continue with the pregnancy. The information offers parents the opportunity to plan for life with a Down's child.

The most accurate tests for Down's involve testing fluid from around the baby (amniocentesis) or tissue from the placenta (chorionic villus sampling (CVS)) for the abnormal chromosomes associated with Down's. Both these tests involve inserting needles through the mother's abdomen and are known to increase the risk of miscarriage. Thus, the tests are not suitable for offering to all pregnant women. Rather, tests that measure markers in the mother's blood, urine or on ultrasound scans of the baby are used for screening. These screening tests are not perfect, they can miss cases of Down's and also give a 'high risk' test results to a number of women whose

babies are not affected by Down's. Thus, pregnancies identified as 'high risk' using these screening tests require further testing using amniocentesis or CVS to confirm a diagnosis of Down's.

What we did

The aim of this review was to find out which of the urine screening tests done during the first 24 weeks of pregnancy are the most accurate at predicting the risk of a pregnancy being affected by Down's. We looked at seven different urine markers that can be used alone, in ratios or in combination, taken before 24 weeks' gestation, thus creating 24 screening tests for Down's. We found 19 studies, involving 18,013 pregnancies of which 527 had pregnancies affected by Down's.

What we found

For the first 24 weeks of pregnancy, the evidence does not support the use of urine tests for Down's syndrome screening. The amount of evidence is limited. These tests are not offered in routine clinical practice.

Other important information to consider

The urine tests themselves have no adverse effects for the woman. However, some women who have a 'high risk' screening test result, and are given amniocentesis or CVS have a risk of miscarrying a baby unaffected by Down's. Parents will need to weigh up this risk when deciding whether or not to have an amniocentesis or CVS following a 'high risk' screening test result.

BACKGROUND

This is one of a series of reviews on antenatal screening for Down's syndrome following a generic protocol (Alldred 2010) - see Published notes for more details.

Target condition being diagnosed

Down's syndrome

Down's syndrome affects approximately one in 800 live-born babies (Cuckle 1987a). It results from a person having three, rather than two, copies of chromosome 21-or the specific area of chromosome 21 implicated in causing Down's syndrome, as a result of trisomy or translocation. If not all cells are affected, the pattern is described as 'mosaic'. Down's syndrome can cause a wide range of physical and mental problems. It is the commonest cause of mental disability, and is also associated with a number of congenital malformations, notably affecting the heart. There is also an increased risk of cancers such as leukaemia, and numerous metabolic problems including diabetes and thyroid disease. Some of these problems may be life-threatening, or lead to considerable ill health, while some individuals with Down's syndrome have only mild problems and can lead a relatively normal life.

There is no cure for Down's syndrome, and antenatal diagnosis allows for preparation for the birth and subsequent care of a baby with Down's syndrome, or for the offer of a termination of pregnancy. Having a baby with Down's syndrome is likely to have a significant impact on family and social life, relationships and parents' work. Special provisions may need to be made for education and care of the child, as well as accommodating the possibility of periods of hospitalisation.

Definitive invasive tests (amniocentesis and chorionic villus sampling (CVS)) exist that allow the diagnosis of Down's syndrome before birth, but carry a risk of miscarriage. No test can predict the severity of problems a person with Down's syndrome will have.

Noninvasive screening tests based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allow an estimate of the risk of a pregnancy being affected and provide parents with information to enable them to make choices about definitive testing. Such screening tests are used during the first and second trimester of pregnancy.

Screening tests for Down's syndrome

Initially, screening was determined solely by using maternal age to classify a pregnancy as high or low risk for trisomy 21, as it was known that older women had a higher chance of carrying a baby with Down's syndrome (Penrose 1933).

Further advances in screening were made in the early 1980s, when Merkatz et al investigated the possibility that low maternal serum alpha-fetoprotein (AFP), obtained from maternal blood in the second trimester of pregnancy could be associated with chromosomal abnormalities in the fetus. Their retrospective case-control

study showed a statistically significant relationship between fetal trisomy, such as Down's syndrome, and lowered maternal serum AFP (Merkatz 1984). This was further explored by Cuckle et al in a larger retrospective trial using data collected as part of a neural tube defect (NTD) screening project (Cuckle 1984). This work was followed by calculation of risk estimates using maternal serum AFP values and maternal age, which ultimately led to the introduction of the two screening parameters in combination (Alfirevic 2004).

In 1987, in a small case-control study of women carrying fetuses with known chromosomal abnormalities, Bogart and colleagues investigated maternal serum levels of human chorionic gonadotrophin (hCG) as a possible screening tool for chromosomal abnormalities in the second trimester (Bogart 1987). This followed the observations that low hCG levels were associated with miscarriages, which are commonly associated with fetal chromosomal abnormalities. They concluded that high hCG levels were associated with Down's syndrome and because hCG levels plateau at 18 to 24 weeks, that this would be the most appropriate time for screening. Later work suggested that the ß sub-unit of hCG was a more effective marker than total hCG (Macri 1990; Macri 1993).

Second trimester unconjugated oestriol (uE3), produced by the fetal adrenals and the placenta, was also evaluated as a potential screening marker. In another retrospective case-control study, uE3 was shown to be lower in Down's syndrome pregnancies compared with unaffected pregnancies. When used in combination with AFP and maternal age, it appeared to identify more pregnancies affected by Down's syndrome than AFP and age alone (Canick 1988). Further work suggested that all three serum markers (AFP, hCG and uE3) showed even higher detection rates when combined with maternal age (Wald 1988a; Wald 1988b) and appeared to be a cost-effective screening strategy (Wald 1992a).

Two other serum markers, produced by the placenta, have been linked with Down's syndrome, namely pregnancy-associated plasma protein A or PAPP-A, and Inhibin A. PAPP-A has been shown to be reduced in the first trimester of Down's syndrome pregnancies, with its most marked reduction in the early first trimester (Bersinger 1995). Inhibin A is high in the second trimester in pregnancies affected by Down's syndrome (Cuckle 1995a; Wallace 1995). There are some issues concerning the biological stability and hence reliability of this marker, and the effect this will have on individual risk.

In addition to serum and ultrasound markers for Down's syndrome, work has been carried out looking at urinary markers. These markers include invasive trophoblast antigen, ß-core fragment, free ßhCG and total hCG (Cole 1999a). There is controversy about their value (Wald 2003a).

Screening and parental choice

Antenatal screening is used for several reasons (Alfirevic 2004), but the most important is to enable parental choice regarding pregnancy management and outcome. Before a woman and her partner opt to have a screening test, they need to be fully informed about the risks, benefits and possible consequences of such a test. This includes the choices they may have to face should the result show that the woman has a high risk of carrying a baby with Down's syndrome and the implications of both false positive and false negative screening tests. They need to be informed of the risk of a miscarriage due to invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal. If, following invasive diagnostic testing, the fetus is shown to have Down's syndrome, further decisions need to be made about continuation or termination of the pregnancy, the possibility of adoption and finally, preparation for parenthood. Equally, if a woman has a test that shows she is at a low risk of carrying a fetus with Down's syndrome, it does not necessarily mean that the baby will be born with a normal chromosomal make up. This possibility can only be excluded by an invasive diagnostic test (Alfirevic 2003).The decisions that may be faced by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can be associated with considerable physical and psychological morbidity. No screening test can predict the severity of problems a person with Down's syndrome will have.

Index test(s)

This review examined urine screening tests used in the first and second trimester of pregnancy (up to 24 weeks' gestation) comprised of the following individual markers; AFP; invasive trophoblast antigen (ITA) (also known as hyperglycosylated hCG); ß-core fragment; free ßhCG; total hCG; uE3 (oestriol); gonadotropin peptide; and various marker ratios. These markers can be used individually, in combination with age, and can also be used in combination with each other. The risks are calculated by comparing a woman's test result for each marker with values for an unaffected population, and multiplying this with her age-related risk. Where several markers are combined, risks are computed using risk equations (often implemented in commercial software) that take into account the correlational relationships between the different markers and marker distributions in affected and unaffected populations.

Alternative test(s)

Down's syndrome can be detected during pregnancy with invasive diagnostic tests such as amniocentesis or CVS, with or without prior screening. These tests are considered to be reference tests rather than index or screening tests. The ability to determine fetal chromosomal make up (also known as a karyotype) from amniotic fluid samples was demonstrated in 1966 by Steele and Breg (Steele

1966), and the first antenatal diagnosis of Down's syndrome was made in 1968 (Vaklenti 1968). Amniocentesis is an invasive procedure that involves taking a small sample of the amniotic fluid (liquor) surrounding the baby, using a needle which goes through the abdominal wall into the uterus, and is usually performed after 15 weeks' gestation. Chorionic villus sampling involves taking a sample of the placental tissue using a needle which goes through the abdominal wall and uterus or a cannula through the cervix. It is usually performed between 10 and 13 weeks' gestation. Amniocentesis and CVS are both methods of obtaining fetal chromosome material, which are then used to diagnose Down's syndrome. Both tests use ultrasound scans to guide placement of the needle. Amniocentesis carries a risk of miscarriage in the order of 1%; transabdominal CVS may carry a similar risk (Alfirevic 2003). Recent developments in the use of cell-free fetal DNA detection in maternal serum are paving the way for noninvasive diagnosis of Down's syndrome and other trisomies, however these tests were not used as reference standards in any of the studies examined.

Many different screening tests are available and offered to pregnant women, and these tests are the subject of additional Cochrane reviews published (Alldred 2012) or currently in preparation, and other published reviews. Tests being assessed in other Cochrane reviews include first trimester serum tests; second trimester serum tests; first trimester ultrasound markers; tests that combine serum and ultrasound markers; and tests that combine markers from the first trimester with markers from the second trimester. Second trimester ultrasound markers have been assessed in a previous systematic review (Smith-Bindman 2001).

Rationale

This is one of a suite of Cochrane reviews, the aim of which is to identify all screening tests for Down's syndrome used in clinical practice, or evaluated in the research setting, in order to try to identify the most accurate test(s) available, and to provide clinicians, policy-makers and women with robust and balanced evidence on which to base decisions about interpreting test results and implementing screening policies to triage the use of invasive diagnostic testing. The full set of reviews is described in the generic protocol (Alldred 2010).

The topic has been split into several different reviews to allow for greater ease of reading and greater accessibility of data, and also to allow the reader to focus on separate groups of tests, for example, first trimester serum tests alone, first trimester ultrasound alone, first trimester serum and ultrasound, second trimester serum alone, first and second trimester serum, combinations of serum and ultrasound markers and urine markers alone. An overview review will compare the best tests, focusing on commonly used strategies from each of these groups to give comparative results between the best tests in the different categories. This review is written with a global perspective in mind, rather than to conform with any specific local or national policy, as not all tests will be available in all areas where screening for Down's syndrome is carried out.

A systematic review of second trimester ultrasound markers in the detection of Down's syndrome fetuses was published in 2001 that concluded that nuchal fold thickening may be useful in detecting Down's syndrome, but that it was not sensitive enough to use as a screening test. The review concluded that the other second trimester ultrasound markers did not usefully distinguish between Down's syndrome and pregnancies without Down's syndrome (Smith-Bindman 2001). There has yet to be a systematic review and meta-analysis of the observed data on serum, urine and first trimester ultrasound markers, in order to draw rigorous and robust conclusions about the diagnostic accuracy of available Down's syndrome screening tests.

OBJECTIVES

The aim of this review was to estimate and compare the accuracy of first and second trimester urine markers for the detection of Down's syndrome in the antenatal period, both as individual markers and as combinations of markers. Accuracy is described by the proportion of fetuses with Down's syndrome detected by screening before birth (sensitivity or detection rate), and the proportion of women with a low risk (normal) screening test result who subsequently had a baby unaffected by Down's syndrome (specificity). We grouped our analyses to focus on investigating the value of adding increasing numbers of markers (comparing single, dual, triple and quadruple tests).

Investigation of sources of heterogeneity

We planned to investigate whether a uniform screening test is suitable for all women, or whether different screening methods are more applicable to different groups, defined by advanced maternal age, ethnic groups and aspects of the pregnancy and medical history such as multiple pregnancy, diabetes and family history of Down's syndrome. We also considered whether there existed evidence of overestimation of test accuracy in studies evaluating risk equations in the derivation sample rather than in a separate validation sample.

METHODS

Criteria for considering studies for this review

Types of studies

We included studies in which all women from a given population had one or more index test(s) compared to a reference standard. Both consecutive series and diagnostic case-control study designs were included. Randomised trials where individuals were randomised to different screening strategies and all verified using a reference standard were also eligible for inclusion. Studies in which test strategies were compared head-to-head, either in the same women, or between randomised groups were identified for inclusion in separate comparisons of test strategies. Studies were excluded if they included less than five Down's syndrome cases, or more than 20% of participants were not followed up.

Participants

Pregnant women at less than 24 weeks' gestation confirmed by ultrasound, who had not undergone previous testing for Down's syndrome in their pregnancy were eligible. Studies were included if the pregnant women were unselected, or if they represented groups with increased risk of Down's syndrome, or difficulty with conventional screening tests including maternal age greater than 35 years old, multiple pregnancy, diabetes mellitus and family history of Down's syndrome.

Index tests

The following index tests were examined; AFP; ITA; ß-core fragment; free ßhCG; total hCG; oestriol (also termed as uE3); gonadotropin peptide and various marker ratios and combinations of these markers combined with maternal age. Combinations without maternal age were not included in the test comparisons (Table 1; Table 2), however, information on such test combinations is provided.

We looked at comparisons of tests in isolation and in various combinations. These included single (one marker), double (two markers), triple (three markers), test strategies, all maternal age-adjusted.

Where tests were used in comparison, we looked at the performance of test comparisons according to predicted probabilities computed using risk equations and dichotomised into high risk and low risk.

Target conditions

Down's syndrome in the fetus due to trisomy, translocation or mosaicism.

Reference standards

We considered several reference standards, involving chromosomal verification and postnatal macroscopic inspection.

Amniocentesis and CVS are invasive chromosomal verification tests undertaken during pregnancy. They are highly accurate, but the process carries a 1% miscarriage rate, and therefore they are only used in pregnancies considered to be at high risk of Down's syndrome, or on the mother's request. All other types of testing (postnatal examination, postnatal karyotyping, birth registers and Down's syndrome registers) are based on information available at the end of pregnancy. The greatest concern is not their accuracy, but the loss of the pregnancy to miscarriage between the urine test and the reference standard. Miscarriage with cytogenetic testing of the fetus is included in the reference standard where available. We anticipated that older studies, and studies undertaken in older women were more likely to have used invasive chromosomal verification tests in all women.

Studies undertaken in younger women and more recent studies were likely to use differential verification as they often only used prenatal karyotypic testing on fetuses considered screen positive/high risk according to the screening test; the reference standard for most unaffected infants being observing a phenotypically normal baby. Although the accuracy of this combined reference standard is considered high, it is methodologically a weaker approach as pregnancies that miscarry between the index test and birth are likely to be lost from the analysis, and miscarriage is more likely to occur in Down's than normal pregnancies. We investigated the impact of the likely missing false negative results in sensitivity analyses.

Search methods for identification of studies

Electronic searches

We applied a sensitive search strategy to search the following databases. We used one broad generic search strategy to identify studies for all reviews in this series.

Databases searched included;

- MEDLINE via OVID (1980 to 25 August 2011)
- EMBASE via Dialog Datastar (1980 to 25 August 2011)
- BIOSIS via EDINA (1985 to 25 August 2011)
- CINAHL via OVID (1982 to 25 August 2011)
- The Database of Abstracts of Reviews of Effectiveness (*The Cochrane Library* 2011, Issue 7)
- MEDION (25 August 2011)
- The Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine (www.ifcc.org/) (25 August 2011)
- The National Research Register (archived 2007)
- Health Services Research Projects in Progress database (HSRPROJ) (25 August 2011)

The search strategy combined three sets of search terms (*see* Appendix 1). The first set was made up of named tests, general terms used for screening/diagnostic tests and statistical terms. Note that the statistical terms were used to increase sensitivity and were not used as a methodological filter to increase specificity. The second set was made up of terms that encompass Down syndrome

and the third set made up of terms to limit the testing to pregnant women. All terms within each set were combined with the Boolean operator OR and then the three sets were combined using AND. The terms used were a combination of subject headings and free text terms. The search strategy was adapted to suit each database searched.

We attempted to identify cumulative papers that reported data from the same data set, and we contacted authors to obtain clarification of the overlap between data presented in these papers, in order to prevent data from the same women being analysed more than once.

Searching other resources

In addition, we examined references cited in studies identified as being potentially relevant, and those cited by previous reviews. We contacted authors of studies where further information was required. We did not apply a diagnostic test filter, and we did not apply language restrictions to the search.

We carried out forward citation searching of relevant items, using the search strategy in ISI citation indices, Google scholar and Pubmed 'related articles'.

Data collection and analysis

Selection of studies

Two review authors screened the titles and abstracts (where available) of all studies identified by the search strategy. We obtained full-text versions of studies identified as being potentially relevant and two review authors independently assessed these for inclusion, using a study eligibility screening pro forma according to the prespecified inclusion criteria. Any disagreement between the two review authors was settled by consensus, or where necessary, by a third party.

Data extraction and management

We developed a data extraction form and piloted the form using a subset of 20 identified studies (from all identified studies in this suite of reviews). Two review authors independently extracted data, and where disagreement or uncertainty existed, a third review author validated the information extracted.

Data on each marker were extracted as binary test positive/test negative results for Down's and non-Down's pregnancies, with a high risk-result, as defined by each individual study, being regarded as test positive (suggestive or diagnostic of Down's syndrome), and a low-risk result being regarded as test negative (suggestive of absence of Down's syndrome). Where results were reported at several thresholds, we extracted data at each threshold.

We noted those in special groups that posed either increased risk of Down's syndrome or difficulty with conventional screening tests, including maternal age greater than 35 years old, multiple pregnancy, diabetes mellitus and family history of Down's syndrome.

Assessment of methodological quality

We used a modified version of the QUADAS tool (Whiting 2003), a quality assessment tool for use in systematic reviews of diagnostic accuracy studies, to assess the methodological quality of included studies. We anticipated that a key methodological issue would be the potential for bias arising from the differential use of invasive testing and follow-up for the reference standard according to index test results, bias arising due to higher loss to miscarriage in false negatives than true negatives. We chose to code this issue as originating from differential verification in the QUADAS tool: we are aware that it could also be coded under delay in obtaining the reference standard, and reporting of withdrawals. We omitted the QUADAS item assessing quality according to length of time between index and reference tests, as Down's syndrome is either present or absent rather than a condition that evolves and resolves, and disregarding the differential reference standard issue thus any length of delay is acceptable. Two review authors assessed each included study separately. Any disagreement between the two authors was settled by consensus, or where necessary, by a third party. Each item in the QUADAS tool was marked as 'yes', 'no' or 'unclear', and scores were summarised graphically. We did not use a summary quality score.

QUADAS criteria included the following 10 questions.

1. Was the spectrum of women representative of the women who will receive the test in practice? (Criteria met if the sample was selected from a wide range of childbearing ages, or selected from a specified 'high-risk' group such as over 35s, family history of Down's syndrome, multiple pregnancy or diabetes mellitus, provided all affected and unaffected fetuses included that could be tested at the time point when the screening test would be applied; criteria not met if the sample taken from a select or unrepresentative group of women (i.e. private practice), was an atypical screening population or recruited at a later time point when selection could be affected by selective fetal loss).
2. Is the reference standard likely to correctly classify the target condition? (Amniocentesis, CVS, postnatal karyotyping, miscarriage with cytogenetic testing of the fetus, a phenotypically normal baby or birth registers are all regarded as meeting this criteria).
3. Did the whole sample or a random selection of the sample receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless of the index test result?
5. Was the reference standard independent of the index test result (i.e. the index test did not form part of the reference standard)?

6. Were the index test results interpreted without knowledge of the results of the reference standard?
7. Were the reference standard results interpreted without knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight, ethnic origin, gestational age) available when test results were interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?

Statistical analysis and data synthesis

We initially examined each test or test strategy at each of the common risk thresholds used to define test positivity by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver operating characteristic (ROC) space. Test strategies were selected for further investigation if they were evaluated in four or more studies or, if there were three or fewer studies, but the individual study results indicated performance likely to be superior to a sensitivity of 70% and specificity of 90%.

Estimation of average sensitivity and specificity

The analysis for each test strategy was undertaken first restricting to studies that reported a common threshold to estimate average sensitivity and specificity for each test at each threshold. Although data on all thresholds were extracted, we present only key common thresholds close to risks of 1:384, 1:250 and the 5% false positive rate (FPR), unless other thresholds were more commonly reported. Where combinations of tests were used in a risk score, we extracted the result for the test combination using the risk score and not the individual components that made up the test.

We undertook meta-analyses using hierarchical summary ROC (HSROC) models, which included estimation of random effects in accuracy and threshold parameters when there were four or more studies. Otherwise, average sensitivity and specificity values were computed by using univariate random-effects logistic regression models to average logit sensitivity and logit specificity separately because of insufficient number of studies to reliably estimate all the parameters in the HSROC model. It is common in this field for studies to report sensitivity for a fixed specificity (usually a 5% FPR). This removes the requirement to account for the correlation between sensitivity and specificity across studies by using a bivariate meta-analytical method since all specificities are the same value. Thus, at a fixed specificity value, logit sensitivities were pooled using a univariate random-effects model. This model was further simplified to a fixed-effect model when there were only two or three studies and heterogeneity was not observed on the SROC plot. All analyses were undertaken using the NLMIXED procedure in SAS (version 9.2; SAS Institute, Cary, NC) and the xtmelogit command in Stata version 11.2 (Stata-Corp, College Station, TX, USA).

Comparisons between tests

We made comparisons between tests, first by utilising all available studies, selecting one threshold from each study to estimate a SROC curve without restricting to a common threshold. The threshold was chosen for each study according to the following order of preference: a) the risk threshold closest to one in 250; b) a multiples of the median (MoM) or presence/absence threshold; c) the performance closest to a 5% FPR or 95th percentile. The 5% FPR was chosen as a cut-off point as this is the cut-off most commonly reported in the literature. The analysis that used all available studies was performed by including the most evaluated or best performing test strategies in a single HSROC model. The model included two indicator terms for each test to allow for differences in accuracy and threshold. As there were very few studies for each test, a symmetric summary ROC curve was assumed. In addition, because the model failed to converge, we assumed fixed-effect for the threshold and accuracy parameters. An estimate of the sensitivity of each test for a 5% FPR was derived from the SROC curve, and we obtained associated confidence intervals using the delta method.

Direct comparisons between tests were based on results of very few studies, and were analysed using a simplified HSROC model with fixed-effect and symmetrical underlying SROC curves because the number of studies was insufficient to estimate between study heterogeneity in accuracy and threshold or asymmetry in the shape of the SROC curves. We used a separate model to make each pairwise comparison. We assessed comparisons between tests by using likelihood ratio tests to test if the differences in accuracy were statistically significant or not. We expressed the differences as ratios of diagnostic odds ratios and reported with 95% confidence intervals. As studies rarely report data cross-classified by both tests for Down's and normal pregnancies, the analytical method did not take full account of the pairing of test results, but the restriction to direct head-to-head comparisons should have removed the potential confounding of test comparisons with other features of the studies. The strength of evidence for differences in performance of test strategies relied on evidence from both the direct and indirect comparisons.

Investigations of heterogeneity

Had there been 10 or more studies available for a test, we planned to investigate heterogeneity by adding covariate terms to the HSROC model to assess the effect of a covariate on accuracy and threshold.

Sensitivity analyses

In many of the included studies, mothers with pregnancies identified as high risk for Down's syndrome by the urine testing were offered immediate definitive testing by amniocentesis, whereas the remainder were assessed for Down's syndrome by inspection at

birth. Such delayed and differential verification will introduce bias most likely through there being greater loss to miscarriage in the Down's syndrome pregnancies that were not detected by the urine testing (the false negative diagnoses). Testing and detection of miscarriages is impractical in many situations, and no clear data are available on the magnitude of these miscarriage rates.

To account for the possible bias introduced by such a mechanism, we planned to perform sensitivity analyses by increasing the percentage of false negatives in studies where delayed verification in test negatives occurred (Mol 1999). We planned to incrementally increase the percentage from 10% to 50%, the final value representing a scenario where a third of more Down's pregnancies than normal pregnancies were likely to miscarry, thought to be higher than the likely value. We intended to conduct the sensitivity analyses on the analysis investigating the effect of maternal age on test sensitivity.

RESULTS

Results of the search

The search for the whole suite of reviews identified a total of 15,394 papers, once the results from each bibliographic database were combined and duplicates were removed. After screening out obviously inappropriate papers based on their title and abstract, 1145 papers remained and we obtained full-text copies for formal assessment of eligibility. From these, a total of 269 papers were deemed eligible and were included in the suite of reviews. We included a total of 19 studies (reported in 29 publications) in this review of urine tests, involving 18,013 pregnancies, of which 527 were Down's syndrome pregnancies.

A total of 24 different test strategies or combinations, at one or more thresholds, were evaluated in the 19 studies. These tests were produced from combinations of seven different urine tests (and their ratios) with and without maternal age: AFP; ITA; ß-core fragment; free ßhCG; total hCG; oestriol; gonadotropin peptide and various marker ratios. Strategies evaluated included three double tests and seven single tests in combination with maternal age, and one triple test, two double tests and 11 single tests without maternal age. Twelve of the 19 studies only evaluated the performance of a single test strategy while the remaining seven evaluated at least two test strategies.

The following combinations evaluated included four or more studies.

1. Second trimester ß-core fragment (six studies; 9615 women with 193 affected Down's pregnancies)
2. Second trimester ß-core fragment and maternal age (five studies; 3419 women with 155 Down's pregnancies)

Methodological quality of included studies

We judged the studies to be of high methodological quality in most categories (Figure 1). Due to the nature of testing for Down's syndrome screening and the potential side effects of invasive testing, differential verification is almost universal in the general screening population, as most women whose screening test result is defined as low risk will have their screening test verified at birth, rather than by invasive diagnosis in the antenatal period. Additionally, it was not always possible to ascertain from the included studies whether or not the results of index tests and reference standards were blinded. It would be difficult to blind clinicians performing invasive diagnostic tests (reference standards) to the index test result, unless all women received the same reference standard, which would not be appropriate in most scenarios. Any biases secondary to a lack of clinician blinding are likely to be minimal.

Figure 1. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.



Most studies seemed to indicate 100% follow-up, however there will inevitably be losses to follow-up due to women moving out of area, for example. Studies sometimes accounted for these and it is unlikely that there were enough losses to follow-up to have introduced significant bias. There was likely under-ascertainment of miscarriage, and very few papers accounted for miscarriage, or performed tissue karyotyping in pregnancies resulting in miscarriage. Some studies attempted to adjust for predicted miscarriage rate and the incidence of Down's syndrome in this specific population, but most did not. We have not attempted to adjust for expected miscarriage rate in this review. There is a higher natural miscarriage rate in the first trimester, however this will be uniform across studies and therefore unlikely to introduce significant bias. Some studies that provided estimates of risk using multivariable equations used the same data set to evaluate performance of the risk equation as was used to derive the equation. This is often thought to lead to over-estimation of test performance.

Findings

1) Second trimester ß-core fragment

Results for this single test were derived from six studies (Cole 1999b; Cuckle 1995b; Cuckle 1999a; Isozaki 1997; Spencer 1996; Wald 2003), and included 9615 women in whom 193 pregnancies were known to be affected by Down's syndrome. Two studies (Cole 1999b; Cuckle 1999a) contributed over 7000 pregnancies to the data. Six studies (Cole 1999b; Cuckle 1995b; Cuckle 1999a; Isozaki 1997; Spencer 1996; Wald 2003) presented data for a cut-point of 5% FPR and the estimated sensitivity was 41% (95% confidence interval (CI) 20 to 66).

2) Second trimester ß-core fragment and maternal age

Results for this single test were derived from five studies (Bahado-Singh 1999; Bahado-Singh 1999a; Cole 1999b; Hsu 1999; Spencer 1996), and included 3419 women in whom 155 pregnancies were known to be affected by Down's syndrome. Cole 1999b contributed over 1000 pregnancies to the data. The studies presented data at a cut-point of 5% FPR and the summary sensitivity was 56% (95% CI 45 to 66).

3) Other test combinations

Of the 22 test combinations evaluated in three or fewer studies, nine test combinations demonstrated estimated sensitivities of more than 70% and estimated specificities of more than 90%. Six of these were evaluated in single studies (see Summary of findings), and the following three test combinations were evaluated in two or more studies.

1. **Second trimester ß-core fragment to oestriol ratio** evaluated in two studies (Cole 1997b; Cole 1999b), with a summary sensitivity of 74% (95% CI 58 to 86) at a cut-point of 5% FPR.
2. **Second trimester ß-core fragment to oestriol ratio and maternal age** evaluated in three studies (Bahado-Singh 1999; Cole 1999b; Hsu 1999), with a summary sensitivity of 71% (95% CI 51 to 86) at a cut-point of 5% FPR.
3. **Second trimester ß-core fragment, oestriol and maternal age** evaluated in two studies (Cole 1999b; Hsu 1999), with a summary sensitivity of 73% (95% CI 57 to 85) at a cut-point of 5% FPR.

Comparative analyses of the five selected test strategies

For each test we obtained the detection rate (sensitivity) for a fixed FPR (1-specificity), a metric which is commonly used in Down's syndrome screening to describe test performance. We chose to estimate detection rates at a 5% FPR in common with much of the literature. Figure 2 shows point estimates of the detection rate (and their 95% CIs) at a 5% FPR based on all available data for the five test strategies; the test strategies are ordered according to decreasing detection rates. The plot shows that all five test strategies have detection rates between 56% and 90%. The combination of second trimester AFP and ß-core fragment to oestriol ratio with maternal age showed the highest detection rate with an estimated detection rate of 90% (CI 55 to 100), based on data from one study with 10 affected cases out of a total of 356 pregnancies. The worst performing strategy was the combination of ß-core fragment to oestriol ratio and maternal age, with an estimated detection rate of 56% (CI 45 to 66), based on data from five studies with 155 affected cases out of a total of 3419 pregnancies.

Figure 2. Detection rates (% sensitivity) at a 5% false positive rate for the five most evaluated or best performing test strategies. The estimates are shown with 95% confidence intervals. The test strategies are ordered on the plot according to decreasing detection rate. The number of studies, cases and women included for each test strategy are shown on the horizontal axis.



Table 1 shows pair-wise direct comparisons (head-to-head) where studies were available. Such comparisons are regarded as providing the strongest evidence as they are unconfounded. The table shows the ratio of diagnostic odds ratio (RDOR) with 95% CI and P values for each test combination, the number of studies (*K*) for which data were available. The table shows that the diagnostic accuracy of the double marker combination of second trimester ß-core fragment and oestriol with maternal age was significantly better (RDOR 2.2 (95% CI 1.1 to 4.5); P = 0.02) than the single marker second trimester ß-core fragment and maternal age test strategy but was not significantly better (RDOR 1.5 (95% CI 0.8 to 2.8); P = 0.21) than that of the second trimester ß-core fragment to oestriol ratio and maternal age test strategy. However, the comparisons in this table were based on two or three studies and are unlikely to be powered to detect differences in detection rates.

Table 2 shows the same comparisons made using all available data (as used to create Figure 2). Results are in agreement with the direct comparisons, and in addition, showed no significant differences between any of the other pair of tests for which direct comparisons were not available. However, these comparisons are potentially confounded by differences between the studies, and the evidence is limited.

Investigation of heterogeneity and sensitivity analyses

None of the tests was evaluated by 10 or more studies and so we were unable to investigate the effect of maternal age or any other potential source of heterogeneity. The planned sensitivity analyses, looking at differential verification and any resultant bias, were also not possible.

Summary of findings

Review Question	What is the accuracy of urine based markers for screening for Down's syndrome?
Population	Pregnant women at less than 24 weeks' gestation confirmed by ultrasound, who had not undergone previous testing for Down's syndrome. Most studies were undertaken in women identified to be high risk based on maternal age
Settings	All settings
Numbers of studies, pregnancies and Down's syndrome cases	19 studies (reported in 29 publications) involving 18,013 pregnancies of which 527 were Down's syndrome pregnancies
Index tests	Risk scores computed using maternal age and first and second trimester urine markers for AFP; ITA; ß-core fragment; free ßhCG; total hCG; oestriol (also termed as uE3); gonadotropin peptide
Reference standards	Chromosomal verification (amniocentesis and CVS undertaken during pregnancy, and postnatal karyotyping) and postnatal macroscopic inspection
Study limitations	Seven studies only used selective chromosomal verification during pregnancy, and were at risk of under-ascertainment of Down's syndrome cases due loss of the pregnancy to miscarriage between the serum test and the reference standard

Test	Studies	Women (Cases)	Sensitivity* (95% CI)	Specificity* (95% CI)	Threshold
Test without maternal age					
Single tests					
First trimester free ßhCG	1	516 (86)	5 (1 to 11)	95 (92 to 97)	5% FPR
First trimester ß-core fragment	1	516 (86)	10 (5 to 19)	95 (92 to 97)	5% FPR
First trimester ITA	2	579 (94)	15 (2 to 62)	95	5% FPR
First trimester total hCG	1	516 (86)	17 (10 to 27)	95 (92 to 97)	5% FPR

Second trimester oestriol	2	1472 (47)	23 (8 to 49)	95	5% FPR
Second trimester total hCG	1	390 (65)	31 (20 to 43)	95 (92 to 97)	5% FPR
Second trimester free ß hCG	3	1517 (107)	32 (12 to 63)	95	5% FPR
Second trimester ß-core fragment	6	9613 (193)	41 (20 to 66)	95	5% FPR
Second trimester ITA	3	2748 (131)	43 (35 to 51)	95	5% FPR
Second trimester ß-core fragment to oestriol ratio	2	1649 (35)	74 (58 to 86)	95	5% FPR
Second trimester gonadotropin test	1	105 (14)	93 (66 to 100)	95 (88 to 98)	1:384 risk
Double tests					
Second trimester AFP and ITA	1	524 (24)	79 (58 to 93)	95 (93 to 97)	5% FPR
Second trimester ß-core fragment and oestriol	1	315 (24)	83 (63 to 95)	95 (92 to 97)	5% FPR
Triple tests					
Second trimester AFP, uE3 and ITA	1	524 (24)	79 (58 to 93)	95 (93 to 97)	5% FPR
Test with maternal age					
Single tests					
Second trimester oestriol	1	474 (69)	49 (37 to 62)	95 (92 to 97)	5% FPR
Second trimester ß-core fragment	5	3419 (155)	56 (45 to 66)	95	5% FPR

Second trimester free ß hCG	2	879 (98)	57 (47 to 67)	95	5% FPR
Second trimester free ß hCG to oestriol ratio	1	474 (69)	64 (51 to 75)	95 (92 to 97)	5% FPR
Second trimester ß-core fragment to free ß hCG	1	474 (69)	67 (54 to 78)	95 (92 to 97)	5% FPR
Second trimester ITA	1	1016 (23)	70 (47 to 87)	95 (93 to 96)	5% FPR
Second trimester ß-core fragment to oestriol ratio	3	2088 (105)	71 (51 to 86)	95	5% FPR
Double tests					
Second trimester oestriol and free ß hCG	1	474 (69)	68 (56 to 79)	95 (92 to 97)	5% FPR
Second trimester ß-core fragment and oestriol	2	1631 (92)	73 (57 to 85)	95	5% FPR
Second trimester AFP and ß-core fragment to oestriol ratio	1	356 (10)	90 (55 to 100)	95 (93 to 97)	1:58 risk

*Tests evaluated by at least one study are presented in the table. Where two studies reported the same threshold, estimates of summary sensitivity and summary specificity were obtained by using univariate fixed effects logistic regression models to pool sensitivities and specificities separately. if the threshold used was a 5% FPR, then only the sensitivities were pooled.

AFP: alpha-fetoprotein; **ß hCG:** beta human chorionic gonadotrophin;**CI:** confidence interval; **CVS:** chorionic villus sampling; **FPR:** false positive rate; **hCG:** beta human chorionic gonadotrophin;**ITA:** invasive trophoblast antigen; **uE3:** unconjugated oestriol

DISCUSSION

Summary of main results

The systematic review found 19 studies evaluating urinary markers for Down's syndrome screening. Very few studies provided unconfounded comparisons of test strategies by applying and comparing several strategies using the same urine sample; the majority of studies only evaluating a single test combination. A summary of results for the 24 strategies is given in Summary of findings. The following key findings were noted.

1. There is evidence from direct comparison to support the use of multiple marker urine tests in combination with age for screening - the double marker combination of second trimester ß-core fragment and oestriol with maternal age test strategy was significantly better (ratio of diagnostic odds ratio (RDOR) 2.2 (95% CI 1.1 to 4.5); P = 0.02) than the single marker second trimester ß-core fragment and maternal age. This is reflected in the indirect comparison of the two tests.

2. There was little evidence that urine markers are of value in screening for Down's syndrome. Marker combinations evaluated by more than three studies showed low detection rates for a 5% false positive rate (FPR). More promising markers were investigated in fewer than three studies.

3. In indirect comparisons, with the exception of the difference in accuracy between the single marker second trimester ß-core fragment and maternal age test and the double marker combination of second trimester ß-core fragment and oestriol with maternal age, there was no significant difference in the detection rates between tests, however, the number of included studies was small.

Strengths and weaknesses of the review

This is the first comprehensive systematic review of urine tests for Down's syndrome screening. We examined papers from around the world, covering a wide cross-section of women in varying populations. We contacted authors to verify data where necessary to give as complete a picture as possible while trying to avoid replication of data.

There were a number of factors that have made meta-analysis of the data difficult, which we have tried to adapt for in order to allow for comparability of data presented in different studies.

1. There were many different cut-points used to define pregnancies as high or low risk for Down's syndrome. This means that direct comparison is more difficult than if all studies used the same cut-point to dichotomise their populations.

2. There were many different risk equations and software applications in use for combination of multiple markers, which were often not described in the papers. This means that risks may be calculated by different formulae, and they may not be directly comparable for this reason.

3. Different laboratories and clinics run different assays and use different machines and methods. This may influence raw results and subsequent risk calculations. Many laboratories have a quality assessment/audit trail, however, this may not necessarily be standard across the board, for example, how many assays are run, how often medians are calculated and adjusted for a given population and how quickly samples are tested from initially being taken.

4. Very few studies make direct comparisons between tests, making it difficult to detect if there is a real difference between tests (i.e. how different tests perform in the same population). There are differences in populations, with assay medians being affected, for example, by race. It is not certain whether it is appropriate to make comparisons between populations which are inherently different.

5. We were unable to perform any of the subgroup analyses that we had originally intended to, as the data simply were not available. The vast majority of papers looking at pregnancies conceived by in vitro fertilisation (IVF), affected by diabetes, multiple gestation or a family history of Down's syndrome involved unaffected pregnancies only.

Applicability of findings to the review question

When planning a screening policy or a clinical screening programme, clinicians and policy makers need to make decisions about a finite number of tests or type of tests that can be offered. These policies are often driven by both the needs of a specific population and by financial resources. Economic analysis was considered to be outside the scope of this review. Many of the tests examined as part of this review are already commercially available and in use in the clinical setting. The studies were carried out on populations of typical pregnant women and therefore, the results should be considered comparable with most pregnant populations encountered in every day clinical practice.

We were unable to extract information about the harms of testing, information about miscarriage rates and uptake of definitive testing as the data were not often available. While it is unlikely that major differences between the tests evaluated here exist in terms of direct harms of testing, as they are all based on a single urine sample, differences in accuracy may lead to differences in the use of definitive testing and its consequent adverse outcomes.

AUTHORS' CONCLUSIONS

Implications for practice

Urine testing for Down's syndrome is not commonly used, with serum and ultrasound testing being widely clinically available.

We would not recommend the introduction of urine testing for Down's syndrome screening on the basis of the review findings, or that urine testing should replace serum or ultrasound testing where it is available. There is a paucity of evidence available to support the use of urine testing in clinical practice where alternatives are available.

For the purposes of meta-analysis and to allow for comparisons to be made between different tests and combinations, we recommend the publication of consensus standard algorithms for estimating risk, and reporting of test performance at a standard set of thresholds. This would be difficult to achieve and implement, but an attempt at consensus should be made.

Implications for research

Further evaluation of urine tests is required before definitive recommendations can be made about their use in clinical practice. Future studies should ensure that adequate sample sizes are recruited, and make comparisons of several alternative test combinations on the same urine samples. Such direct comparisons minimise confounding and allow a clear focus on testing the incremental benefit of increasingly complex and expensive testing strategies. The reporting of test accuracy studies can be improved by adhering to the STARD reporting guideline Bossuyt 2003. Three key aspects are: 1) formally testing the statistical significance of differences in test performance in direct comparisons and estimating incremental changes in detection rates (together with confidence intervals), 2) clearly reporting the number of mothers studied and their results, and 3) reporting the numbers of women who are lost to follow-up.

ACKNOWLEDGEMENTS

We acknowledge the assistance of the Pregnancy and Childirth Cochrane Review Group Editorial base with writing the searches and other aspects of this review.

As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team) and a member of the Pregnancy and Childbirth Group's international panel of consumers.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

REFERENCES

References to studies included in this review

Bahado-Singh 1998 *{published data only}*
Bahado-Singh RO, Oz UA, Deren O, Acuna E, Cermik D, Mahoney MJ, et al. A new screening protocol combining urine beta-core fragment and ultrasonography for Down syndrome detection. *American Journal of Obstetrics and Gynecology* 1998;**178**(4):779–82.

Bahado-Singh 1998b *{published data only}*
Bahado-Singh RO, Oz U, Kovanci E, Cermik D, Flores D, Copel J, et al. New triple screen test for Down syndrome: combined urine analytes and serum AFP. *Journal of Maternal-Fetal Medicine* 1998;**7**(3):111–4.

Bahado-Singh 1999 *{published data only}*
Bahado-Singh R, Oz U, Kovanci E, Cermik D, Copel J, Mahoney MJ, et al. A high-sensitivity alternative to "routine" genetic amniocentesis: multiple urinary analytes, nuchal thickness, and age. *American Journal of Obstetrics and Gynecology* 1999;**180**(1 pt 1):169–73.

Bahado-Singh 1999a *{published data only}*
Bahado Singh, Oz U, Rinne K, Hunter D, Cole L, Mahoney MJ, et al. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of Down syndrome. *American Journal of Obstetrics and Gynecology* 1999;**181**(4):929–33.

Bahado-Singh 2000 *{published data only}*
* Bahado-Singh R, Oz U, Shahabi S, Omrani A, Mahoney M, Cole L. Urine hyperglycosylated hCG plus ultrasound biometry for detection of down syndrome in the second trimester in a high-risk population. *Obstetrics & Gynecology* 2000;**95**(6 pt 1):889–94.
Cole LA, Omrani A, Cermik D, Singh RO, Mahoney MJ. Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening. *Prenatal Diagnosis* 1998;**18**(9): 926–33.
Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: a new basis for gestational Down syndrome screening. *Clinical Chemistry* 1999;**45**(12):2109–19.
Cole LA, Shahabi S, Oz UA, Rinne KM, Omrani A, Bahado-Singh RO, et al. Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG. *Prenatal Diagnosis* 1999;**19**(4):351–9.

Bahado-Singh 2000a *{published data only}*
Bahado-Singh, Oz U, Shahabi S, Mahoney MJ, Baumgarten A, Cole L. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum

triple screen for Down syndrome detection in high-risk pregnancies. *American Journal of Obstetrics and Gynecology* 2000;**183**(5):1114–8.

Canick 1995 ***{published data only}***
Canick JA, Kellner LH, Saller DN Jr, Palomaki GE, Walker RP, Osathanondh R. Second-trimester levels of maternal urinary gonadotropin peptide in down syndrome pregnancy. *Prenatal Diagnosis* 1995;**15**(8):739–44.

Cole 1997a ***{published data only}***
Cole LA, Jacobs M, Isozaki T, Palomaki GE, Bahado-Singh RO, Mahoney MJ. Screening for Down syndrome using urine hCG free beta-subunit in the second trimester of pregnancy. *Prenatal Diagnosis* 1997;**17**(12):1107–11.

Cole 1997b ***{published data only}***
Cole LA, Acuna E, Isozaki T, Palomaki GE, Bahado-Singh RO, Mahoney MO. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies. *Prenatal Diagnosis* 1997;**17**(12):1125–33.

Cole 1999b ***{published data only}***
Cole LA, Rinne KM, Mahajan SM, Oz UA, Shahabi S, Mahoney MJ, et al. Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment.[see comment]. *Prenatal Diagnosis* 1999;**19**(4):340–50.

Cuckle 1995b ***{published data only}***
Cuckle HS, Iles RK, Chard T. Urinary beta-core human chorionic gonadotrophin: a new approach to Down's syndrome screening. *Prenatal Diagnosis* 1994;**14**(10): 953–8.
* Cuckle HS, Iles RK, Sehmi IK, Chard T, Oakey RE, Davies S, et al. Urinary multiple marker screening for Down's syndrome.[see comment]. *Prenatal Diagnosis* 1995; **15**(8):745–51.

Cuckle 1999 ***{published data only}***
Cuckle HS, Shahabi S, Sehmi IK, Jones R, Cole LA. Maternal urine hyperglycosylated hCG in pregnancies with Down syndrome. *Prenatal Diagnosis.* 1999;**19**(10):918–20.

Cuckle 1999a ***{published data only}***
Cuckle HS, Canick JA, Kellner LH. Collaborative study of maternal urine beta -core human chorionic gonadotrophin screening for Down syndrome. *Prenatal Diagnosis* 1999;**19** (10):911–7.

Hsu 1999 ***{published data only}***
Hsu JJ, Hsu TY, Hsieh TT, Soong YK, Hsieh FJ, Spencer K. Urine free beta-hCG and total estriol for Down syndrome screening during the second trimester in an Asian population. *Obstetrics & Gynecology* 1999;**94**(1):107–11.
Hsu JJ, Hung TH, Liou JD, Hsieh TT, Soong YK. Elevated second-trimester maternal urine free beta-human chorionic gonadotropin levels in Asian pregnancies with fetal chromosomal abnormalities. *Fetal Diagnosis and Therapy* 1998;**13**(6):352–6.
* Hsu JJ, Spencer K, Aitken DA, Crossley J, Choi T, Ozaki M, et al. Urinary free beta hCG, beta core fragment and total oestriol as markers of Down syndrome in the second trimester of pregnancy. *Prenatal Diagnosis* 1999;**19**:146–58.
Hsu JJ, Spencer K, Hung TH, Hsieh TT, Soong YK. Second-trimester maternal urine human chorionic gonadotrophin beta-core fragment concentrations in Asian pregnancies with fetal chromosomal abnormalities. *Human Reproduction* 1999;**14**(9):2381–5.

Isozaki 1997 ***{published data only}***
Isozaki T, Palomaki GE, Bahado-Singh RO, Cole LA. Screening for Down syndrome pregnancy using beta-core fragment: prospective study. *Prenatal Diagnosis* 1997;**17**(5): 407–13.

Palomaki 2004a ***{published data only}***
Palomaki GE, Knight GJ, Roberson MM, Cunningham GC, Lee JE, Strom CM, et al. Invasive trophoblast antigen (hyperglycosylated human chorionic gonadotropin) in second-trimester maternal urine as a marker for down syndrome: preliminary results of an observational study on fresh samples. *Clinical Chemistry* 2004;**50**(1):182–9.

Spencer 1996 ***{published data only}***
Spencer K, Aitken DA, Macri JN, Buchanan PD. Urine free beta hCG and beta core in pregnancies affected by Down's syndrome. *Prenatal Diagnosis* 1996;**16**(7):605–13.

Wald 2003 ***{published data only}***
Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. *Seminars in Perinatology* 2005;**29**(4):225–35.
Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective.[see comment]. *BJOG: an international journal of obstetrics and gynaecology* 2004;**111**(6):521–31.
Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). *Journal of Medical Screening* 2003;**10**(2):56–104.
* Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). *Health Technology Assessment (Winchester, England)* 2003;**7**(11):1–77.

Weinans 2000 ***{published data only}***
Weinans MJ, Butler SA, Mantingh A, Cole LA. Urinary hyperglycosylated hCG in first trimester screening for chromosomal abnormalities. *Prenatal Diagnosis* 2000;**20** (12):976–8.

References to studies excluded from this review

Abbas 1995 ***{published data only}***
Abbas A, Chard T, Nicolaides K. Fetal and maternal hCG concentration in aneuploid pregnancies. *British Journal of Obstetrics and Gynaecology* 1995;**102**(7):561–3.

Abdul-Hamid 2004 ***{published data only}***
Abdul-Hamid S, Fox R, Martin I. Maternal serum screening for trisomy 21 in women with a false positive result in last pregnancy. *Journal of Obstetrics & Gynaecology* 2004;**24**(4): 374–6.

Abraha 1999 *{published data only}*
Abraha HD, Noble PL, Nicolaides KH, Sherwood RA. Maternal serum S100 protein in normal and Down syndrome pregnancies. *Prenatal Diagnosis* 1999;**19**(4): 334–6.

Adekunle 1999 *{published data only}*
Adekunle O, Gopee A, el-Sayed M, Thilaganathan B. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. *British Journal of Radiology* 1999;**72**(857):457–60.

Aitken 1993 *{published data only}*
Aitken DA, McCaw G, Crossley JA, Berry E, Connor JM, Spencer K, et al. First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. *Prenatal Diagnosis* 1993;**13**(8):681–9.

Aitken 1996a *{published data only}*
Aitken DA, Syvertsen BS, Crossley JA, Berry E, Connor JM. Heat-stable and immunoreactive placental alkaline phosphatase in maternal serum from Down's syndrome and trisomy 18 pregnancies.[see comment]. *Prenatal Diagnosis* 1996;**16**(11):1051–4.

Aitken 1996b *{published data only}*
Aitken DA, Wallace EM, Crossley JA, Swanston IA, Van Pareren Y, Van Maarle M, et al. Dimeric Inhibin A as a marker for Down's syndrome in early pregnancy. *New England Journal of Medicine* 1996;**334**(19):1231–6.

Akbas 2001 *{published data only}*
Akbas SH, Ozben T, Alper O, Ugur A, Yucel G, Luleci G. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18. *Clinical Chemistry & Laboratory Medicine* 2001;**39**(6):487–90.

Antona 1998 *{published data only}*
Antona D, Wallace EM, Shearing C, Ashby JP, Groome NP. Inhibin A and pro-alphaC Inhibin A in Down syndrome and normal pregnancies. *Prenatal Diagnosis* 1998;**18**(11): 1122–6.

Antsaklis 1999 *{published data only}*
Antsaklis A, Papantoniou N, Mesogitis S, Michalas S, Aravantinos D. Pregnant women of 35 years of age or more: maternal serum markers or amniocentesis?. *Journal of Obstetrics and Gynaecology* 1999;**19**(3):253–6.

Ashwood 1987 *{published data only}*
Ashwood ER, Cheng E, Luthy DA. Maternal serum alpha-fetoprotein and fetal trisomy-21 in women 35 years and older: implications for alpha-fetoprotein screening programs. *American Journal of Medical Genetics* 1987;**26**(3): 531–9.

Asrani 2005 *{published data only}*
Asrani CH. Triple marker. *National Journal of Homoeopathy* 2005;**7**(3):174.

Audibert 2001b *{published data only}*
Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(1): 26–31.

Axt-Fleidner 2006 *{published data only}*
Axt-Fliedner R, Schwarze A, Kreiselmaier P, Krapp M, Smrcek J, Diedrich K. Umbilical cord diameter at 11-14 weeks of gestation: relationship to nuchal translucency, ductus venous blood flow and chromosomal defects. *Fetal Diagnosis and Therapy* 2006;**21**(4):390–5.

Azuma 2002 *{published data only}*
Azuma M, Yamamoto R, Wakui Y, Minobe S, Satomura S, Fujimoto S. A novel method for the detection of Down syndrome with the use of four serum markers. *American Journal of Obstetrics and Gynecology* 2002;**187**(1):197–201.

Baghagho 2004 *{published data only}*
Baghagho EE, Kharboush IF, El-Kaffash DM, KarKour TA, Ismail SR, Mortada MM. Maternal serum alpha fetoprotein among pregnant females in Alexandria. *Journal of the Egyptian Public Health Association* 2004;**79**(1-2):59–81.

Bahado-Singh 1995 *{published data only}*
Bahado Singh, Goldstein I, Uerpairojkit B, Copel JA, Mahoney MJ, Baumgarten A. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results. *American Journal of Obstetrics and Gynecology* 1995;**173**(4):1106–0.

Bahado-Singh 1996 *{published data only}*
Bahado-Singh RO, Tan A, Deren O, Hunter D, Copel J, Mahoney MJ. Risk of Down syndrome and any clinically significant chromosome defect in pregnancies with abnormal triple-screen and normal targeted ultrasonography results. *American Journal of Obstetrics and Gynecology* 1996; **175**(4 Pt 1):824–9.

Bahado-Singh 1999b *{published data only}*
Bahado-Singh RO, Oz AU, Flores D, Cermik D, Acuna E, Mahoney MJ, et al. Nuchal thickness, urine ß-core fragment level, and maternal age for down syndrome screening. *American Journal of Obstetrics and Gynecology* 1999;**180**(2 Pt 1):491–5.

Bahado-Singh 2002 *{published data only}*
Bahado-Singh RO, Shahabi S, Karaca M, Mahoney MJ, Cole L, Oz UA. The comprehensive midtrimester test: high-sensitivity Down syndrome test. *American Journal of Obstetrics and Gynecology* 2002;**186**(4):803–8.

Bahado-Singh 2003 *{published data only}*
Bahado-Singh RO, Cheng CC, Matta P, Small M, Mahoney MJ. Combined serum and ultrasound screening for detection of fetal aneuploidy. *Seminars in Perinatology* 2003; **27**(2):145–51.

Bar-Hava 2001 *{published data only}*
Bar-Hava I, Yitzhak M, Krissi H, Shohat M, Shalev J, Czitron B, et al. Triple-test screening in in vitro fertilization pregnancies. *Journal of Assisted Reproduction and Genetics* 2001;**18**(4):226–9.

Barkai 1996 *{published data only}*
Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H. Down's syndrome screening marker levels following assisted reproduction. *Prenatal Diagnosis* 1996;**16**(12):1111–4.

Barnabei 1995 *{published data only}*
Barnabei VM, Krantz DA, Macri JN, Larsen JW Jr. Enhanced twin pregnancy detection within an open neural tube defect and Down syndrome screening protocol using free-ß hCG and AFP. *Prenatal Diagnosis* 1995;**15**(12): 1131–4.

Bartels 1988 *{published data only}*
Bartels I, Lindemann A. Maternal levels of pregnancy-specific ß 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. *Human Genetics* 1988;**80**(1): 46–8.

Bartels 1993 *{published data only}*
Bartels I, Hoppe-Sievert B, Bockel B, Herold S, Caesar J. Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol to maternal weight and smoking. *Prenatal Diagnosis* 1993; **13**(2):123–30.

Barth 1991 *{published data only}*
Barth WH Jr, Frigoletto FD Jr, Krauss CM, MacMillin MD, Stryker JM, Benacerraf BR. Ultrasound detection of fetal aneuploidy in women with elevated maternal serum alpha-fetoprotein. *Obstetrics & Gynecology* 1991;**77**(6): 897–900.

Baviera 2004 *{published data only}*
Baviera G, Carbone C, Corrado F, Mastrantonio P. Placental growth hormone in Down's syndrome screening. *Journal of Maternal-Fetal & Neonatal Medicine* 2004;**16**(4):241–3.

Bazzett 1998 *{published data only}*
Bazzett LB, Yaron Y, O'Brien JE, Critchfield G, Kramer RL, Ayoub M, et al. Fetal gender impact on multiple-marker screening results. *American Journal of Medical Genetics* 1998;**76**(5):369–71.

Bellver 2005 *{published data only}*
Bellver J, Lara C, Soares SR, Ramirez A, Pellicer A, Remohi J, et al. First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction. *Human Reproduction* 2005;**20**(9):2623–7.

Benn 1995 *{published data only}*
Benn PA, Horne D, Briganti S, Greenstein RM. Prenatal diagnosis of diverse chromosome abnormalities in a population of women identified by triple-marker testing as screen positive for Down syndrome. *American Journal of Obstetrics and Gynecology* 1995;**173**(2):496–501.

Benn 1996 *{published data only}*
Benn PA, Horne D, Craffey A, Collins R, Ramsdell L, Greenstein R. Maternal serum screening for birth defects: results of a Connecticut regional program. *Connecticut Medicine* 1996;**60**(6):323–7.

Benn 1997 *{published data only}*
Benn PA, Clive JM, Collins R. Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. *Clinical Chemistry* 1997;**43** (2):333–7.

Benn 1998 *{published data only}*
Benn PA. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies. *Prenatal Diagnosis* 1998;**18** (4):319–24.

Benn 2001 *{published data only}*
Benn PA, Ying J, Beazoglou T, Egan JF. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. *Prenatal Diagnosis* 2001;**21**(1):46–51.

Benn 2002 *{published data only}*
Benn PA, Kaminsky LM, Ying J, Borgida AF, Egan JF. Combined second-trimester biochemical and ultrasound screening for Down syndrome. *Obstetrics & Gynecology* 2002;**100**(6):1168–76.

Benn 2003a *{published data only}*
Benn PA, Fang M, Egan JFX, Horne D, Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. *Obstetrics and Gynecology* 2003;**101** (3):451–4.

Benn 2003b *{published data only}*
Benn P. Improved antenatal screening for Down's syndrome. *Lancet* 2003;**361**(9360):794–5.

Benn 2005a *{published data only}*
Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. *Prenatal Diagnosis* 2005;**25**(8):645–52.

Benn 2005b *{published data only}*
Benn P, Donnenfeld AE. Sequential Down syndrome screening: the importance of first and second trimester test correlations when calculating risk. *Journal of Genetic Counseling* 2005;**14**(6):409–13.

Berry 1995 *{published data only}*
Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Analysis of maternal serum alpha-fetoprotein and free ß human chorionic gonadotrophin in the first trimester: implications for Down's syndrome screening. *Prenatal Diagnosis* 1995;**15**(6):555–65.

Berry 1997 *{published data only}*
Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. *British Journal of Obstetrics and Gynaecology* 1997;**104**(7): 811–7.

Bersinger 1994 *{published data only}*
Bersinger NA, Brizot ML, Johnson A, Snijders RJ, Abbott J, Schneider H, et al. First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific ß 1-glycoprotein in fetal trisomies. *British Journal of Obstetrics and Gynaecology* 1994;**101**(11):970–4.

Bersinger 2000 *{published data only}*
Bersinger NA, Xin WZ. Glycosylation of pregnancy-associated plasma protein a (PAPP-A) and pregnancy-specific (ß)(1)-glycoprotein (SP1): relevance for fetal down syndrome screening and for placental function studies. *Immuno-Analyse et Biologie Specialisee* 2000;**15**(6):402–8.

Bersinger 2001 *{published data only}*
Bersinger NA, Chanson A, Crazzolara S, Hänggi W, Pescia G, Scheier M, et al. Serum levels of placenta protein markers: the relevance of differences between spontaneous and after in vitro fertilization pregnancies for fetal trisomy screening. *Journal fur Fertilitat und Reproduktion* 2001;**11** (3):7–13.

Bersinger 2003 *{published data only}*
Bersinger NA, Noble P, Nicolaides KH. First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies. *Prenatal Diagnosis* 2003;**23** (2):157–62.

Bersinger 2004 *{published data only}*
Bersinger NA, Wunder D, Vanderlick F, Chanson A, Pescia G, Janecek P, et al. Maternal serum levels of placental proteins after in vitro fertilisation and their implications for prenatal screening. *Prenatal Diagnosis* 2004;**24**(6):471–7.

Bersinger 2005 *{published data only}*
Bersinger NA, Vanderlick F, Birkhäuser MH, Janecek P, Wunder D. First trimester serum concentrations of placental proteins in singleton and multiple IVF pregnancies: implications for Down syndrome screening. *Immuno-Analyse et Biologie Specialisee* 2005;**20**(1):21–7.

Biggio 2004 *{published data only}*
Biggio JR Jr, Morris TC, Owen J, Stringer JSA. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. *American Journal of Obstetrics and Gynecology* 2004;**190**(3):721–9.

Bindra 2002 *{published data only}*
Bindra R, Heath V, Nicolaides KH. Screening for chromosomal defects by fetal nuchal translucency at 11 to 14 weeks. *Clinical Obstetrics and Gynecology* 2002;**45**(3): 661–70.

Blundell 1999 *{published data only}*
Blundell G, Ashby JP, Martin C, Shearing CH, Langdale-Brown B, Keeling J, et al. Clinical follow-up of high mid-trimester maternal serum intact human chorionic gonadotrophin concentrations in singleton pregnancies. *Prenatal Diagnosis* 1999;**19**(3):219–23.

Boots 1989 *{published data only}*
Boots LR, Davis RO, Foster JM, Goldenberg RL. Maternal serum alpha-fetoprotein prenatal screening for Down syndrome. *Alabama Medicine* 1989;**59**(1):25–7.

Borruto 2002 *{published data only}*
Borruto F, Comparetto C, Acanfora L, Bertini G, Rubaltelli FF. Role of ultrasound evaluation of nuchal translucency in prenatal diagnosis. *Clinical & Experimental Obstetrics & Gynecology* 2002;**29**(4):235–41.

Boue 1990 *{published data only}*
Boue A, Muller F. Screening for Down's syndrome with maternal serum human chorionic gonadotropin at midtrimester. *Current Opinion in Pediatrics* 1990;**2**(6): 1157–60.

Bradley 1994 *{published data only}*
Bradley LA, Horwitz JA, Dowman AC, Ponting NR, Peterson LM. Triple marker screening for fetal Down syndrome. *International Pediatrics* 1994;**9**(3):168–74.

Braithwaite 1996 *{published data only}*
Braithwaite JM, Economides DL. Nuchal translucency and screening for Down's syndrome. *Contemporary Reviews in Obstetrics and Gynaecology* 1996;**8**(2):75–81.

Brambati 1995 *{published data only}*
Brambati B, Cislaghi C, Tului L, Alberti E, Amidani M, Colombo U, et al. First-trimester Down's syndrome screening using nuchal translucency: a prospective study in women undergoing chorionic villus sampling. *Ultrasound in Obstetrics & Gynecology* 1995;**5**(1):9–14.

Brambati 1996 *{published data only}*
Brambati B, Tului L, Alberti E. Sonography in the first trimester screening of trisomy 21 and other fetal aneuploidies. *Early Pregnancy* 1996;**2**(3):155–67.

Brizot 1995a *{published data only}*
Brizot ML, Bersinger NA, Xydias G, Snijders RJ, Nicolaides KH. Maternal serum Schwangerschafts protein-1 (SP1) and fetal chromosomal abnormalities at 10-13 weeks' gestation. *Early Human Development.* 1995;**43**(1):31–6.

Brizot 1995b *{published data only}*
Brizot ML, Kuhn P, Bersinger NA, Snijders RJ, Nicolaides KH. First trimester maternal serum alpha-fetoprotein in fetal trisomies. *British Journal of Obstetrics and Gynaecology* 1995;**102**(1):31–4.

Brizzi 1989b *{published data only}*
Brizzi L, Cariati E, Periti E, Nannini R, Torricelli F, Cappelli G, et al. Evaluation of maternal serum alpha-fetoprotein and ultrasound examination to screen fetal chromosomal abnormalities. *Journal of Nuclear Medicine & Allied Sciences* 1989;**33**(3 Suppl):85–8.

Brock 1990 *{published data only}*
Brock DJ, Barron L, Holloway S, Liston WA, Hillier SG, Seppala M. First-trimester maternal serum biochemical indicators in Down syndrome. *Prenatal Diagnosis* 1990;**10** (4):245–51.

Campogrande 2001 *{published data only}*
Campogrande M, Viora E, Errante G, Bastonero S, Sciarrone A, Grassi Pirrone P, et al. Correlations between first and second trimester markers for Down's syndrome screening. *Journal of Medical Screening* 2001;**8**(3):163–4.

Canick 1988 *{published data only}*
Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. *British Journal of Obstetrics and Gynaecology* 1988;**95**(4):330–3.

Canick 1995b *{published data only}*
Canick JA, Kellner LH, Saller DN Jr, Palomaki GE, Walker RP, Osathanondh R. Second-trimester levels of maternal urinary gonadotropin peptide in down syndrome pregnancy. *Prenatal Diagnosis* 1995;**15**(8):739–44.

Canini 2002 *{published data only}*
Canini S, Prefumo F, Famularo L, Venturini PL, Palazzese V, De Biasio P. Comparison of first trimester, second trimester and integrated Down's syndrome screening results in unaffected pregnancies. *Clinical Chemistry & Laboratory Medicine* 2002;**40**(6):600–3.

Cans 1998 *{published data only}*
Cans C, Amblard F, Devillard F, Pison H, Jalbert P, Jouk PS. Population screening for aneuploidy using maternal age and ultrasound. *Prenatal Diagnosis* 1998;**18**(7):683–92.

Carreras 1991 *{published data only}*
Carreras de Paz JJ, Silva Mendoza JM, Violante Diaz M, Cerrillo Hinojosa M, Ahued Ahued JR. [Proposed normal values for alpha fetoprotein in maternal serum for the detection of neural tube closure defects and Down syndrome. Preliminary study]. [Spanish]. *Ginecologia y Obstetricia de Mexico* 1991;**59**:261–4.

Chen 1999 *{published data only}*
Chen FM. Integrated screening for Down's syndrome. *Journal of Family Practice* 1999;**48**(11):846–7.

Chen 2002 *{published data only}*
Chen M, Lam YH, Tang MH, Lee CP, Sin SY, Tang R, et al. The effect of ethnic origin on nuchal translucency at 10-14 weeks of gestation. *Prenatal Diagnosis* 2002;**22**(7):576–8.

Chen 2004 *{published data only}*
Chen M, Lam YH, Lee CP, Tang MHY. Ultrasound screening of fetal structural abnormalities at 12 to 14 weeks in Hong Kong. *Prenatal Diagnosis* 2004;**24**(2):92–7.

Chen 2005 *{published data only}*
Chen CP, Lin CJ, Wang W. Impact of second-trimester maternal serum screening on prenatal diagnosis of Down syndrome and the use of amniocentesis in the Taiwanese population. *Taiwanese Journal of Obstetrics and Gynecology* 2005;**44**(1):31–5.

Cheng 1993 *{published data only}*
Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. *Obstetrics & Gynecology* 1993;**81**(1): 72–7.

Cheng 1999 *{published data only}*
Cheng PJ, Liu CM, Chang SD, Lin YT, Soong YK. Elevated second-trimester maternal serum hCG in women undergoing haemodialysis. *Prenatal Diagnosis* 1999;**19**(10): 955–8.

Cheng 2004a *{published data only}*
Cheng CC, Bahado-Singh RO, Chen SC, Tsai MS. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. *International Journal of Gynaecology & Obstetrics* 2004;**84**(1):5–9.

Cheng 2004b *{published data only}*
Cheng PJ, Chu DC, Chueh HY, See LC, Chang HC, Weng DR. Elevated maternal midtrimester serum free ß-human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results. *American Journal of Obstetrics and Gynecology* 2004; **190**(2):442–7.

Chitayat 2002 *{published data only}*
Chitayat D, Farrell SA, Huang T, Meier C, Wyatt PR, Summers AM. Double-positive maternal serum screening results for down syndrome and open neural tube defects: an indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes. *American Journal of Obstetrics and Gynecology* 2002;**187**(3):758–63.

Christiansen 2002 *{published data only}*
Christiansen M, Hogdall EV, Larsen SO, Hogdall C. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. *Prenatal Diagnosis* 2002;**22**(5):385–7.

Christiansen 2007 *{published data only}*
Christiansen M, Sorensen TL, Norgaard-Pedersen B. Human placental lactogen is a first-trimester maternal serum marker of Down syndrome. *Prenatal Diagnosis* 2007; **27**(1):1–5.

Chung 2000 *{published data only}*
Chung BL, Kim YP, Nam MH. The application of three-dimensional ultrasound to nuchal translucency thickness measurement at 10-14 weeks of gestation. *Prenatal and Neonatal Medicine* 2000;**5**(1):17–21.

CNGOF 1996 *{published data only}*
Anon. Blood screening of Down's syndrome (Trisomy 21) and reimbursement of karyotype for women under 38. *Revue Francaise de Gynecologie et d'Obstetrique* 1996;**91**(11): 575–7.

Cole 1996 *{published data only}*
Cole L, Isozaki T, Palomaki G, Canick J, Iles R, Kellner L, et al. Detection of ß-core fragment in second trimester Down's syndrome pregnancies. [Review]. *Early Human Development* 1996;**47 Suppl**:S47–S8.

Comas 2001 *{published data only}*
Comas C, Antolín E, Torrents M, Muñoz A, Figueras F, Echevarría M, et al. Early screening for chromosomal abnormalities: new strategies combining biochemical, sonographic and doppler parameters. *Prenatal and Neonatal Medicine* 2001;**6**(2):95–102.

Comas 2002a *{published data only}*
Comas C, Torrents M, Munoz A, Antolin E, Figueras F, Echevarria M. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker?. *Obstetrics & Gynecology* 2002;**100**(4): 648–54.

Comas 2002b *{published data only}*
Comas C, Carrera JM. Early sonographic screening for chromosomal abnormalities. *Ultrasound Review of Obstetrics and Gynecology* 2002;**2**(2):88–91.

Comstock 2006 *{published data only}*
Comstock CH, Malone FD, Ball RH, Nyberg DA, Saade GR, Berkowitz RL, et al. FASTER Research Consortium. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening?. *American Journal of Obstetrics and Gynecology.* 2006;**195**(3):843–7.

Conde-Agudelo 1998 *{published data only}*
Conde-Agudelo A, Kafury-Goeta AC. Triple-marker test as screening for down syndrome: a meta-analysis. *Obstetrical and Gynecological Survey* 1998;**53**(6):369–76.

Crossley 1991 *{published data only}*
Crossley JA, Aitken DA, Connor JM. Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein, and age. *Prenatal Diagnosis* 1991;**11**(2):83–101.

Crossley 1993 *{published data only}*
Crossley JA, Aitken DA, Connor JM. Second-trimester unconjugated oestriol levels in maternal serum from chromosomally abnormal pregnancies using an optimized assay.[see comment]. *Prenatal Diagnosis* 1993;**13**(4): 271–80.

Crossley 1996 *{published data only}*
Crossley JA, Berry E, Aitken DA, Connor JM. Insulin-dependent diabetes mellitus and prenatal screening results: current experience from a regional screening programme. *Prenatal Diagnosis* 1996;**16**(11):1039–42.

Crossley 2002a *{published data only}*
Crossley JA, Aitken DA, Waugh SM, Kelly T, Connor JM. Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotrophin, and effect on detection of Down syndrome pregnancies in second-trimester screening. *Prenatal Diagnosis* 2002;**22**(3):247–55.

Cuckle 1984 *{published data only}*
Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. *Lancet* 1984;**i**(8383):926–9.

Cuckle 1987a *{published data only}*
Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. *British Journal of Obstetrics and Gynaecology* 1987;**94**(5):387–402.

Cuckle 1987b *{published data only}*
Cuckle HS, Nanchahal K, Wald NJ. Maternal serum alpha-fetoprotein and ethnic origin. *British Journal of Obstetrics and Gynaecology* 1987;**94**(11):1111–2.

Cuckle 1990 *{published data only}*
Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, et al. The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. *British Journal of Obstetrics and Gynaecology* 1990;**97**(3):272–4.

Cuckle 1996 *{published data only}*
Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM. Combining Inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(12):1095–100.

Cuckle 1999b *{published data only}*
Cuckle HS, Sehmi I, Jones R, Evans LW. Maternal serum activin A and follistatin levels in pregnancies with Down syndrome. *Prenatal Diagnosis.* 1999;**19**(6):513–6.

Cuckle 1999c *{published data only}*
Cuckle HS, Van Lith JM. Appropriate biochemical parameters in first-trimester screening for Down syndrome.[see comment]. *Prenatal Diagnosis* 1999;**19**(6): 505–12.

Cullen 1990 *{published data only}*
Cullen MT, Gabrielli S, Green JJ, Rizzo N, Mahoney MJ, Salafia C, et al. Diagnosis and significance of cystic hygroma in the first trimester. *Prenatal Diagnosis* 1990;**10** (10):643–51.

Cusick 2004 *{published data only}*
Cusick W, Provenzano J, Sullivan CA, Gallousis FM, Rodis JF. Fetal nasal bone length in euploid and aneuploid fetuses between 11 and 20 weeks' gestation: a prospective study. *Journal of Ultrasound in Medicine* 2004;**23**(10):1327–33.

D'Ottavio 1997 *{published data only}*
D'Ottavio G, Meir YJ, Rustico MA, Pecile V, Fischer-Tamaro L, Conoscenti G, et al. Screening for fetal anomalies by ultrasound at 14 and 21 weeks. *Ultrasound in Obstetrics & Gynecology* 1997;**10**(6):375–80.

Dancoine 2001 *{published data only}*
Dancoine F, Couplet G, Mainardi A, Sukno F, Jaumain P, Nowak E, et al. Antenatal screening for Dawn's syndrome with serum markers: influence of maternal weight, smoking habits and diabetes. *Immuno-Analyse et Biologie Specialisee* 2001;**16**(6):381–9.

De Biasio, 1999 *{published data only}*
De Biasio, Siccardi M, Volpe G, Famularo L, Santi F, Canini S. First-trimester screening for down syndrome using nuchal translucency measurement with free ß-hCG and PAPP-A between 10 and 13 weeks of pregnancy - the combined test. *Prenatal Diagnosis* 1999;**19**(4):360–3.

De Biasio, 2001 *{published data only}*
De Biasio, Ferrero S, Prefumo F, Canini S, Marchini P, Bruzzone I, et al. Down's syndrome: first trimester approach. *Italian Journal of Gynaecology and Obstetrics* 2001;**13**(1):22–6.

De Biasio 2000 *{published data only}*
De Biasio P, Canini S, Prefumo F, Famularo L, Venturini PL. Extent of correlation between first and second trimester markers for Down's syndrome screening. *Journal of Medical Screening* 2000;**7**(3):163.

De Graaf 1991 *{published data only}*
De Graaf I, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, Van Lith JM. Co-variables in first trimester maternal serum screening. *Prenatal Diagnosis* 1991;**20**(3):186–9.

De Graaf 1999 *{published data only}*
De Graaf I, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, Van Lith JM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. *Prenatal Diagnosis* 1999;**19**(5):458–62.

DeVore 2001 *{published data only}*
DeVore GR, Romero R. Combined use of genetic sonography and maternal serum triple-marker screening: an effective method for increasing the detection of trisomy 21 in women younger than 35 years.[see comment]. *Journal of Ultrasound in Medicine.* 2001;**20**(6):645–54.

Dickerson 1994 *{published data only}*
Dickerson VM. Multiple marker screening. *Western Journal of Medicine* 1994;**161**(2):161.

Dimaio 1987 *{published data only}*
Dimaio MS, Baumgarten A, Greenstein RM, Saal HM, Mahoney MJ. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels. *New England Journal of Medicine* 1987;**317**(6): 342–6.

Doran 1986 *{published data only}*
Doran TA, Cadesky K, Wong PY, Mastrogiacomo C, Capello T. Maternal serum alpha-fetoprotein and fetal autosomal trisomies. *American Journal of Obstetrics and Gynecology* 1986;**154**(2):277–81.

Drugan 1996a *{published data only}*
Drugan A, Reichler A, Bronstein M, Johnson MP, Sokol RJ, Evans MI. Abnormal biochemical serum screening versus 2nd-trimester ultrasound-detected minor anomalies as predictors of aneuploidy in low-risk women. *Fetal Diagnosis and Therapy* 1996;**11**(5):301–5.

Drugan 1996b *{published data only}*
Drugan A, O'Brien JE, Dvorin E, Krivchenia EL, Johnson MP, Sokol RJ, et al. Multiple marker screening in multifetal gestations: failure to predict adverse pregnancy outcomes. *Fetal Diagnosis and Therapy* 1996;**11**(1):16–9.

Drysdale 2002 *{published data only}*
Drysdale K, Ridley D, Walker K, Higgins B, Dean T. First-trimester pregnancy scanning as a screening tool for high-risk and abnormal pregnancies in a district general hospital setting. *Journal of Obstetrics & Gynaecology* 2002;**22**(2): 159–65.

Ebell 1999 *{published data only}*
Ebell M. Is the integrated test better for screening for Down's syndrome than the traditional triple test?. *Evidence-Based Practice* 1999;**2**(11):4–5.

Economides 1998 *{published data only}*
Economides DL, Whitlow BJ, Kadir R, Lazanakis M, Verdin SM. First trimester sonographic detection of chromosomal abnormalities in an unselected population. *British Journal of Obstetrics and Gynaecology* 1998;**105**(1):58–62.

Erickson 2004 *{published data only}*
Erickson JA, Ashwood ER, Gin CA. Evaluation of a dimeric inhibin-A assay for assessing fetal Down syndrome: establishment, comparison, and monitoring of median concentrations for normal pregnancies. *Archives of Pathology & Laboratory Medicine* 2004;**128**(4):415–20.

Evans 1996 *{published data only}*
Evans MI, O'Brien JE, Dvorin E, Krivchenia EL, Drugan A, Hume RF Jr, et al. Similarity of insulin-dependent diabetics' and non-insulin-dependent diabetics' levels of ß-hCG and unconjugated estriol with controls: no need to adjust as with alpha-fetoprotein. *Journal of the Society for Gynecologic Investigation* 1996;**3**(1):20–2.

Falcon 2005 *{published data only}*
Falcon O, Cavoretto P, Peralta CF, Csapo B, Nicolaides KH. Fetal head-to-trunk volume ratio in chromosomally abnormal fetuses at 11 + 0 to 13 + 6 weeks of gestation. *Ultrasound in Obstetrics & Gynecology* 2005;**26**(7):755–60.

Falcon 2006 *{published data only}*
Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH. Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan: association with chromosomal defects and reproducibility of the method. *Ultrasound in Obstetrics & Gynecology* 2006; **27**(6):609–12.

Ford 1998 *{published data only}*
Ford C, Moore AJ, Jordan PA, Bartlett WA, Wyldes MP, Jones AF, et al. The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population.[see comment]. *British Journal of Obstetrics and Gynaecology* 1998;**105**(8):855–9.

Frishman 1997 *{published data only}*
Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH, Saller DN Jr. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. *Obstetrics & Gynecology* 1997;**90**(1):98–101.

Fukada 2000 *{published data only}*
Fukada Y, Takizawa M, Amemiya A, Yoda H, Kohno K, Hoshi K. Detection of aneuploidy with fetal nuchal translucency and maternal serum markers in Japanese women. *Acta Obstetricia et Gynecologica Scandinavica* 2000; **79**(12):1124–5.

Ghidini 1998 *{published data only}*
Ghidini A, Spong CY, Grier RE, Walker CN, Pezzullo JC. Is maternal serum triple screening a better predictor of Down syndrome in female than in male fetuses?. *Prenatal Diagnosis* 1998;**18**(2):123–6.

Goldie 1995 *{published data only}*
Goldie DJ, Astley JP, Beaman JM, Bickley DA, Gunneberg A, Jones SR. Screening for Down's syndrome: the first two years experience in Bristol. *Journal of Medical Screening* 1995;**2**(4):207–10.

Gonçalves 2004 *{published data only}*
Gonçalves LF, Espinoza J, Lee W, Schoen ML, Devers P, Mazor M, et al. Phenotypic characteristics of absent and hypoplastic nasal bones in fetuses with down syndrome:

description by 3-dimensional ultrasonography and clinical significance. *Journal of Ultrasound in Medicine* 2004;**23** (12):1619–27.

Goodburn 1994 *{published data only}*
Goodburn SF, Yates JR, Raggatt PR, Carr C, Ferguson-Smith ME, Kershaw AJ, et al. Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. *Prenatal Diagnosis* 1994;**14**(5): 391–402.

Grozdea 2002 *{published data only}*
Grozdea J, De La Farge F, Bourrouillou G, Calot M, Cambus JP, Valdiguie P. Maternal serum urea resistant alkaline phosphatase in Down syndrome pregnancy. *Early Human Development* 2002;**67**(1-2):55–9.

Gyselaers 2004a *{published data only}*
Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans DP, Martens GE, De Jonge ET, et al. Screening for trisomy 21 in Flanders: a 10 years review of 40.490 pregnancies screened by maternal serum. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 2004;**115**(2):185–9.

Gyselaers 2004b *{published data only}*
Gyselaers WJA, Vereecken AJ, Van Herck, Straetmans DPL, De Jonge, Ombelet WUA, et al. Single-step maternal serum screening for trisomy 21 in the era of combined or integrated screening. *Gynecologic and Obstetric Investigation* 2004;**58**(4):221–4.

Gyselaers 2006a *{published data only}*
Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans DP, Ombelet WU, Nijhuis JG. Nuchal translucency thickness measurements for fetal aneuploidy screening: Log NT-MoM or Delta-NT, performer-specific medians and ultrasound training. *Journal of Medical Screening* 2006;**13** (1):4–7.

Gyselaers 2006b *{published data only}*
Gyselaers WJ, Roets ER, Van Holsbeke CD, Vereecken AJ, Van Herck EJ, Straetmans DP, et al. Sequential triage in the first trimester may enhance advanced ultrasound scanning in population screening for trisomy 21. *Ultrasound in Obstetrics & Gynecology* 2006;**27**(6):622–7.

Hackshaw 1995 *{published data only}*
Hackshaw AK, Densem J, Wald NJ. Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free alpha and free ß-hCG. *Prenatal Diagnosis* 1995;**15**(12):1125–30.

Hackshaw 2001 *{published data only}*
Hackshaw AK, Wald NJ. Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. *Prenatal Diagnosis* 2001;**21**(1):58–61.

Haddow 1992 *{published data only}*
Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick J, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. *New England Journal of Medicine* 1992;**327**(9):588–93.

Hafner 1995 *{published data only}*
Hafner E, Schuchter K, Philipp K. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency. *Ultrasound in Obstetrics & Gynecology* 1995;**6**(5):330–3.

Hallahan 1998 *{published data only}*
Hallahan TW, Krantz DA, Tului L, Alberti E, Buchanan PD, Orlandi F, et al. Comparison of urinary free ß (hCG) and ß-core (hCG) in prenatal screening for chromosomal abnormalities. *Prenatal Diagnosis* 1998;**18**(9):893–900.

Harrison 2006 *{published data only}*
Harrison G, Goldie D. Second-trimester Down's syndrome serum screening: double, triple or quadruple marker testing?. *Annals of Clinical Biochemistry* 2006;**43**(1):67–72.

Harry 2006 *{published data only}*
Harry WG, Reed KL. Nuchal translucency and first-trimester screening. *Journal of the Society for Gynecologic Investigation* 2006;**13**(3):153–4.

Hayashi 1995 *{published data only}*
Hayashi M, Kozu H. Maternal urinary ß-core fragment of hCG/creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. *Prenatal Diagnosis* 1995;**15**(1):11–6.

Hayashi 1996 *{published data only}*
Hayashi M, Kozu H, Takei H. Maternal urinary free ß-subunit of human chorionic gonadotrophin: creatinine ratios and fetal chromosomal abnormalities in the second trimester of pregnancy. *British Journal of Obstetrics and Gynaecology* 1996;**103**(6):577–80.

Heikkila 1997 *{published data only}*
Heikkila A, Ryynanen M, Kirkinen P, Saarikoski S. Results and views of women in population-wide pregnancy screening for trisomy 21 in east Finland. *Fetal Diagnosis and Therapy* 1997;**12**(2):93–6.

Heinonen 1996 *{published data only}*
Heinonen S, Ryynanen M, Kirkinen P, Hippelainen M, Saarikoski S. Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down's syndrome screening. *Fertility and Sterility* 1996;**66**(3): 398–403.

Herman 2000 *{published data only}*
Herman A, Weinraub Z, Dreazen E, Arieli S, Rozansky S, Bukovsky I, et al. Combined first trimester nuchal translucency and second trimester biochemical screening tests among normal pregnancies. *Prenatal Diagnosis* 2000; **20**(10):781–4.

Herman 2003 *{published data only}*
Herman A, Dreazen E, Tovbin Y, Reish O, Bukovsky I, Maymon R. Correlation and overlapping between nuchal translucency and triple test among Down syndrome-affected pregnancies. *Fetal Diagnosis and Therapy* 2003;**18** (3):196–200.

Herrou 1992 *{published data only}*
Herrou M, Leporrier N, Leymarie P. Screening for fetal Down syndrome with maternal serum hCG and oestriol: a prospective study. *Prenatal Diagnosis* 1992;**12**(11):887–92.

Hershey 1985 *{published data only}*
Hershey DW, Crandall BF, Schroth PS. Maternal serum alpha-fetoprotein screening of fetal trisomies. *American Journal of Obstetrics and Gynecology* 1985;**153**(2):224–5.

Hershey 1986 *{published data only}*
Hershey DW, Crandall BF, Perdue S. Combining maternal age and serum alpha-fetoprotein to predict the risk of Down syndrome. *Obstetrics & Gynecology* 1986;**68**(2):177–80.

Hewitt 1993 *{published data only}*
Hewitt B. Nuchal translucency in the first trimester. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 1993;**33**(4):389–91.

Hogdall 1992 *{published data only}*
Hogdall CK, Hogdall EV, Arends J, Norgaard-Pedersen B, Smidt-Jensen S, Larsen SO. CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters. *Prenatal Diagnosis* 1992;**12**(3):223–7.

Hong Kong Practitioner 2001 *{published data only}*
Anon. Screening tests in pregnancy. *Hong Kong Practitioner* 2001;**23**(10):461–5.

Howe 2000 *{published data only}*
Howe DT, Gornall R, Wellesley D, Boyle T, Barber J. Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans. *BMJ* 2000;**320**(7235):606–10.

Hsiao 1991 *{published data only}*
Hsiao KJ, Lee SY, Chuang HC. [Antenatal screening of maternal alpha-fetoprotein with dried-blood spot samples on filter paper]. [Chinese]. *Journal of the Formosan Medical Association* 1991;**90**(6):598–604.

Hsieh 1999 *{published data only}*
Hsieh TT, Hsu JJ, Lo LM, Liou JD, Soong YK. Maternal urine alpha-fetoprotein concentrations between 14 and 21 weeks of gestation. *Changgeng Yi Xue Za Zhi* 1999;**22**(2):234–9.

Hsu 1997b *{published data only}*
Hsu JJ, Hsieh TT, Soong YK. Influence of maternal age and weight on second-trimester serum alpha-fetoprotein, total and free ß human chorionic gonadotropin levels. *Changgeng Yi Xue Za Zhi.* 1997;**20**(3):181–6.

Hsu 1998a *{published data only}*
Hsu JJ, Hsieh TT, Hung TH, Chiang CH. Midtrimester maternal serum free ß-human chorionic gonadotropin levels: normal reference values for Taiwanese women. *Changgeng Yi Xue Za Zhi* 1998;**21**(3):277–82.

Hsu 1999b *{published data only}*
Hsu JJ, Hsieh TT, Hung TH, Chen KC, Soong YK. Urine free ß-human chorionic gonadotropin levels between 14 and 21 weeks of gestation in Taiwanese pregnancies. *Changgeng Yi Xue Za Zhi* 1999;**22**(1):11–6.

Huang 2003 *{published data only}*
Huang T, Summers AM, Wyatt PR, Meier C, Cote GB. Maternal serum marker medians in Aboriginal Canadian women. *Prenatal Diagnosis* 2003;**23**(2):98–100.

Huggon 2004 *{published data only}*
Huggon IC, Turan O, Allan LD. Doppler assessment of cardiac function at 11-14 weeks' gestation in fetuses with normal and increased nuchal translucency. *Ultrasound in Obstetrics & Gynecology* 2004;**24**(4):390–8.

Hui 2003 *{published data only}*
Hui PW, Tang MH, Lam YH, Ng EH, Yeung WS, Ho PC. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. *Human Reproduction* 2003;**18**(3):572–5.

Hui 2005 *{published data only}*
Hui PW, Tang MH, Lam YH, Yeung WS, Ng EH, Ho PC. Nuchal translucency in pregnancies conceived after assisted reproduction technology. *Ultrasound in Obstetrics & Gynecology* 2005;**25**(3):234–8.

Hultén 2004 *{published data only}*
Hultén M. Combined serum and nuchal translucency screening in the first trimester achieves 85% to 90% detection rate for Down and Edward syndromes. *Evidence-Based Healthcare* 2004;**8**(2):82–4.

Hung 2003 *{published data only}*
Hung JH, Fu CY, Yuan CC, Chen CL, Yang ML, Shu LP, et al. Nuchal translucence incorporated into a one-stage multifactorial screening model for Down syndrome prediction at second-trimester pregnancy. *Ultrasound in Medicine & Biology* 2003;**29**(12):1667–74.

Hurley 1993 *{published data only}*
Hurley PA, Ward RH, Teisner B, Iles RK, Lucas M, Grudzinskas JG. Serum PAPP-A measurements in first-trimester screening for Down syndrome. *Prenatal Diagnosis* 1993;**13**(10):903–8.

Huttly 2004 *{published data only}*
Huttly W, Rudnicka A, Wald NJ. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. *Prenatal Diagnosis* 2004;**24**(10):804–7.

Hwa 2004 *{published data only}*
Hwa HL, Yen MF, Hsieh FJ, Ko TM, Chen TH. Evaluation of second trimester maternal serum screening for Down's Syndrome using the Spiegelhalter-Knill-Jones (S-KJ) approach. *Journal of Perinatal Medicine* 2004;**32**(5):407–12.

Iles 1996 *{published data only}*
Iles RK. Urinary analysis for Down's syndrome: Is the measurement of urinary ß-core the future of biochemical screening for Down's syndrome. *Early Human Development* 1996;**47**(Suppl.):S41–S45.

Ind 1994 *{published data only}*
Ind TEJ, Iles RK, Cuckle HS, Chard T. Second trimester maternal serum placental alkaline phosphatase

concentrations in Down's syndrome. *Journal of Obstetrics and Gynaecology* 1994;**14**(5):305–8.

Jean-Pierre 2005 *{published data only}*
Jean-Pierre C. Fetal nasal bone: review of first trimester findings. *Ultrasound Review of Obstetrics and Gynecology* 2005;**5**(2):102–4.

Johnson 1991 *{published data only}*
Johnson A, Cowchock FS, Darby M, Wapner R, Jackson LG. First-trimester maternal serum alpha-fetoprotein and chorionic gonadotropin in aneuploid pregnancies. *Prenatal Diagnosis* 1991;**11**(7):443–50.

Johnson 1993 *{published data only}*
Johnson MP, Johnson A, Holzgreve W, Isada NB, Wapner RJ, Treadwell MC, et al. First-trimester simple hygroma: cause and outcome. *American Journal of Obstetrics and Gynecology* 1993;**168**(1):156–61.

Jorgensen 1999 *{published data only}*
Jorgensen FS, Valentin L, Salvesen KA, Jorgensen C, Jensen FR, Bang J, et al. MULTISCAN--a Scandinavian multicenter second trimester obstetric ultrasound and serum screening study. *Acta Obstetricia et Gynecologica Scandinavica* 1999;**78**(6):501–10.

Josefsson 1998 *{published data only}*
Josefsson A, Molander E, Selbing A. Nuchal translucency as a screening test for chromosomal abnormalities in a routine first trimester ultrasound examination. *Acta Obstetricia et Gynecologica Scandinavica* 1998;**77**(5):497–9.

Jou 2001 *{published data only}*
Jou HJ, Shih JC, Wu SC, Li TC, Tzeng CY, Hsieh FJ. First-trimester Down's syndrome screening by fetal nuchal translucency measurement in Taiwan. *Journal of the Formosan Medical Association* 2001;**100**(4):257–61.

Kagan 2006 *{published data only}*
Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects.[see comment]. *Obstetrics & Gynecology* 2006;**107**(1):6–10.

Kautzmann 1995 *{published data only}*
Kautzmann M, Solis RL, Luberta A, Fernandez JL, Navarro J, Rodriguez L, et al. Study of the efficiency of screening for trisomy 21 based on maternal serum levels of AFP and hCG combined with maternal age. *Journal of Clinical Ligand Assay* 1995;**18**(3):181–5.

Keith 1992 *{published data only}*
Keith D. Maternal serum screening for neural tube defects and Down syndrome. *Clinical Laboratory Science* 1992;**5**(5):274–6.

Kelekci 2004 *{published data only}*
Kelekci S, Yazicioglu HF, Oguz S, Inan I, Yilmaz B, Sonmez S. Nasal bone measurement during the 1st trimester: is it useful?. *Gynecologic & Obstetric Investigation* 2004;**58**(2):91–5.

Kellner 1995a *{published data only}*
Kellner LH, Weiner Z, Weiss RR, Neuer M, Martin GM, Mueenuddin M, et al. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-ß subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.[see comment]. *American Journal of Obstetrics and Gynecology* 1995;**173**(4):1306–9.

Kellner 1995b *{published data only}*
Kellner LH, Weiss RR, Weiner Z, Neuer M, Martin GM, Schulman H, et al. The advantages of using triple-marker screening for chromosomal abnormalities. *American Journal of Obstetrics and Gynecology* 1995;**172**(3):831–6.

Kellner 1997 *{published data only}*
Kellner LH, Canick JA, Palomaki GE, Neveux LM, Saller DN Jr, Walker RP, et al. Levels of urinary ß-core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome. *Prenatal Diagnosis* 1997;**17**(12):1135–41.

Knight 1990 *{published data only}*
Knight GJ, Palomaki GE. Maternal serum alpha fetoprotein screening for fetal down syndrome. *Journal of Clinical Immunoassay* 1990;**13**(1):23–9.

Knight 2001 *{published data only}*
Knight GJ, Palomaki GE, Neveux LM, Haddow JE, Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. *Journal of Medical Screening* 2001;**8**(1):2–7.

Knight 2005 *{published data only}*
Knight GJ, Palomaki GE, Neveux LM, Smith DE, Kloza EM, Pulkkinen A, et al. Integrated serum screening for Down syndrome in primary obstetric practice. *Prenatal Diagnosis* 2005;**25**(12):1162–7.

Koos 2006 *{published data only}*
Koos BJ. First-trimester screening: lessons from clinical trials and implementation. *Current Opinion in Obstetrics and Gynecology* 2006;**18**(2):152–5.

Kornman 1996 *{published data only}*
Kornman LH, Morssink LP, Beekhuis JR, de Wolf BT, Heringa MP, Mantingh A. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice.[see comment]. *Prenatal Diagnosis* 1996;**16**(9):797–805.

Kornman 1997 *{published data only}*
Kornman LH, Morssink LP, Wortelboer MJ, Beekhuis JR, de Wolf BT, Pratt JJ, et al. Maternal urinary ß-core hCG in chromosomally abnormal pregnancies in the first trimester. *Prenatal Diagnosis* 1997;**17**(2):135–9.

Kramer 1998 *{published data only}*
Kramer RL, Yaron Y, O'Brien JE, Critchfield G, Ayoub M, Johnson MP, et al. Effect of adjustment of maternal serum alpha-fetoprotein levels in insulin-dependent diabetes mellitus. *American Journal of Medical Genetics* 1998;**75**(2):176–8.

Krantz 1996 *{published data only}*
Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free ß-human chorionic gonadotropin and pregnancy-associated plasma protein A. *American Journal of Obstetrics and Gynecology* 1996;**174**(2):612–6.

Krantz 2005 *{published data only}*
Krantz DA, Hallahan TW, Macri VJ, Macri JN. Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program. *Prenatal Diagnosis* 2005;**25**(8):635–40.

Kulch 1993 *{published data only}*
Kulch P, Keener S, Matsumoto M, Crandall BF. Racial differences in maternal serum human chorionic gonadotropin and unconjugated oestriol levels. *Prenatal Diagnosis* 1993;**13**(3):191–5.

Lai 1998 *{published data only}*
Lai FM, Yeo GS. Down syndrome screening in Singapore--the effectiveness of a second trimester serum screening policy modelled on 29,360 pregnancies in KK Women's and Children's Hospital. *Singapore Medical Journal* 1998;**39**(2): 69–75.

Lai 2003 *{published data only}*
Lai TH, Chen SC, Tsai MS, Lee FK, Wei CF. First-trimester screening for Down syndrome in singleton pregnancies achieved by intrauterine insemination. *Journal of Assisted Reproduction and Genetics* 2003;**20**(8):327–31.

Laigaard 2006a *{published data only}*
Laigaard J, Cuckle H, Wewer UM, Christiansen M. Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9-12 weeks' gestation. *Prenatal Diagnosis* 2006;**26**(8):689–91.

Laigaard 2006b *{published data only}*
Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, et al. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(10):973–9.

Lam 1997 *{published data only}*
Lam YH, Tang MH, Tang LC, Lee CP, Ho PK. Second-trimester maternal urinary gonadotrophin peptide screening for fetal Down syndrome in Asian women. *Prenatal Diagnosis* 1997;**17**(12):1101–6.

Lam 1998 *{published data only}*
Lam YH, Ghosh A, Tang MH, Tang LC, Lee CP, Sin SY, et al. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong. *Prenatal Diagnosis* 1998;**18**(6): 585–9.

Lam 1999a *{published data only}*
Lam YH, Yeung WS, Tang MH, Ng EH, So WW, Ho PC. Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. *Human Reproduction* 1999;**14**(8):2120–3.

Lam 1999b *{published data only}*
Lam YH, Tang MH. Second-trimester maternal serum inhibin-A screening for fetal Down syndrome in Asian women. *Prenatal Diagnosis* 1999;**19**(5):463–7.

Lam 2000 *{published data only}*
Lam YH, Tang MH, Lee CP, Sin SY, Tang R, Wong HS, et al. Acceptability of serum screening as an alternative to cytogenetic diagnosis of down syndrome among women 35 years or older in Hong Kong. *Prenatal Diagnosis* 2000;**20** (6):487–90.

Lam 2001 *{published data only}*
Lam YH, Tang MH. The effect of fetal gender on second-trimester maternal serum inhibin-A concentration. *Prenatal Diagnosis* 2001;**21**(8):662–4.

Lambert-Messerlian 1996 *{published data only}*
Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. *Journal of Medical Screening* 1996;**3**(2):58–62.

Lambert-Messerlian 1998 *{published data only}*
Lambert-Messerlian, Luisi S, Florio P, Mazza V, Canick JA, Petraglia F. Second trimester levels of maternal serum total activin A and placental inhibin/activin alpha and ßA subunit messenger ribonucleic acids in Down syndrome pregnancy. *European Journal of Endocrinology* 1998;**138**(4): 425–9.

Lehavi 2005 *{published data only}*
Lehavi O, Aizenstein O, Evans MI, Yaron Y. 2nd-trimester maternal serum human chorionic gonadotropin and alpha-fetoprotein levels in male and female fetuses with Down syndrome. *Fetal Diagnosis and Therapy* 2005;**20**(3):235–8.

Leung 2006 *{published data only}*
Leung TY, Spencer K, Leung TN, Fung TY, Lau TK. Higher median levels of free ß-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population. *Fetal Diagnosis and Therapy* 2006;**21**(1):140–3.

Leymarie 1993 *{published data only}*
Leymarie P, Leporrier N. Maternal serum markers and prenatal screening for Down syndrome. *Archives Francaises de Pediatrie* 1993;**50**(5):455–7.

Li 1998 *{published data only}*
Li G, Huang X. [Clinical uses of maternal serum markers in the prenatal diagnosis] [Chinese]. *Chung-Hua Fu Chan Ko Tsa Chih* 1998;**33**(4):252–4.

Li 1999 *{published data only}*
Li W, Zhou Y. [Measurement of pregnancy-associated plasma protein A in maternal peripheral blood and Down syndrome] [Chinese]. *Chung-Hua Fu Chan Ko Tsa Chih* 1999;**34**(10):631–3.

Liao 1997 *{published data only}*
Liao S, Wang Y, Ye G. [AFP, uE3, ß-hCG levels applied for prenatal diagnosis of Down's syndrome]. [Chinese]. *Chung-Hua Fu Chan Ko Tsa Chih* 1997;**32**(11):655–8.

Liao 2001 *{published data only}*
Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. *Human Reproduction* 2001;**16**(7):1501–4.

Lim 2002 *{published data only}*
Lim KI, Pugash D, Dansereau J, Wilson RD. Nuchal index: a gestational age independent ultrasound marker for the detection of Down syndrome. *Prenatal Diagnosis* 2002;**22**(13):1233–7.

Lippman 1987 *{published data only}*
Lippman A, Evans JA. Screening for maternal serum alpha-fetoprotein: what about the low side?. *Canadian Medical Association Journal* 1987;**136**(8):801–4.

Liu 2003 *{published data only}*
Liu JT, Hao N, Sun NH, Wang FY, Xu YH, Gai MY, et al. [Screening by maternal serum markers for Down's syndrome]. [Chinese]. *Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae* 2003;**25**(2):156–9.

Lustig 1988 *{published data only}*
Lustig L, Clarke S, Cunningham G, Schonberg R, Tompkinson G. California's experience with low MS-AFP results. *American Journal of Medical Genetics* 1988;**31**(1):211–22.

MacDonald 1991 *{published data only}*
MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.[see comment]. *Obstetrics & Gynecology* 1991;**77**(1):63–8.

Macintosh 1994 *{published data only}*
Macintosh MCM, Iles R, Teisner B, Sharma K, Chard T, Grudzinskas J, et al. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks. *Prenatal Diagnosis* 1994;**14**(3):203–8.

Macintosh 1997 *{published data only}*
Macintosh MCM, Nicolaides KH, Noble P, Chard T, Gunn L, Iles R. Urinary ß-core hCG: screening for aneuploidies in early pregnancy (11-14 weeks' gestation). *Prenatal Diagnosis* 1997;**17**(5):401–5.

Macri 1994 *{published data only}*
Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, et al. Maternal serum Down syndrome screening: free ß-protein is a more effective marker than human chorionic gonadotropin.[see comment]. *American Journal of Obstetrics and Gynecology* 1990;**163**(4):1248–53.
* Macri JN, Spencer K, Garver K, Buchanan PD, Say B, Carpenter NJ, et al. Maternal serum free ß hCG screening: results of studies including 480 cases of Down syndrome.[see comment]. *Prenatal Diagnosis* 1994;**14**(2):97–103.
Spencer K, Macri JN. Early detection of Down's syndrome using free ß human choriogonadotropin. *Annals of Clinical Biochemistry* 1992;**19**(3):349–50.

Macri 1996 *{published data only}*
Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchanan PD. Prenatal maternal dried blood screening with alpha-fetoprotein and free ß-human chorionic gonadotropin for open neural tube defect and Down syndrome. *American Journal of Obstetrics and Gynecology* 1996;**174**(2):566–72.

Malone 1998 *{published data only}*
Malone FD, D'Alton ME. Ultrasound clinics. Fetal nuchal fold translucency screening. *Contemporary OB/GYN* 1998;**43**(3):117–8.

Malone 2003 *{published data only}*
Malone FD, D'Alton ME. First-trimester sonographic screening for Down syndrome. *Obstetrics and Gynecology* 2003;**102**(5):1066–79.

Mangione 2001 *{published data only}*
Mangione R, Guyon F, Taine L, Wen ZQ, Roux D, Vergnaud A, et al. Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency. *Fetal Diagnosis and Therapy* 2001;**16**(6):360–3.

Maymon 2001a *{published data only}*
Maymon R, Shulman A. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. *Human Reproduction* 2001;**16**(4):691–5.

Maymon 2001b *{published data only}*
Maymon R, Dreazen E, Buckovsky I, Weinraub Z, Herman A. Does a 'notched' nuchal translucency indicate Down syndrome fetuses or other adverse pregnancy outcome?. *Prenatal Diagnosis* 2001;**21**(5):403–8.

Maymon 2002 *{published data only}*
Maymon R, Shulman A. Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons. *Human Reproduction* 2002;**17**(4):1081–5.

Maymon 2004 *{published data only}*
Maymon R, Shulman A. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies. *Prenatal Diagnosis* 2004;**24**(2):125–9.

Maymon 2005 *{published data only}*
Maymon R, Cuckle H, Jones R, Reish O, Sharony R, Herman A. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening. *Prenatal Diagnosis* 2005;**25**(12):1102–6.

McDuffie 1996 *{published data only}*
McDuffie RS Jr, Haverkamp AD, Stark CF, Haverkamp C, Barth CK. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization. *Journal of Maternal-Fetal Medicine* 1996;**5**(2):70–3.

Meier 2002 *{published data only}*
Meier C, Huang T, Wyatt PR, Summers AM. Accuracy of expected risk of Down syndrome using the second-trimester triple test. *Clinical Chemistry* 2002;**48**(4):653–5.

Merkatz 1984 *{published data only}*
Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. *American Journal of Obstetrics and Gynecology* 1984;**148**(7):886–94.

Merz 2005 *{published data only}*
Merz E. The fetal nasal bone in the first trimester - precise assessment using 3D sonography. *Ultraschall in der Medizin* 2005;**26**(5):365–6.

Metzenbauer 2001 *{published data only}*
Metzenbauer M, Hafner E, Hoefinger D, Schuchter K, Stangl G, Ogris E, et al. Three-dimensional ultrasound measurement of the placental volume in early pregnancy: method and correlation with biochemical placenta parameters. *Placenta* 2001;**22**(6):602–5.

Metzenbauer 2002 *{published data only}*
Metzenbauer M, Hafner E, Schuchter K, Philipp K. First-trimester placental volume as a marker for chromosomal anomalies: preliminary results from an unselected population. *Ultrasound in Obstetrics & Gynecology* 2002;**19**(3):240–2.

Mikic 1999 *{published data only}*
Mikic TS, Johnson P. Second trimester maternal serum ß human chorionic gonadotrophin and pregnancy outcome. *British Journal of Obstetrics and Gynaecology* 1999;**106**(6):598–600.

Miller 1991 *{published data only}*
Miller CH, O'Brien TJ, Chatelain S, Butler BB, Quirk JG. Alteration in age-specific risks for chromosomal trisomy by maternal serum alpha-fetoprotein and human chorionic gonadotropin screening. *Prenatal Diagnosis* 1991;**11**(3):153–8.

Milunsky 1989 *{published data only}*
Milunsky A, Jick SS, Bruell CL, Maclaughlin DS, Tsung Y-K, Jick H, et al. Predictive values relative risks and overall benefits of high and low maternal serum alpha fetoprotein screening in singleton pregnancies - new epidemiological data. *American Journal of Obstetrics and Gynecology* 1989;**161**(2):291–7.

Milunsky 1996 *{published data only}*
Milunsky A, Nebiolo L. Maternal serum triple analyte screening and adverse pregnancy outcome. *Fetal Diagnosis and Therapy* 1996;**11**(4):249–53.

Minobe 2002 *{published data only}*
Minobe S. [A study on the screening of prenatal trisomy 21 using the fucosylated alpha-fetoprotein ratio measured by a liquid-phase binding assay]. [Japanese]. *Hokkaido Igaku Zasshi - Hokkaido Journal of Medical Science* 2002;**77**(6):527–32.

Miyamura 1999 *{published data only}*
Miyamura T, Saito N, Touno A, Nagata S, Hidaki T, Ishimaru T, et al. Multicenter study for maternal serum triple markers to establish Japanese standards: maternal serum marker study group, Japan Association of Prenatal Diagnostics. *Acta Obstetrica et Gynaecologica Japonica* 1999;**51**(11):1042–8.

Moghadam 1998 *{published data only}*
Moghadam S, Engel W, Bougoussa M, Hennen G, Igout A, Sancken U. Maternal serum placental growth hormone and insulinlike growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: implications for prenatal diagnosis of trisomy 21. *Fetal Diagnosis and Therapy* 1998;**13**(5):291–7.

Monni 2000 *{published data only}*
Monni G, Zoppi MA, Ibba RM, Putzolu M, Floris M. Nuchal translucency in multiple pregnancies. *Croatian Medical Journal* 2000;**41**(3):266–9.

Monni 2002 *{published data only}*
Monni G, Zoppi MA. New ultrasonographic markers of aneuploidies: nasal bones. *Ultrasound Review of Obstetrics and Gynecology* 2002;**2**(4):229–34.

Mooney 1994 *{published data only}*
Mooney RA, Peterson J, French CA, Saller DN Jr, Arvan DA. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome. *Obstetrics and Gynecology* 1994;**84**(2):298–303.

Muller 1994 *{published data only}*
Muller F, Bussieres L, Pelissier MC, Oury JF, Boue C, Uzan S, et al. Do racial differences exist in second-trimester maternal hCG levels? A study of 23,369 women. *Prenatal Diagnosis* 1994;**14**(7):633–6.

Muller 1996b *{published data only}*
Muller F, Dommergues M, Bussieres L, Aegerter P, Le Fiblec B, Uzan S, et al. Prenatal screening for Down syndrome: should first trimester ultrasound replace maternal serum screening?. *Early Human Development* 1996;**47 Suppl**:S37–S39.

Muller 1999 *{published data only}*
Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D. Maternal serum s100b protein is ineffective for Down syndrome screening. *Prenatal Diagnosis* 1999;**19**(11):1086.

Muller 2002a *{published data only}*
Muller F, Dreux S, Oury JF, Luton D, Uzan S, Uzan M, et al. Down syndrome maternal serum marker screening after 18 weeks' gestation. *Prenatal Diagnosis* 2002;**22**(11):1001–4.

Muller 2002b *{published data only}*
Muller F, Forestier F, Dingeon B, for the ABA Study Group. Second trimester trisomy 21 maternal serum marker screening. Results of a countrywide study of 854, 902 women. *Prenatal Diagnosis* 2002;**22**(10):925–9.

Muller 2003 *{published data only}*
Muller F, Dreux S, Lemeur A, Sault C, Desgres J, Bernard MA, et al. Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome. *Prenatal Diagnosis* 2003;**23**(13):1073–6.

Murta 2002 *{published data only}*
Murta CG, Moron AF, Avila MA, Weiner CP. Application of ductus venosus Doppler velocimetry for the detection of

fetal aneuploidy in the first trimester of pregnancy. *Fetal Diagnosis and Therapy* 2002;**17**(5):308–14.

Musone 2000 ***{published data only}***
Musone R, Bonafiglia R, Menditto A, Paccone M, Cassese E, Russo G, et al. Fetuses with cystic hygroma. A retrospective study. *Panminerva Medica* 2000;**42**(1):39–43.

Musto 1986 ***{published data only}***
Musto JD, Pizzolante JM, Chesarone VP, Sassi AM, Sane R. Alpha-fetoprotein: an enhanced-sensitivity assay for neural tube defect and Down syndrome evaluation. *Clinical Chemistry* 1986;**32**(7):1412.

Myrick 1990 ***{published data only}***
Myrick JE, Caudill SP, Hubert IL, Robinson MK, Adams MJ Jr, Pueschel SM. Identification of haptoglobin alpha-2FF variants in mid-trimester maternal serum as potential markers for Down syndrome. *Applied & Theoretical Electrophoresis* 1990;**1**(5):233–41.

Neveux 1996a ***{published data only}***
Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. *Prenatal Diagnosis* 1996;**16**(12):1115–9.

Neveux 1996b ***{published data only}***
Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. *Prenatal Diagnosis* 1996;**16**(1):29–34.

Ng 2004 ***{published data only}***
Ng EK, El-Sheikhah A, Chiu RW, Chan KC, Hogg M, Bindra R, et al. Evaluation of human chorionic gonadotropin ß-subunit mRNA concentrations in maternal serum in aneuploid pregnancies: a feasibility study. *Clinical Chemistry* 2004;**50**(6):1055–7.

Nicolaides 1992 ***{published data only}***
Nicolaides KH, ZAR G, Snijders RJM, Gosden CM. Fetal nuchal oedema associated malformations and chromosomal defects. *Fetal Diagnosis and Therapy* 1992;**7**(2):123–31.

Nicolaides 2000 ***{published data only}***
Nicolaides KH, Cicero S, Liao AW. One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation. *Prenatal and Neonatal Medicine* 2000;**5**(3): 145–54.

Nicolaides 2004 ***{published data only}***
Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. *American Journal of Obstetrics and Gynecology* 2004;**191**(1):45–67.

Nicolaides 2005a ***{published data only}***
Nicolaides KH, Wegrzyn P. [First trimester diagnosis of chromosomal defects][Polish]. *Ginekologia Polska* 2005;**76** (1):1–8.

Nicolaides 2005b ***{published data only}***
Nicolaides KH, Wegrzyn P. [Sonographic features of chromosomal defects at 11(+0) to 13(+6) weeks of gestation] [Polish]. *Ginekologia Polska* 2005;**76**(6):423–30.

Nicolaides 2005c ***{published data only}***
Nicolaides KH, Wegrzyn P. [Increased nuchal translucency with normal karyotype]. [Polish]. *Ginekologia Polska* 2005; **76**(8):593–601.

Nicolaides 2005d ***{published data only}***
Nicolaides KH, Wegrzyn P. [Fetal nuchal translucency]. [Polish]. *Ginekologia Polska* 2005;**76**(3):179–86.

Nicolaides 2005e ***{published data only}***
Nicolaides KH, Wegrzyn P. [Fetal nuchal translucency thickness and risk for chromosomal defects]. [Polish]. *Ginekologia Polska* 2005;**76**(4):257–63.

Nicolaides 2005f ***{published data only}***
Nicolaides Kypros H. First-trimester screening for chromosomal abnormalities. *Seminars in Perinatology (Philadelphia)* 2005;**29**(4):190–4.

Niemimaa 2001 ***{published data only}***
Niemimaa M, Heinonen S, Seppala M, Hippelainen M, Martikainen H, Ryynanen M. First-trimester screening for Down's syndrome in in vitro fertilization pregnancies. *Fertility & Sterility* 2001;**76**(6):1282–3.

Niemimaa 2002 ***{published data only}***
Niemimaa M, Suonpaa M, Heinonen S, Seppala M, Bloigu R, Ryynanen M. Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A in twin pregnancies in the first trimester. *Prenatal Diagnosis* 2002;**22**(3):183–5.

Niemimaa 2003 ***{published data only}***
Niemimaa M, Heinonen S, Seppala M, Ryynanen M. The influence of smoking on the pregnancy-associated plasma protein A, free ß human chorionic gonadotrophin and nuchal translucency. *BJOG: an international journal of obstetrics and gynaecology* 2003;**110**(7):664–7.

Noble 1997 ***{published data only}***
Noble PL, Snijders RJ, Abraha HD, Sherwood RA, Nicolaides KH. Maternal serum free ß-hCG at 10 to 14 weeks of gestation in trisomic twin pregnancies. *British Journal of Obstetrics and Gynaecology* 1997;**104**(6):741–3.

Norgaard-Pedersen 1990 ***{published data only}***
Norgaard-Pedersen B, Larsen SO, Arends J, Svenstrup B, Tabor A. Maternal serum markers in screening for Down syndrome. *Clinical Genetics* 1990;**37**(1):35–43.

Norton 1992 ***{published data only}***
Norton ME, Golbus MS. Maternal serum CA 125 for aneuploidy detection in early pregnancy. *Prenatal Diagnosis* 1992;**12**(9):779–81.

O'Brien 1997a ***{published data only}***
Brien JE, Dvorin E, Yaron Y, Ayoub M, Johnson MP, Hume RF Jr, et al. Differential increases in AFP, hCG, and uE3 in twin pregnancies: Impact on attempts to quantify Down syndrome screening calculations. *American Journal of Medical Genetics* 1997;**73**(2):109–12.

O'Brien 1997b ***{published data only}***
Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-ethnicity-specific variation in multiple-

marker biochemical screening: Alpha-fetoprotein, hCG, and estriol. *Obstetrics and Gynecology* 1997;**89**(3):355–8.

Odibo 2004 *{published data only}*
Odibo AO, Sehdev HM, Dunn L, McDonald R, Macones GA. The association between fetal nasal bone hypoplasia and aneuploidy. *Obstetrics & Gynecology* 2004;**104**(6): 1229–33.

Ognibene 1999 *{published data only}*
Ognibene A, Ciuti R, Tozzi P, Messeri G. Maternal serum superoxide dismutase (SOD): a possible marker for screening Down syndrome affected pregnancies.[see comment]. *Prenatal Diagnosis* 1999;**19**(11):1058–60.

Olajide 1989 *{published data only}*
Olajide F, Kitau MJ, Chard T. Maternal serum AFP levels in the first trimester of pregnancy. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 1989;**30**(2): 123–8.

Onda 1996 *{published data only}*
Onda T, Kitagawa M, Takeda O, Sago H, Kubonoya K, Iinuma K, et al. Triple marker screening in native Japanese women. *Prenatal Diagnosis* 1996;**16**(8):713–7.

Onda 1998 *{published data only}*
Onda T, Tanaka T, Takeda O, Kitagawa M, Kuwabara Y, Yamamoto H, et al. Agreement between predicted risk and prevalence of Down syndrome in second-trimester triple-marker screening in Japan. *Prenatal Diagnosis* 1998;**18**(9): 956–8.

Onda 2000 *{published data only}*
Onda T, Tanaka T, Yoshida K, Nakamura Y, Kudo R, Yamamoto H, et al. Triple marker screening for trisomy 21, trisomy 18 and open neural tube defects in singleton pregnancies of native Japanese pregnant women. *Journal of Obstetrics & Gynaecology Research* 2000;**26**(6):441–7.

Orlandi 2002 *{published data only}*
Orlandi F, Rossi C, Allegra A, Krantz D, Hallahan T, Orlandi E, et al. First trimester screening with free ß-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. *Prenatal Diagnosis* 2002;**22**(8): 718–21.

Páez 2004 *{published data only}*
Páez L, Peña E, González F, Bello F, Bellorín J, Espinoza F, et al. Plasma protein "A" and chorionic gonadotropin at first trimester pregnancy. *Informe Medico* 2004;**6**(2):99–109.

Palka 1998 *{published data only}*
Palka G, Guanciali Franchi P, Papponetti M, Marcuccitti J, Morizio E, Calabrese G, et al. Prenatal diagnosis using the triple test. *Minerva Ginecologica* 1998;**50**(10):411–5.

Palomaki 1989 *{published data only}*
Palomaki GE, Williams J, Haddow JE. Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. *American Journal of Obstetrics and Gynecology* 1989;**160**(3): 575–81.

Palomaki 1993 *{published data only}*
Palomaki GE, Knight GJ, Haddow JE, Canick JA, Wald NJ, Kennard A. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening. *Obstetrics and Gynecology* 1993;**81**(5):675–8.

Palomaki 1994 *{published data only}*
Palomaki GE, Knight GJ, Haddow JE. Human chorionic gonadotropin and unconjugated oestriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome. *Prenatal Diagnosis* 1994;**14**(1): 65–8.

Palomaki 1996 *{published data only}*
Palomaki GE, Neveux LM, Haddow JE. Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials?. *Journal of Medical Screening* 1996;**3**(1):12–7.

Palomaki 2005 *{published data only}*
Palomaki GE, Knight GJ, Neveux LM, Pandian R, Haddow JE. Maternal serum invasive trophoblast antigen and first-trimester Down syndrome screening. *Clinical Chemistry* 2005;**51**(8):1499–504.

Panburana 2001 *{published data only}*
Panburana P, Ajjimakorn S, Tungkajiwangoon P. First trimester Down Syndrome screening by nuchal translucency in a Thai population. *International Journal of Gynaecology & Obstetrics* 2001;**75**(3):311–2.

Pandya 1994 *{published data only}*
Pandya PP, Brizot ML, Kuhn P, Snijders RJ, Nicolaides KH. First-trimester fetal nuchal translucency thickness and risk for trisomies. *Obstetrics & Gynecology* 1994;**84**(3):420–3.

Pandya 1995 *{published data only}*
Pandya PP, Santiago C, Snijders RJM, Nicolaides KH. First trimester fetal nuchal translucency. *Current Opinion in Obstetrics and Gynecology* 1995;**7**(2):95–102.

Paul 2001 *{published data only}*
Paul C, Krampl E, Skentou C, Jurkovic D, Nicolaides KH. Measurement of fetal nuchal translucency thickness by three-dimensional ultrasound. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(5):481–4.

Peralta 2005 *{published data only}*
Peralta CF, Falcon O, Wegrzyn P, Faro C, Nicolaides KH. Assessment of the gap between the fetal nasal bones at 11 to 13 + 6 weeks of gestation by three-dimensional ultrasound. *Ultrasound in Obstetrics & Gynecology* 2005;**25**(5):464–7.

Perenc 1998 *{published data only}*
Perenc M, Dudarewicz L, Kaluzewski B. Analysis of triple test results in 27 cases of twin pregnancies. *Acta Geneticae Medicae et Gemellologiae* 1998;**47**(3-4):249–54.

Perheentupa 2002 *{published data only}*
Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen M, Martikainen H. Maternal serum (ß)-HCG and (alpha)-fetoprotein concentrations in singleton pregnancies following assisted reproduction. *Human Reproduction* 2002; **17**(3):794–7.

Perona 1998 *{published data only}*
Perona M, Mancini G, Dall'Amico D, Guaraldo V, Carbonara A. Influence of smoking habits on Down's

syndrome risk evaluation at mid-trimester through biochemical screening. *International Journal of Clinical & Laboratory Research* 1998;**28**(3):179–82.

Petervari 2000 *{published data only}*
Petervari L, Varga A, Tanko A, Szabo L, Godo G. [Significance of nuchal edema in fetuses of pregnant women under 35 years of age]. [Hungarian]. *Orvosi Hetilap* 2000; **141**(8):399–402.

Petrocik 1989 *{published data only}*
Petrocik E, Wassman ER, Kelly JC. Prenatal screening for Down syndrome with maternal serum human chorionic gonadotropin levels.[see comment]. *American Journal of Obstetrics and Gynecology* 1989;**161**(5):1168–73.

Phillips 1992 *{published data only}*
Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. *Obstetrics & Gynecology* 1992;**80**(3):353–8.

Phillips 1993 *{published data only}*
Phillips OP, Shulman LP, Elias S, Simpson JL. Maternal serum screening for fetal Down syndrome using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated estriol in adolescents. *Adolescent and Pediatric Gynecology* 1993;**6**(2):91–4.

Pinette 2003 *{published data only}*
Pinette MG, Egan JF, Wax JR, Blackstone J, Cartin A, Benn PA. Combined sonographic and biochemical markers for Down syndrome screening. *Journal of Ultrasound in Medicine* 2003;**22**(11):1185–90.

Platt 2004 *{published data only}*
Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz D, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. *Obstetrics and Gynecology* 2004; **104**(4):661–6.

Podobnik 1995 *{published data only}*
Podobnik M, Singer Z, Podobnik-Sarkanji S, Bulic M. First trimester diagnosis of cystic hygromata using transvaginal ultrasound and cytogenetic evaluation. *Journal of Perinatal Medicine* 1995;**23**(4):283–91.

Prefumo 2002 *{published data only}*
Prefumo F, Thilaganathan B. Agreement between predicted risk and prevalence of Down syndrome in first trimester nuchal translucency screening. *Prenatal Diagnosis* 2002;**22** (10):917–8.

Prefumo 2004 *{published data only}*
Prefumo F, Sairam S, Bhide A, Penna L, Hollis B, Thilaganathan B. Maternal ethnic origin and fetal nasal bones at 11-14 weeks of gestation. *BJOG: an international journal of obstetrics & gynaecology* 2004;**111**(2):109–12.

Price 1998 *{published data only}*
Price KM, Van Lith JM, Silman R, Mantingh A, Grudzinskas JG. First trimester maternal serum concentrations of fetal antigen 2 in normal pregnancies and those affected by trisomy 21. *Human Reproduction* 1998;**13**(6):1706–8.

Raty 2000 *{published data only}*
Raty R, Virtanen A, Koskinen P, Laitinen P, Forsstrom J, Salonen R, et al. Maternal midtrimester serum AFP and free ß-hCG levels in in vitro fertilization twin pregnancies. *Prenatal Diagnosis* 2000;**20**(3):221–3.

Räty 2002 *{published data only}*
Räty R, Virtanen A, Koskinen P, Anttila L, Forsström J, Laitinen P, et al. Serum free (ß)-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down's syndrome. *Human Reproduction* 2002;**17**(2):481–4.

Rembouskos 2004 *{published data only}*
Rembouskos G, Cicero S, Longo D, Vandecruys H, Nicolaides KH. Assessment of the fetal nasal bone at 11-14 weeks of gestation by three-dimensional ultrasound. *Ultrasound in Obstetrics & Gynecology* 2004;**23**(3):232–6.

Ren 1992 *{published data only}*
Ren S-G, Braunstein GD. Human chorionic gonadotropin. *Seminars in Reproductive Endocrinology* 1992;**10**(2):95–105.

Renier 1998 *{published data only}*
Renier MA, Vereecken A, Van Herck E, Straetmans D, Ramaekers P, Buytaert P. Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down's syndrome. *Human Reproduction* 1998;**13**(3):744–8.

Resta 1990 *{published data only}*
Resta RG, Nyberg D. The role of ultrasound in screening for Down syndrome. *Birth Defects: Original Article Series* 1990;**26**(3):104.

Reynders 1997 *{published data only}*
Reynders CS, Pauker SP, Benacerraf BR. First trimester isolated fetal nuchal lucency: significance and outcome. *Journal of Ultrasound in Medicine* 1997;**16**(2):101–5.

Reynolds 1989 *{published data only}*
Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. *Annals of Clinical Biochemistry* 1989;**27**(5):452–8.

Reynolds 1999 *{published data only}*
Reynolds TM, Schaeffer HJ, Schlensker S. Estimation of Down's syndrome risks in the first trimester of pregnancy: experience of testing with PAPP-A, total hCG and free ß- hCG levels in maternal blood samples in a German population. *Clinical Laboratory* 1999;**45**(1-2):49–53.

Ribbert 1996 *{published data only}*
Ribbert LS, Kornman LH, de Wolf BT, Simons AH, Jansen CA, Beekhuis JR, et al. Maternal serum screening for fetal Down syndrome in IVF pregnancies. *Prenatal Diagnosis* 1996;**16**(1):35–8.

Rice 2005 *{published data only}*
Rice JD, McIntosh SF, Halstead AC. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies. *Prenatal Diagnosis* 2005;**25**(3): 234–8.

Rich 1991 *{published data only}*
Rich N, Boots L, Davis R, Finley S. Efficiency of maternal serum hCG AFP and free estriol in the identification of trisomy 21 and other complications of pregnancy. *Journal of the Alabama Academy of Science* 1991;**62**(2-3):135.

Roberts 1995 *{published data only}*
Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First trimester fetal nuchal translucency: problems with screening the general population. 1. *British Journal of Obstetrics and Gynaecology* 1995;**102**(5):381–5.

Robertson 1991 *{published data only}*
Robertson EF. Maternal serum screening for neural tube defects and Down's syndrome.[see comment]. *Medical Journal of Australia* 1991;**155**(2):67–8.

Rode 2003 *{published data only}*
Rode L, Wojdemann KR, Shalmi AC, Larsen SO, Sundberg K, Norgaard-Pedersen B, et al. Combined first- and second-trimester screening for Down syndrome: an evaluation of proMBP as a marker. *Prenatal Diagnosis* 2003;**23**(7):593–8.

Ronge 2006 *{published data only}*
Ronge R. Combined first trimester screening for Down's syndrome is superior to quadruple test. *Geburtshilfe und Frauenheilkunde* 2006;**66**(4):332.

Rose 1995 *{published data only}*
Rose NC, Mennuti MT. Multiple marker screening for women 35 and older. *Contemporary OB/GYN* 1995;**40**(9): 55–6.

Ross 1997 *{published data only}*
Ross HL, Elias S. Maternal serum screening for fetal genetic disorders. *Obstetrics & Gynecology Clinics of North America* 1997;**24**(1):33–47.

Rotmensch 1996 *{published data only}*
Rotmensch S, Liberati M, Kardana A, Copel JA, Ben-Rafael Z, Cole LA. Nicked free ß-subunit of human chorionic gonadotropin: a potential new marker for Down syndrome screening. *American Journal of Obstetrics and Gynecology* 1996;**174**(2):609–11.

Rotmensch 1999 *{published data only}*
Rotmensch S, Celentano C, Shalev J, Vishne TH, Lipitz S, Ben-Rafael Z, et al. Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. *Journal of Assisted Reproduction and Genetics* 1999;**16**(1):8–12.

Rozenberg 2006 *{published data only}*
Rozenberg P, Bussieres L, Chevret S, Bernard JP, Malagrida L, Cuckle H, et al. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. *American Journal of Obstetrics and Gynecology* 2006;**195**(5):1379–87.

Rudnicka 2002 *{published data only}*
Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. *Prenatal Diagnosis* 2002;**22**(10):893–7.

Ryall 1992 *{published data only}*
Ryall RG, Staples AJ, Robertson EF, Pollard AC. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses. *Prenatal Diagnosis* 1992;**12**(4):251–61.

Ryall 2001 *{published data only}*
Ryall RG, Callen D, Cocciolone R, Duvnjak A, Esca R, Frantzis N, et al. Karyotypes found in the population declared at increased risk of Down syndrome following maternal serum screening. *Prenatal Diagnosis* 2001;**21**(7): 553–7.

Sabriá 2002 *{published data only}*
Sabriá J, Cabrero D, Bach C. Aneuploidy screening: ultrasound versus biochemistry. *Ultrasound Review of Obstetrics and Gynecology* 2002;**2**(4):221–8.

Sacchini 2003 *{published data only}*
Sacchini C, El-Sheikhah A, Cicero S, Rembouskos G, Nicolaides KH. Ear length in trisomy 21 fetuses at 11-14 weeks of gestation. *Ultrasound in Obstetrics & Gynecology* 2003;**22**(5):460–3.

Saller 1997 *{published data only}*
Saller DN Jr, Canick JA, Kellner LH, Rose NC, Garza J, French CA, et al. Maternal serum analyte levels in pregnancies with fetal Down syndrome resulting from translocations. *American Journal of Obstetrics and Gynecology* 1997;**177**(4):879–81.

Salomon 2001 *{published data only}*
Salomon LJ, Bernard JP, Taupin P, Benard C, Ville Y. Relationship between nuchal translucency at 11-14 weeks and nuchal fold at 20-24 weeks of gestation. *Ultrasound in Obstetrics & Gynecology* 2001;**18**(6):636–7.

Salonen 1997 *{published data only}*
Salonen R, Turpeinen U, Kurki L, Lappalainen M, Ammala P, Hiilesmaa V, et al. Maternal serum screening for Down's syndrome on population basis. *Acta Obstetricia et Gynecologica Scandinavica* 1997;**76**(9):817–21.

Saltvedt 2005 *{published data only}*
Saltvedt S, Almstrom H, Kublickas M, Valentin L, Bottinga R, Bui TH, et al. Screening for Down syndrome based on maternal age or fetal nuchal translucency: a randomized controlled trial in 39,572 pregnancies. *Ultrasound in Obstetrics & Gynecology* 2005;**25**(6):537–45.

Saridogan 1996 *{published data only}*
Saridogan E, Djahanbakhch O, Naftalin AA. Screening for Down's syndrome: experience in an inner city health district. *British Journal of Obstetrics and Gynaecology* 1996; **103**(12):1205–11.

Savoldelli 1993 *{published data only}*
Savoldelli G, Binkert F, Achermann J, Schmid W. Ultrasound screening for chromosomal anomalies in the first trimester of pregnancy. *Prenatal Diagnosis* 1993;**13**(6): 513–8.

Schiott 2006 *{published data only}*
Schiott KM, Christiansen M, Petersen OB, Sorensen TL, Uldbjerg N. The "Consecutive Combined Test"--using

double test from week 8 + 0 and nuchal translucency scan, for first trimester screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(12):1105–9.

Schuchter 1998 ***{published data only}***
Schuchter K, Wald N, Hackshaw AK, Hafner E, Liebhart E. The distribution of nuchal translucency at 10-13 weeks of pregnancy. *Prenatal Diagnosis* 1998;**18**(3):281–6.

Scott 1995 ***{published data only}***
Scott F, Boogert A, Smart S, Anderson J. Maternal serum screening and routine 18-week ultrasound in the detection of all chromosomal abnormalities. *Australian & New Zealand Journal of Obstetrics & Gynaecology* 1995;**35**(2): 165–8.

Seeds 1990 ***{published data only}***
Seeds JW, Watson WJ. Ultrasound and maternal serum alpha-fetoprotein screening: a complementary relationship. *Ultrasound Quarterly* 1990;**8**(2):145–66.

Seki 1995 ***{published data only}***
Seki K, Mitsui C, Nagata I. Measurement of urinary free ß-human chorionic gonadotropin by immunoradiometric assay. *Gynecologic and Obstetric Investigation* 1995;**40**(3): 162–7.

Shenhav 2003 ***{published data only}***
Shenhav S, Gemer O, Sherman DJ, Peled R, Segal S. Midtrimester triple-test levels in women with chronic hypertension and altered renal function. *Prenatal Diagnosis* 2003;**23**(2):166–7.

Shintaku 1989 ***{published data only}***
Shintaku Y, Takabayashi T, Sasaki H, Ozawa N, Shinkawa O, Hamazaki Y, et al. [Screening for chromosomal anomalies with maternal serum alpha-fetoprotein]. [Japanese]. *Nippon Sanka Fujinka Gakkai Zasshi - Acta Obstetrica et Gynaecologica Japonica* 1989;**41**(2):185–90.

Shulman 2003 ***{published data only}***
Shulman A, Maymon R. Mid-gestation Down syndrome screening test and pregnancy outcome among unstimulated assisted-conception pregnancies. *Prenatal Diagnosis* 2003; **23**(8):625–8.

Simon-Bouy 1999 ***{published data only}***
Simon-Bouy B. [Markers for trisomy 21][French]. *Fertilite Contraception Sexualite* 1999;**27**(9):289–91.

Simpson 1986 ***{published data only}***
Simpson JL, Baum LD, Marder R, Elias S, Ober C, Martin AO. Maternal serum alpha-fetoprotein screening: low and high values for detection of genetic abnormalities. *American Journal of Obstetrics and Gynecology* 1986;**155**(3):593–7.

Smith 1990 ***{published data only}***
Smith C, Grube GL, Wilson S. Maternal serum alpha-fetoprotein screening and the role of ultrasound. *Journal of Diagnostic Medical Sonography* 1990;**6**(6):312–6.

Smith 1996 ***{published data only}***
Smith ER, Petersen J, Okorodudu AO, Bissell MG. Does the addition of unconjugated estriol in maternal serum screening improve the detection of trisomy 21? A meta-analysis. *Clinical Laboratory Management Review* 1996;**10** (2):176–81.

Smith 1999 ***{published data only}***
Smith NC, Hau C. A six year study of the antenatal detection of fetal abnormality in six Scottish health boards. *British Journal of Obstetrics and Gynaecology* 1999;**106**(3): 206–12.

Smith-Bindman 2001 ***{published data only}***
Smith-Bindman R, Hosmer W, Feldstein VA, Deeks JJ, Goldberg JD. Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis.[see comment]. *JAMA* 2001;**285**(8):1044–55.

Smith-Bindman 2003 ***{published data only}***
Smith-Bindman R, Chu P, Bacchetti P, Waters JJ, Mutton D, Alberman E. Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes. *American Journal of Obstetrics and Gynecology* 2003;**187**(4): 980–5.

Snijders 1995 ***{published data only}***
Snijders RJM, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risk for chromosomal defects. *Fetal Diagnosis and Therapy* 1995;**10**(6):356–67.

Snijders 1999 ***{published data only}***
Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. *Ultrasound in Obstetrics & Gynecology* 1999;**13** (3):167–70.

Soergel 2006 ***{published data only}***
Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany. *Fetal Diagnosis and Therapy* 2006;**21**(3):264–8.

Sokol 1998 ***{published data only}***
Sokol AI, Kramer RL, Yaron Y, O'Brien JE, Muller F, Johnson MP, et al. Age-specific variation in aneuploidy incidence among biochemical screening programs. *American Journal of Obstetrics and Gynecology* 1998;**179**(4):971–3.

Sonek 2003 ***{published data only}***
Sonek JD. Nasal bone evaluation with ultrasonography: a marker for fetal aneuploidy. *Ultrasound in Obstetrics & Gynecology* 2003;**22**(1):11–5.

Spencer 1985 ***{published data only}***
Spencer K, Carpenter P. Screening for Down's syndrome using serum alpha fetoprotein: a retrospective study indicating caution. *BMJ (Clinical Research Ed.)* 1985;**290** (6486):1940–3.

Spencer 1991a ***{published data only}***
Spencer K. Evaluation of an assay of the free ß-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. *Clinical Chemistry* 1991;**37**(6):809–14.

Spencer 1991b ***{published data only}***
Spencer K. Maternal serum CA125 is not a second trimester marker for Down's syndrome. *Annals of Clinical Biochemistry* 1991;**28**(3):299–300.

Spencer 1992 *{published data only}*
Spencer K, Coombes EJ, Mallard AS, Ward AM. Free ß human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers.[see comment]. *Annals of Clinical Biochemistry* 1992;**29**(5):506–18.

Spencer 1993a *{published data only}*
Spencer K, Carpenter P. Prospective study of prenatal screening for Down's syndrome with free ß human chorionic gonadotrophin.[see comment]. *BMJ* 1993;**307**(6907): 764–9.

Spencer 1993b *{published data only}*
Spencer K, Macri JN, Carpenter P, Anderson R, Krantz DA. Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free ß-hCG subunit. *Clinical Chemistry* 1993;**39**(6):1064–8.

Spencer 1993c *{published data only}*
Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. *Annals of Clinical Biochemistry* 1993;**30**(Pt 2):219–20.

Spencer 1993d *{published data only}*
Spencer K, Macri JN, Anderson RW, Aitken DA, Berry E, Crossley JA, et al. Dual analyte immunoassay in neural tube defect and Down's syndrome screening: results of a multicentre clinical trial. *Annals of Clinical Biochemistry* 1993;**30**(4):394–401.

Spencer 1993e *{published data only}*
Spencer K. Free alpha-subunit of human chorionic gonadotropin in Down syndrome. *American Journal of Obstetrics and Gynecology* 1993;**168**(1):132–5.

Spencer 1995 *{published data only}*
Spencer K. The influence of gravidity on Down's syndrome screening with free ß hCG. *Prenatal Diagnosis* 1995;**15**(1): 87–9.

Spencer 1996a *{published data only}*
Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric inhibin-A in Down's syndrome screening. *Prenatal Diagnosis* 1996;**16**(12):1101–10.

Spencer 1997 *{published data only}*
Spencer K, Noble P, Snijders RJ, Nicolaides KH. First-trimester urine free ß hCG, ß core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free ß hCG. *Prenatal Diagnosis* 1997;**17**(6):525–38.

Spencer 1998a *{published data only}*
Spencer K. The influence of smoking on maternal serum AFP and free ß hCG levels and the impact on screening for Down syndrome. *Prenatal Diagnosis* 1998;**18**(3):225–34.

Spencer 1998b *{published data only}*
Spencer K, Carpenter P. Is prostate-specific antigen a marker for pregnancies affected by Down syndrome?. *Clinical Chemistry* 1998;**44**(11):2362–5.

Spencer 1999a *{published data only}*
Spencer K. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free ß hCG: a seven year review. *British Journal of Obstetrics and Gynaecology* 1999;**106**(12):1287–93.

Spencer 1999b *{published data only}*
Spencer K. Accuracy of Down's syndrome risks produced in a prenatal screening program. *Annals of Clinical Biochemistry* 1999;**36**(1):101–3.

Spencer 2000a *{published data only}*
Spencer K, Berry E, Crossley JA, Aitken DA, Nicolaides KH. Is maternal serum total hCG a marker of trisomy 21 in the first trimester of pregnancy?. *Prenatal Diagnosis* 2000; **20**(4):311–7.

Spencer 2000b *{published data only}*
Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free ß-hCG and PAPP-A, combined with fetal nuchal translucency thickness. *Prenatal Diagnosis* 2000;**20**(2):91–5.

Spencer 2000c *{published data only}*
Spencer K. The influence of smoking on maternal serum PAPP-A and free ß hCG levels in the first trimester of pregnancy. *Prenatal Diagnosis* 1999;**19**(11):1065–6.

Spencer 2000d *{published data only}*
Spencer K, Ong CY, Liao AW, Nicolaides KH. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. *Prenatal Diagnosis* 2000;**20** (10):792–4.

Spencer 2000e *{published data only}*
Spencer K. The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free ß-hCG. *Prenatal Diagnosis* 2000;**20**(8):648–51.

Spencer 2000f *{published data only}*
Spencer K, Ong CY, Liao AW, Nicolaides KH. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. *Prenatal Diagnosis* 2000;**20**(6):491–4.

Spencer 2000g *{published data only}*
Spencer K, Tul N, Nicolaides KH. Maternal serum free ß-hCG and PAPP-A in fetal sex chromosome defects in the first trimester. *Prenatal Diagnosis* 2000;**20**(5):390–4.

Spencer 2000h *{published data only}*
Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. *Prenatal Diagnosis* 2000;**20**(8):652–6.

Spencer 2000i *{published data only}*
Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free ß-hCG and PAPP-A at 10-14 weeks of gestation. *Prenatal Diagnosis* 2000;**20**(8):673–5.

Spencer 2001 *{published data only}*
Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester

using fetal nuchal translucency and maternal serum free ßhCG and PAPP-A. *BJOG: an international journal of obstetrics and gynaecology* 2001;**108**(10):1043–6.

Spencer 2001a ***{published data only}***
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. First trimester maternal serum placenta growth factor (PIGF) concentrations in pregnancies with fetal trisomy 21 or trisomy 18. *Prenatal Diagnosis* 2001;**21**(9):718–22.

Spencer 2001b ***{published data only}***
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. Maternal serum levels of dimeric Inhibin A in pregnancies affected by trisomy 21 in the first trimester. *Prenatal Diagnosis* 2001;**21**(6):441–4.

Spencer 2001c ***{published data only}***
Spencer K, Liao AW, Skentou H, Ong CY, Nicolaides KH. Maternal serum levels of total activin-A in first-trimester trisomy 21 pregnancies. *Prenatal Diagnosis* 2001;**21**(4): 270–3.

Spencer 2001d ***{published data only}***
Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free ß-hCG or PAPP-A levels?. *Prenatal Diagnosis* 2001;**21**(9):715–7.

Spencer 2002a ***{published data only}***
Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free ß-hCG and PAPP-A. *Prenatal Diagnosis* 2002;**22**(10):877–9.

Spencer 2002b ***{published data only}***
Spencer K. Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry. *Prenatal Diagnosis* 2002;**22**(3):244–6.

Spencer 2002c ***{published data only}***
Spencer K, Cuckle HS. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates?. *Prenatal Diagnosis* 2002; **22**(10):903–6.

Spencer 2002d ***{published data only}***
Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. *Annals of Clinical Biochemistry* 2002;**39**(6):567–76.

Spencer 2003a ***{published data only}***
Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome. *Annals of Clinical Biochemistry* 2003;**40**(3):219–31.

Spencer 2003b ***{published data only}***
Spencer K. The influence of different sample collection types on the levels of markers used for Down's syndrome screening as measured by the Kryptor Immunosassay system. *Annals of Clinical Biochemistry* 2003;**40**(2):166–8.

Spencer 2003c ***{published data only}***
Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free ß-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. *Prenatal Diagnosis* 2003;**23**(10):851–5.

Spencer 2003d ***{published data only}***
Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. *BJOG: an international journal of obstetrics and gynaecology* 2003;**110**(3):279–80.

Spencer 2004 ***{published data only}***
Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. *Prenatal Diagnosis* 2004;**24**(3):169–73.

Spencer 2005a ***{published data only}***
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. *Prenatal Diagnosis* 2005;**25**(10):927–9.

Spencer 2005b ***{published data only}***
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. *Prenatal Diagnosis* 2005;**25**(5): 365–9.

Spencer 2005c ***{published data only}***
Spencer K. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free ß-hCG and pregnancy-associated plasma protein-A assays.[see comment]. *Annals of Clinical Biochemistry* 2005;**42**(1):30–40.

Spong 1999 ***{published data only}***
Spong CY, Ghidini A, Stanley-Christian H, Meck JM, Seydel FD, Pezzullo JC. Risk of abnormal triple screen for Down syndrome is significantly higher in women with female fetuses. *Prenatal Diagnosis* 1999;**19**(4):337–9.

Stevens 1998 ***{published data only}***
Stevens SL. The use of nuchal lucency as a screening tool in first trimester sonography. *Journal of Diagnostic Medical Sonography* 1998;**14**(6):251–4.

Stoll 1992 ***{published data only}***
Stoll C. A new approach of prenatal prevention of constitutional disabilities - the study of markers of maternal serum. *Journal de Medecine de Strasbourg* 1992;**23**(1):25–7.

Su 2002a ***{published data only}***
Su YN, Hsu JJ, Lee CN, Cheng WF, Kung CC, Hsieh FJ. Raised maternal serum placenta growth factor concentration

during the second trimester is associated with Down syndrome. *Prenatal Diagnosis* 2002;**22**(1):8–12.

Suchet 1995 ***{published data only}***
Suchet IB. Ultrasonography of the fetal neck in the first and second trimesters. Part 2. Anomalies of the posterior nuchal region. *Canadian Association of Radiologists Journal* 1995;**46**(5):344–52.

Suchy 1990 ***{published data only}***
Suchy SF, Yeager MT. Down syndrome screening in women under 35 with maternal serum hCG. *Obstetrics & Gynecology* 1990;**76**(1):20–4.

Summers 2003a ***{published data only}***
Summers AM, Farrell SA, Huang T, Meier C, Wyatt PR. Maternal serum screening in Ontario using the triple marker test. *Journal of Medical Screening* 2003;**10**(3):107–11.

Summers 2003b ***{published data only}***
Summers AM, Huang T, Meier C, Wyatt PR. The implications of a false positive second-trimester serum screen for Down syndrome. *Obstetrics & Gynecology* 2003; **101**(6):1301–6.

Suntharasaj 2005 ***{published data only}***
Suntharasaj T, Ratanasiri T, Chanprapaph P, Kengpol C, Kor-anantakul O, Leetanaporn R, et al. Variability of nuchal translucency measurement: a multicenter study in Thailand. *Gynecologic & Obstetric Investigation* 2005;**60**(4): 201–5.

Sutton 2004 ***{published data only}***
Sutton JM, Cole LA. Sialic acid-deficient invasive trophoblast antigen (sd-ITA): a new urinary variant for gestational Down syndrome screening. *Prenatal Diagnosis* 2004;**24**(3):194–7.

Suzuki 1998 ***{published data only}***
Suzuki Y, Takada J, Iwaki T, Isaka K, Takayama M. Screening for trisomy 21 in the first trimester by measurement of serum PAPP-A and free ß-hCG. *Acta Obstetrica et Gynaecologica Japonica* 1998;**50**(1):37–40.

Tabor 1987 ***{published data only}***
Tabor A, Larsen SO, Nielsen J, Nielsen J, Philip J, Pilgaard B, et al. Screening for Down's syndrome using an iso-risk curve based on maternal age and serum alpha-fetoprotein level. *British Journal of Obstetrics and Gynaecology* 1987;**94** (7):636–42.

Tanski 1999 ***{published data only}***
Tanski S, Rosengren SS, Benn PA. Predictive value of the triple screening test for the phenotype of Down syndrome. *American Journal of Medical Genetics* 1999;**85**(2):123–6.

Thilaganathan 1998 ***{published data only}***
Thilaganathan B, Khare M, Williams B, Wathen NC. Influence of ethnic origin on nuchal translucency screening for Down's syndrome. *Ultrasound in Obstetrics & Gynecology* 1998;**12**(2):112–4.

Thilaganathan 1999 ***{published data only}***
Thilaganathan B. First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: a happy union?. *Ultrasound in Obstetrics & Gynecology* 1999;**13**(4):229–30.

Tislaric 2002 ***{published data only}***
Tislaric D, Brajenovic-Milic B, Ristic S, Latin V, Zuvic-Butorac M, Bacic J, et al. The influence of smoking and parity on serum markers for Down's syndrome screening. *Fetal Diagnosis and Therapy* 2002;**17**(1):17–21.

Torok 1997 ***{published data only}***
Torok O, Veress L, Szabo M, Zsupan I, Buczko Z, Bolodar A, et al. [Biochemical and ultrasonic screening of chromosomal aneuploidies in the second trimester of pregnancy]. [Hungarian]. *Orvosi Hetilap* 1997;**138**(3): 123–7.

Tsai 2001 ***{published data only}***
Tsai MS, Huang YY, Hwa KY, Cheng CC, Lee FK. Combined measurement of fetal nuchal translucency, maternal serum free ß-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. *Journal of the Formosan Medical Association* 2001; **100**(5):319–25.

Valerio 1996 ***{published data only}***
Valerio D, Aiello R, Altieri V, Fagnoni P. Maternal serum screening of fetal chromosomal abnormalities by AFP, UE3, hCG and free-ß hCG. Prospective and retrospective results. *Minerva Ginecologica* 1996;**48**(5):169–73.

Van Blerk 1992 ***{published data only}***
Van Blerk M, Smitz J, De Catte L, Kumps C, Van der Elst J, Van Steirteghem AC. Second-trimester cancer antigen 125 and Down's syndrome.[see comment]. *Prenatal Diagnosis* 1992;**12**(12):1062–6.

Van Heesch, 2006 ***{published data only}***
Van Heesch PN, Schielen PC, Wildhagen MF, Den Hollander K, Steegers EA, Wildschut HI. Combined first trimester screening for trisomy 21: lack of agreement between risk calculation methods. *Journal of Perinatal Medicine* 2006;**34**(2):162–5.

Van Lith 1991 ***{published data only}***
Van Lith JM, Mantingh A, Beekhuis JR, De Bruijn HW, Breed AS. First trimester CA 125 and Down's syndrome. *British Journal of Obstetrics and Gynaecology* 1991;**98**(5): 493–4.

Van Lith 1993 ***{published data only}***
Van Lith JM, Mantingh A, De Bruijn HW. Maternal serum CA 125 levels in pregnancies with chromosomally-normal and -abnormal fetuses. Dutch Working Party on Prenatal Diagnosis. *Prenatal Diagnosis* 1993;**13**(12):1123–31.

Van Lith 1994 ***{published data only}***
Van Lith JM, Mantingh A, Pratt JJ. First-trimester maternal serum immunoreactive inhibin in chromosomally normal and abnormal pregnancies. Dutch Working Party on Prenatal Diagnosis. *Obstetrics and Gynecology* 1994;**83**(5 Pt 1):661–4.

Veress 1986 ***{published data only}***
Veress L, Szabo M, Horvath K, Polgar K, Papp Z. [Low maternal serum alpha-fetoprotein concentration and Down

syndrome]. [Hungarian]. *Orvosi Hetilap* 1986;**127**(20): 1232–3.

Veress 1988 ***{published data only}***
Veress L, Szabo M, Polgar K, Takacs L, Papp Z. [Prenatal screening for Down's syndrome by measuring the AFP concentration in the maternal serum]. [Hungarian]. *Orvosi Hetilap* 1988;**129**(31):1677.

Vintzileos 2003 ***{published data only}***
Vintzileos A, Walters C, Yeo L. Absent nasal bone in the prenatal detection of fetuses with trisomy 21 in a high-risk population. *Obstetrics & Gynecology* 2003;**101**(5):905–8.

Wald 1988a ***{published data only}***
Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. *BMJ* 1988;**297**(6653):883–7.

Wald 1988b ***{published data only}***
Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. *British Journal of Obstetrics and Gynaecology* 1988;**95**(4): 334–41.

Wald 1991 ***{published data only}***
Wald N, Cuckle H, Wu TS, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. *British Journal of Obstetrics and Gynaecology* 1991;**98**(9):905–8.

Wald 1992a ***{published data only}***
Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.[see comment]. *BMJ* 1992;**305**(6850):391–4.

Wald 1992b ***{published data only}***
Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. *British Journal of Obstetrics and Gynaecology* 1992;**99**(1): 51–3.

Wald 1992c ***{published data only}***
Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight.[see comment]. *British Journal of Obstetrics and Gynaecology* 1992;**99**(2):144–9.

Wald 1993 ***{published data only}***
Wald N, Densem J, Stone R, Cheng R. The use of free ß-hCG in antenatal screening for Down's syndrome.[see comment]. *British Journal of Obstetrics and Gynaecology* 1993;**100**(6):550–7.

Wald 1994a ***{published data only}***
Wald NJ, Densem JW. Maternal serum free alpha-human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. *Prenatal Diagnosis* 1994;**14**(8):717–9.

Wald 1994b ***{published data only}***
Wald NJ, Watt HC. Choice of serum markers in antenatal screening for Down's syndrome. *Journal of Medical Screening* 1994;**1**(2):117–20.

Wald 1996a ***{published data only}***
Wald NJ, Watt HC. Serum markers for Down's syndrome in relation to number of previous births and maternal age. *Prenatal Diagnosis* 1996;**16**(8):699–703.

Wald 1996b ***{published data only}***
Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group.[see comment]. *British Journal of Obstetrics and Gynaecology.* 1996;**103**(5):407–12.

Wald 1996d ***{published data only}***
Wald NJ, Watt HC, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(10):923–6.

Wald 1996e ***{published data only}***
Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. *Prenatal Diagnosis* 1996;**16**(2): 143–53.

Wald 1997 ***{published data only}***
Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.[see comment]. *Prenatal Diagnosis* 1997;**17**(9): 821–9.

Wald 1998 ***{published data only}***
Wald NJ, Watt HC, Haddow JE, Knight GJ. Screening for Down syndrome at 14 weeks of pregnancy. *Prenatal Diagnosis* 1998;**18**(3):291–3.

Wald 1999a ***{published data only}***
Wald NJ, Hackshaw AK, Diamandis EP, Melegos DN. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. *Prenatal Diagnosis* 1999;**19**(7):674–6.

Wald 1999b ***{published data only}***
Wald NJ, Watt HC, Norgaard-Pederson B, Christiansen M. SP1 in pregnancies with Down syndrome in the first trimester of pregnancy. *Prenatal Diagnosis* 1999;**19**(6): 517–20.

Wald 1999c ***{published data only}***
Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. *British Journal of Obstetrics and Gynaecology* 1999;**106**(12):1304–6.

Wald 1999d ***{published data only}***
Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters.[see comment]. *New England Journal of Medicine* 1999;**341**(7):461–7.

Wald 2003b *{published data only}*
Wald NJ, Rish S, Hackshaw AK. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. *Prenatal Diagnosis* 2003;**23**(7):588–92.

Wald 2003c *{published data only}*
Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test.[see comment]. *Lancet* 2003;**361**(9360):835–6.

Wald 2006 *{published data only}*
Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(9):769–77.

Wallace 1994 *{published data only}*
Wallace EM, Harkness LM, Burns S, Liston WA. Evaluation of maternal serum immunoreactive inhibin as a first trimester marker of Down's syndrome. *Clinical Endocrinology* 1994;**41**(4):483–6.

Wallace 1997 *{published data only}*
Wallace EM, Crossley JA, Ritoe SC, Groome NP, Aitken DA. Maternal serum inhibin-A in pregnancies complicated by insulin dependent diabetes mellitus. *British Journal of Obstetrics and Gynaecology* 1997;**104**(8):946–8.

Ward 2005 *{published data only}*
Ward A. Nuchal translucency measurement. Synergy (http://www.highbeam.com/doc/1P3-866108421.html) (accessed 2007) 2005.

Watt 1996a *{published data only}*
Watt HC, Wald NJ, Smith D, Kennard A, Densem J. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(8):691–8.

Watt 1996b *{published data only}*
Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome. *Prenatal Diagnosis* 1996;**16**(10):927–9.

Weinans 2001 *{published data only}*
Weinans MJN, Pratt JJ, de Wolf HM, Mantingh A. First-trimester maternal serum human thyroid-stimulating hormone in chromosomally normal and Down syndrome pregnancies. *Prenatal Diagnosis* 2001;**21**(9):723–5.

Weinans 2004 *{published data only}*
Weinans MJN, Kooij L, Müller MA, Bilardo KM, Van Lith JMM, Tymstra T. A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study. *Prenatal Diagnosis* 2004;**24**(5):347–51.

Welborn 1994 *{published data only}*
Welborn JL, Timm NS. Trisomy 21 and cystic hygromas in early gestational age fetuses. *American Journal of Perinatology* 1994;**11**(1):19–20.

Wenstrom 1993 *{published data only}*
Wenstrom KD, Williamson RA, Grant SS, Hudson JD, Getchell JP. Evaluation of multiple-marker screening for Down syndrome in a statewide population. *American Journal of Obstetrics and Gynecology* 1993;**169**(4):793–7.

Wenstrom 1995a *{published data only}*
Wenstrom KD, Owen J, Boots L, Ethier M. The influence of maternal weight on human chorionic gonadotropin in the multiple-marker screening test for fetal Down syndrome. *American Journal of Obstetrics and Gynecology* 1995;**173**(4):1297–300.

Wenstrom 1995b *{published data only}*
Wenstrom KD, Desai R, Owen J, Dubard MB, Boots L. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women greater than or equal 35 years old. *American Journal of Obstetrics and Gynecology* 1995;**173**(4):1287–92.

Whitlow 1998a *{published data only}*
Whitlow BJ, Lazanakis ML, Kadir RA, Chatzipapas I, Economides DL. The significance of choroid plexus cysts, echogenic heart foci and renal pyelectasis in the first trimester. *Ultrasound in Obstetrics & Gynecology* 1998;**12**(6):385–90.

Whitlow 1998b *{published data only}*
Whitlow BJ, Economides DL. First trimester detection of fetal abnormalities in an unselected population. *Contemporary Reviews in Obstetrics and Gynaecology* 1998;**10**(4):245–53.

Whitlow 1999 *{published data only}*
Whitlow BJ, Chatzipapas IK, Lazanakis ML, Kadir RA, Economides DL. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population. *British Journal of Obstetrics and Gynaecology* 1999;**106**(9):929–36.

Williamson 1994 *{published data only}*
Williamson R. Expanded maternal serum alpha fetoprotein screening. *Iowa Medicine* 1994;**84**(9):397–400.

Wilson 2000 *{published data only}*
Wilson K. New first-trimester prenatal screening for down syndrome. *Laboratory Medicine* 2000;**31**(11):591.

Wojdemann 2001 *{published data only}*
Wojdemann KR, Larsen SO, Shalmi A, Sundberg K, Christiansen M, Tabor A. First trimester screening for Down syndrome and assisted reproduction: no basis for concern. *Prenatal Diagnosis* 2001;**21**(7):563–5.

Wong 2003 *{published data only}*
Wong SF, Choi H, Ho LC. Nasal bone hypoplasia: is it a common finding amongst chromosomally normal fetuses of southern Chinese women?. *Gynecologic & Obstetric Investigation* 2003;**56**(2):99–101.

Wright 2006 *{published data only}*
Wright D, Bradbury I, Cuckle H, Gardosi J, Tonks A, Standing S, et al. Three-stage contingent screening for Down syndrome. *Prenatal Diagnosis* 2006;**26**(6):528–34.

Yagel 1998 *{published data only}*
Yagel S, Anteby EY, Hochner-Celnikier D, Ariel I, Chaap T, Ben Neriah Z. The role of midtrimester targeted fetal organ screening combined with the "triple test" and maternal age in the diagnosis of trisomy 21: a retrospective study.

American Journal of Obstetrics and Gynecology 1998;**178**(1): 40–4.

Yamamoto 2001a ***{published data only}***
Yamamoto R, Azuma M, Kishida T, Yamada H, Satomura S, Fujimoto S. Total alpha-fetoprotein and Lens culinaris agglutinin-reactive alpha-fetoprotein in fetal chromosomal abnormalities. *BJOG: an international journal of obstetrics and gynaecology* 2001;**108**(11):1154–8.

Yamamoto 2001b ***{published data only}***
Yamamoto R, Azuma M, Hoshi N, Kishida T, Satomura S, Fujimoto S. Lens culinaris agglutinin-reactive alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal screening for Down's syndrome. *Human Reproduction* 2001;**16**(11):2438–44.

Yamamoto 2001c ***{published data only}***
Yamamoto R, Azuma M, Wakui Y, Kishida T, Yamada H, Okuyama K, et al. Alpha-fetoprotein microheterogeneity: a potential biochemical marker for Down's syndrome. *Clinica Chimica Acta* 2001;**304**(1-2):137–41.

Yaron 2001 ***{published data only}***
Yaron Y, Wolman I, Kupferminc MJ, Ochshorn Y, Many A, Orr-Urtreger A. Effect of fetal gender on first trimester markers and on Down syndrome screening. *Prenatal Diagnosis* 2001;**21**(12):1027–30.

Ye 1995 ***{published data only}***
Ye G, Liao S, Zhao X. The possibility of prenatal screening for fetal abnormalities in second-trimester pregnancies by measuring AFP, ß-HCG and uE-3 levels. *Xi'an Yike Daxue Xuebao* 1995;**16**(4):408–11.

Yoshida 2000 ***{published data only}***
Yoshida K, Kuwabara Y, Tanaka T, Onda T, Kudo R, Yamamoto H, et al. Dimeric Inhibin A as a fourth marker for Down's syndrome maternal serum screening in native Japanese women. *Journal of Obstetrics and Gynaecology Research* 2000;**26**(3):171–4.

Zeitune 1991 ***{published data only}***
Zeitune M, Aitken DA, Crossley JA, Yates JR, Cooke A, Ferguson-Smith MA. Estimating the risk of a fetal autosomal trisomy at mid-trimester using maternal serum alpha-fetoprotein and age: a retrospective study of 142 pregnancies. *Prenatal Diagnosis* 1991;**11**(11):847–57.

Zelop 2005 ***{published data only}***
Zelop CM, Milewski E, Brault K, Benn P, Borgida AF, Egan JFX. Variation of fetal nasal bone length in second-trimester fetuses according to race and ethnicity. *Journal of Ultrasound in Medicine* 2005;**24**(11):1487–9.

Zhao 1998 ***{published data only}***
Zhao Xiaolan, Ye Guoling, Liu Qi. Using maternal serum PAPP-A and other pregnancy-associated proteins in screening for fetal abnormalities. *Xi'an Yike Daxue Xuebao* 1998;**19**(1):94-6, 110.

Zoppi 2003 ***{published data only}***
Zoppi MA, Ibba RM, Floris M, Manca F, Axiana C, Monni G. Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses. *BJOG: an international journal of obstetrics and gynaecology* 2003;**110**(6):584–8.

Additional references

Alfirevic 2003
Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. *Cochrane Database of Systematic Reviews* 2003, Issue 3. [DOI: 10.1002/14651858.CD003252]

Alfirevic 2004
Alfirevic Z, Neilson JP. Antenatal screening for Down's syndrome. *BMJ* 2004;**9**(329(7470)):811–2.

Alldred 2010
Alldred SK, Deeks JJ, Neilson JP, Alfirevic Z. Antenatal screening for Down's syndrome: generic protocol. *Cochrane Database of Systematic Reviews* 2010, Issue 4. [DOI: 10.1002/14651858.CD007384.pub2]

Alldred 2012
Alldred SK, Deeks JJ, Guo B, Neilson JP, Alfirevic Z. Second trimester serum tests for Down's Syndrome screening. *Cochrane Database of Systematic Reviews* 2012, Issue 6. [DOI: 10.1002/14651858.CD009925]

Bersinger 1995
Bersinger NA, Zakher A, Huber U, Pescia G, Schneider H. A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies. *Archives of Gynecology and Obstetrics* 1995; **256**(4):185–92.

Bogart 1987
Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. *Prenatal Diagnosis* 1987;**7** (9):623–30.

Bossuyt 2003
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003;**326**(7379):41–4. [PUBMED: 12511463]

Cole 1999a
Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated hCG (invasive trophoblast antigen) immunoassay: a new basis for gestational Down syndrome screening. *Clinical Chemistry* 1999;**45**:2109–19.

Cuckle 1995a
Cuckle HS, Holding S, Jones R, Wallace EM, Groome NP. Maternal serum dimeric inhibin A in second-trimester Down's syndrome pregnancies. Prenatal Diagnosis 1995; Vol. 15, issue 4:385–6.

Macri 1990
Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND, Young JA, et al. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human

chorionic gonadotropin. *American Journal of Obstetrics and Gynecology* 1990;**163**(4 Pt 1):1248–53.

Macri 1993

Macri JN, Spencer K, Aitken D, Garver K, Buchanan PD, Muller F, et al. First-trimester free beta (hCG) screening for Down syndrome. *Prenatal Diagnosis* 1993;**13**(7):557–62.

Mol 1999

Mol BW, Lijmer JG, Van der Meulen J, Pajkrt E, Bilardo CM, Bossuyt PM. Effect of study design on the association between nuchal translucency measurement and Down syndrome. *Obstetrics and Gynecology* 1999;**94**(5 Pt 2): 864–9.

Penrose 1933

Penrose LS. The relative effects of parental and maternal age in mongolism. *Journal of Genetics* 1933;**27**:219–24.

Steele 1966

Steele MW, Breg WR. Chromosome analysis of human amniotic-fluid cells. *Lancet* 1966;**i**:383–5.

Vaklenti 1968

Vaklenti C, Schutta E.J, Kehaty T. Prenatal diagnosis of Down's syndrome. *Lancet* 1968;**ii**:220.

Wald 2003a

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). *Health Technology Assessment (Winchester, England)* 2003;**7**(11):1–77.

Wallace 1995

Wallace EM, Grant VE, Swanston IA, Groome NP. Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down's syndrome. *Prenatal Diagnosis* 1995;**15**(4):359–62.

Whiting 2003

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Medical Research Methodology* 2003;**3**:25.

* *Indicates the major publication for the study*

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Bahado-Singh 1998

Clinical features and settings	High-risk referral for invasive testing.
Participants	511 participants. USA. August 1996 to January 1997. Singleton pregnancies. Pregnant women. Mean age 37.1 years (SD 2.8 years). 15-24 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 18 cases. Reference standard: amniocentesis.
Index and comparator tests	Mid-trimester urine ß-core fragment testing (monoclonal antibody B210 assay, 2-step sandwich method, standardised for creatinine)
Follow-up	100% karyotyping.
Aim of study	To ascertain the screening efficiency of a new mid-trimester Down's syndrome detection protocol that combines maternal urine testing and ultrasonographic examination
Notes	Amniocentesis was being conducted on the basis of maternal age. Women who have amniocentesis just due to abnormal screening results were excluded from the study

Table of Methodological Quality

Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women received a reference standard.
Differential verification avoided? All tests	Yes	All women underwent the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.

Bahado-Singh 1998 (*Continued*)

Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results.
Index test results blinded? All tests	Yes	Urine testing was conducted blind from the results of amniocentesis.
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Bahado-Singh 1998b

Clinical features and settings	High-risk referral for invasive testing.
Participants	356 participants: 10 cases and 346 controls. USA. Dates not reported. Singleton pregnancies. Pregnant women. 14-24 weeks' gestation.
Study design	Case-control study.
Target condition and reference standard(s)	Down's syndrome: 10 cases. Reference standard: amniocentesis.
Index and comparator tests	Seond trimester urine ß-core fragment testing (monoclonal antibody B210 assay, 2-step sandwich method, standardised for creatinine) Second trimester serum AFP. Risk cut points of 1/10, 1/20, 1/30, 1/58, 1/270, 1/526.
Follow-up	100% karyotyping.
Aim of study	To determine Down's syndrome screening efficiency of a new protocol that combines maternal serum AFP and beta core fragment/total oestriol ratio
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**

Bahado-Singh 1998b (*Continued*)

Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women underwent a reference standard.
Differential verification avoided? All tests	Yes	All women underwent the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Bahado-Singh 1999

Clinical features and settings	High-risk referral for invasive testing.
Participants	457 participants. USA. August 1996 - June 1997. Pregnant women. Mean age 37.1 years. Singleton pregnancies. 15-24 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 13 cases. Reference standard: amniocentesis.

Bahado-Singh 1999 (*Continued*)

Index and comparator tests	Maternal age. Urinary ß core fragment (monoclonal antibody B210 assay, 2-step sandwich method, standardised for creatinine) Urinary beta core fragment/total urinary oestriol ratio.
Follow-up	100% karyotyping.
Aim of study	To evaluate Down's syndrome screening efficiency of a new algorithm of multiple urinary biochemical and ultrasound markers
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women received a reference standard.
Differential verification avoided? All tests	Yes	All women received the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results.
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results.
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Bahado-Singh 1999a

Clinical features and settings	High-risk referral for invasive testing.
Participants	926 participants. USA. November 1995 - March 1999. Pregnant women. Singleton pregnancies. 15-24 weeks' gestation. Euploid/Down's karyotype only.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 21 cases. Reference standard: amniocentesis.
Index and comparator tests	Maternal age. Second trimester urinary ß core fragment (Spot specimens of urine - 2-step sandwich assay B120 monoclonal antibody) Second trimester serum AFP. Frozen serum samples tested for second trimester uE3 and free ßhCG (details of serum testing methods not given)
Follow-up	100% karyotyping.
Aim of study	To compare Down's syndrome screening efficiency of elevated maternal urine level of beta core fragment with that of a traditional serum triple test
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women received a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.

Bahado-Singh 1999a (*Continued*)

Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results.
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Bahado-Singh 2000

Clinical features and settings	High-risk referral for invasive testing.
Participants	1016 participants. USA. May 1995 - June 1998. Singleton pregnancies. Pregnant women. Mean age 37.1 years (19.3-46 years). 14-24 weeks' gestation. Euploid or Down's pregnancies only.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 23 cases. Reference standard: amniocentesis.
Index and comparator tests	Second trimester urinary hyperglycosylated hCG (Specific monoclonal antibody developed. 2-step enzyme immunometric assay standardised for creatinine levels)
Follow-up	100% karyotyping.
Aim of study	To evaluate the measurement of levels of urine hyperglycosylated hCG in conjunction with ultrasound biometry for Down's syndrome risk prediction in an at risk group
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**

Bahado-Singh 2000 (*Continued*)

Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results.
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Bahado-Singh 2000a

Clinical features and settings	High-risk referral for invasive testing.
Participants	524 participants. USA - single hospital. August 1995 - April 1999. Singleton pregnancies. Pregnant women. Mean age 36.6 years (SD 5.3 years) in those with Down's detected and 37.0 years (SD 3.4 years) in those with euploid pregnancies 14-22 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 24 cases. Reference standard: amniocentesis.

Bahado-Singh 2000a (*Continued*)

Index and comparator tests	Maternal age. Second trimester serum hCG (IMX total β-hCG kit, Abbott Laboratories), uE3 (DSL-1400 Ultra-sensitive unconjugated Estriol Radioimmunoassay kit) and AFP (IMX AFP kit, Abbott Laboratories) Second trimester urinary beta core fragment (Spot specimens of urine - 2-step sandwich assay B120 monoclonal antibody) Frozen samples tested for second trimester urinary hyperglycosylated hCG (Specific monoclonal antibody developed. 2-step enzyme immunometric assay standardised for creatinine levels)
Follow-up	100% karyotyping.
Aim of study	To compare the concentration of hyperglycosylated human chorionic gonadotropin with serum triple screen for second trimester Down's syndrome detection
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results.
Index test results blinded? All tests	Unclear	Unclear if index test interpreted with knowledge of reference standard results.
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements

Bahado-Singh 2000a (*Continued*)

Withdrawals explained? All tests	No	No details of withdrawals given.

Canick 1995

Clinical features and settings	Referral for termination of pregnancy, amniocentesis or routine examination
Participants	105 participants: 14 cases and 91 controls. USA. Dates not reported. Singleton pregnancies. Pregnant women. 15-21 weeks' gestation.
Study design	Case-control study.
Target condition and reference standard(s)	Down's syndrome: 14 cases. Reference standard: karyotyping on termination of pregnancy or amniocentesis
Index and comparator tests	Maternal age. Frozen samples tested for: second trimester urinary gonadotropin peptide (Triton UGP EIA assay, Alameda); second trimester serum hCG (MAIAclone hCG assay, Serono-Baker Diagnostics, Allentown)
Follow-up	No details given for any follow-up to birth. Reported that the fetal karyotype of control samples was not always known but assumed that none were aneuploid pregnancies
Aim of study	To assess whether urinary gonadotropin peptide is better than serum hCG as a second trimester screening marker
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Routine screening and selective testing of high-risk women as done in practice
Acceptable reference standard? All tests	Yes	Karyotyping or follow-up to birth.
Partial verification avoided? All tests	No	Not all women received a reference standard.
Differential verification avoided? All tests	No	Women had different reference standards.

Canick 1995 (*Continued*)

Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Unclear	Unclear if index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Cole 1997a

Clinical features and settings	High-risk referral for invasive testing.
Participants	722 participants. USA - single hospital. August 1995 - May 1996. Pregnant women. Singleton pregnancy. 12-24 weeks' gestation.
Study design	Cohort study.
Target condition and reference standard(s)	Down's syndrome: 13 cases. Reference standard: amniocentesis.
Index and comparator tests	Second trimester urinary hCG free beta subunit (Immunoenzymometric assay with autoantibody FBT11)
Follow-up	100% karyotyping.
Aim of study	To evaluate use of second trimester urinary free beta-subunit for Down's syndrome screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description

Cole 1997a (*Continued*)

Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Cole 1997b

Clinical features and settings	High-risk referral for invasive testing.
Participants	492 participants. USA - single hospital. August 1995 - May 1996. Pregnant women. Singleton pregnancy. 12-24 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 12 cases. Reference standard: amniocentesis.
Index and comparator tests	Second trimester urinary hCG free beta subunit (B210 2-step sandwich assay) Second trimester urinary total oestriol (radioimmunoassay, kit from Diagnostics Products

Cole 1997b (*Continued*)

	Corporation, Los Angeles)
Follow-up	100% karyotyping.
Aim of study	To evaluate use of urinary free beta core fragment combined with urinary total oestriol for Down's syndrome screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Routine screening of typical pregnant population.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Unclear	Unclear if index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Cole 1999b

Clinical features and settings	High-risk referral for invasive testing.
Participants	1157 participants. USA - 3 hospitals. May 1995 - March 1998. Pregnant women. Singleton pregnancy. 11-22 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 23 cases. Reference standards: amniocentesis or CVS.
Index and comparator tests	Urinary hCG beta-core subunit (B210 2-step sandwich assay). Urinary total oestriol (radioimmunoassay, kit by Diagnostic Products Corporation, Los Angeles)
Follow-up	100% karyotyping.
Aim of study	To evaluate use of urinary free beta-subunit for Down's syndrome screening
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis or CVS.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	No	Women had CVS or amniocentesis depending on their stage of pregnancy
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results

Cole 1999b (*Continued*)

Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice.
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Cuckle 1995b

Clinical features and settings	High-risk referral for invasive testing and testing for bacterial analysis
Participants	315 participants. UK. Dates not specified. Pregnant women: 24 cases undergoing invasive testing and 294 controls undergoing testing for bacterial analysis 11-23 weeks' gestation.
Study design	Case-control study.
Target condition and reference standard(s)	Down's syndrome: 24 cases. Reference standards: amniocentesis or CVS for cases and follow-up for controls
Index and comparator tests	Urinary beta core fragment (Modified radioimmunoassay method) Urinary total oestrogen (continuous flow reaction based on the Kuber method)
Follow-up	No details given of methods of follow-up.
Aim of study	To evaluate the use of multiple urinary markers rather than serum in order to screen for Down's syndrome
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Karyotyping or follow-up to birth.
Partial verification avoided? All tests	Yes	All women had a reference standard.

Cuckle 1995b (*Continued*)

Differential verification avoided? All tests	No	Women had different reference standards.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results.
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements.
Withdrawals explained? All tests	No	No details of withdrawals given.

Cuckle 1999

Clinical features and settings	High-risk referral for invasive testing and routine screening
Participants	349 participants: 45 cases and 304 controls. UK. Dates not specified. Pregnant women. 14-19 weeks' gestation.
Study design	Retrospective case-control study.
Target condition and reference standard(s)	Down's syndrome: 45 cases. Reference standard: amniocentesis, CVS or follow-up to birth
Index and comparator tests	Frozen samples tested for urinary hyperglycosylated hCG (Immunoassays by 'Cole' method corrected for creatinine levels using Jaffes method)
Follow-up	Details of follow-up not reported.
Aim of study	To determine the distribution of hyperglycosylated hCG levels in pregnancies with Down's syndrome
Notes	

Table of Methodological Quality

Cuckle 1999 (*Continued*)

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Routine screening of typical pregnant population.
Acceptable reference standard? All tests	Yes	Amniocentesis, CVS or follow-up.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	No	Women had different reference standards.
Incorporation avoided? All tests	Yes	Index tests did not form part of the reference standard.
Reference standard results blinded? All tests	Yes	Reference standard conducted before the index test.
Index test results blinded? All tests	Unclear	Index test conducted after the reference standard and no evidence of blinding
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Cuckle 1999a

Clinical features and settings	High-risk referral for invasive testing and routine screening
Participants	6730 participants. USA, UK and other European countries -multicentre study. Dates not reported. Pregnant women. 14-19 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 39 cases. Reference standard: amniocentesis, CVS or postnatal examination
Index and comparator tests	Maternal urine beta core hCG (Chiron manual assay).

Cuckle 1999a (*Continued*)

Follow-up	Methods of follow-up not reported.
Aim of study	A prospective evaluation of urine beta core hCG for Down's syndrome
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Karyotyping or follow-up to birth.
Partial verification avoided? All tests	Unclear	Unclear if all women received a reference standard.
Differential verification avoided? All tests	No	Women had different reference standards.
Incorporation avoided? All tests	Yes	Index tests did not form part of the reference standard.
Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results
Index test results blinded? All tests	Yes	Index test conducted without knowledge of the reference standard
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Hsu 1999

Clinical features and settings	High-risk referral for invasive testing.
Participants	474 participants: 69 cases and 405 controls. Taiwan and UK. Dates not specified. Pregnant women.

Hsu 1999 (*Continued*)

	Median age cases 36.0 years (21-44 years), controls 34.5 years (23-43 years) 14-26 weeks' gestation.
Study design	Retrospective case-control study.
Target condition and reference standard(s)	Down's syndrome: 69 cases. Reference standard: amniocentesis.
Index and comparator tests	Maternal age. Urinary beta core fragment (UGP) (UGF-EIA Toa kit). Urinary free beta hCG (CIS immunoradiometric assay). Urinary total oestriol (Orthoclinical diagnostics oestriol (total) II radioimmunoassay kit) All adjusted for creatinine concentration. Modelled to standardised population for England and Wales 1991-1994. Cases from Taiwan
Follow-up	100% karyotyping.
Aim of study	To investigate levels of urinary beta core fragment, free beta hCG and total oestriol in a new large set of Down's syndrome pregnancies
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Unclear	Unclear if index test interpreted without knowledge of reference standard results

Hsu 1999 (*Continued*)

Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice.
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements.
Withdrawals explained? All tests	No	No details of withdrawals given.

Isozaki 1997

Clinical features and settings	High-risk referral for invasive testing.
Participants	726 participants. USA - single centre. August 1995 - May 1996. Pregnant women. Mean age 35.4 years (SD 4.0 years) in mothers of Down's syndrome babies and 37 years (SD 4.3 years) in mothers of healthy babies Singleton pregnancies. 12-24 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 13 cases. Reference standard: amniocentesis.
Index and comparator tests	Urinary beta core fragment (B210 monoclonal antibody, 2-step sandwich assay)
Follow-up	100% karyotyping.
Aim of study	To present data for prospectively collected samples of urinary beta core fragment for Down's syndrome screening
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.

Isozaki 1997 (*Continued*)

Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice.
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements.
Withdrawals explained? All tests	No	No details of withdrawals given.

Palomaki 2004a

Clinical features and settings	High-risk referral for invasive testing.
Participants	2,055 participants. USA - multicentre study. January 2001 - January 2003. Pregnant women with mean age 38.9 years. 15-20 weeks' gestation.
Study design	Prospective cohort study.
Target condition and reference standard(s)	Down's syndrome: 28 cases. Reference standard: amniocentesis.
Index and comparator tests	Urinary invasive trophoblastic antigen (ITA) (B207 (detection) and B152 (capture) anti-hCG monoclonal antibodies)
Follow-up	100% karyotyping.
Aim of study	To evaluate ITA as a potential marker for Down's syndrome in the second trimester of pregnancy
Notes	Clean catch of random urine provided. Sent same day at 4 degrees Celcius on an ice pack. Aliquoted into 1 mL plastic tubes. 1 urine aliquot shipped to lab for testing. Rest stored at -70 degrees Celcius. Most samples assayed within 24 hours of reaching lab and all within 48 hours. Anti-ITA antibody produced. Sample corrected for creatinine levels

Palomaki 2004a (*Continued*)

Table of Methodological Quality		
Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Selective testing of high-risk population as done in practice
Acceptable reference standard? All tests	Yes	Amniocentesis.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Spencer 1996

Clinical features and settings	High-risk referral for invasive testing.
Participants	429 participants: 29 cases and 400 controls. UK. Date not specified. Pregnant women. Singleton pregnancies. 14-24 (cases) and 9-22 (controls) weeks' gestation.
Study design	Case-control study.

Spencer 1996 (*Continued*)

Target condition and reference standard(s)	Down's syndrome: 29 cases. Reference standards: amniocentesis or CVS.
Index and comparator tests	Urine free beta hCG (CIS immunoradiometric assay). Urinary beta core fragment (Ciba Corning diagnostics UGP enzyme immunoassay)
Follow-up	100% karyotyping.
Aim of study	To evaluate whether free beta hCG is elevated in the urine of pregnancies affected by Down's syndrome and investigate whether urine free beta hCG may be used as possible screening markers
Notes	

Table of Methodological Quality

Item	**Authors' judgement**	**Description**
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	Amniocentesis or CVS.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	No	Women had different reference standards.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice.
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

Wald 2003

Clinical features and settings	Routine screening.
Participants	606 participants: 101 cases, 505 controls matched for gestation, duration of storage and centre UK and Austria - multicentre trial. September 1996 - April 2000. Pregnant women. 9-13 and 14-20 weeks' gestation.
Study design	Case-control study.
Target condition and reference standard(s)	Down's syndrome: 101 cases. Reference standards: invasive testing (following second trimester screening) or follow-up to birth
Index and comparator tests	First trimester NT (midsagittal section, optimal magnification of thickness of translucent space between inner skin surface and fascia covering cervical spine (white black interface (outer) - black white interface (inner), 41 models of ultrasound machine, 20 minutes allotted scanning time) First and second trimester serum AFP, hCG, uE3, PAPP-A, free beta hCG (time resolved fluoroimmunoassay, AutoDELFIA) First and second trimester inhibin A (Sandwich enzyme-linked immunosorbent assay, Oxford Bio-innovation) First and second trimester urinary beta core fragment, total hCG, ITA and free beta hCG (ITA and beta core fragment, Quest diagnostics USA)
Follow-up	Follow-up by: 1) Staff at local hospitals completed a study outcome form at, or just after. delivery, 2) Study records of CVS, amniocentesis or karyotype at birth linked to information from cytogenic laboratories, 3) Study records linked to records of cases of Down's syndrome from the National Down's Syndrome Cytogenetic Register, 4) Information obtained from local obstetrical outcome records, 5) Forms sent to all women with a request to return details of the outcome of their pregnancy, 6) Individual searches in respect of women whose outcomes of pregnancy had not been obtained by any of the previous methods. 4% of women in the total cohort did not have a documented outcome of pregnancy. Unclear if any of these women were included in this nested case-control study
Aim of study	To identify the most effective, safe and cost-effective strategy for antenatal screening for Down's syndrome using NT, maternal serum and urine markers in the first and second trimesters of pregnancy and maternal age in various combinations
Notes	Performance of screening assessed at 17 weeks' gestation. Study tried to be non-interventional in the first trimester - second trimester testing was aimed to be used as the basis for any referral for invasive testing

Table of Methodological Quality

Item	Authors' judgement	Description

Representative spectrum? All tests	Yes	Routine screening of typical pregnant population.
Acceptable reference standard? All tests	Yes	Karyotyping or follow-up to birth.
Partial verification avoided? All tests	Unclear	Unclear if all women received a reference standard.
Differential verification avoided? All tests	No	Women received different reference standards.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	No	Reference standard interpreted with knowledge of index test results
Index test results blinded? All tests	Unclear	Serum testing conducted after reference standard and unclear if interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice.
Uninterpretable results reported? All tests	Yes	Rates of NT failure on average 9%. Pre-10 weeks' gestation, > 33% failure rate, declined to 7% at 12 weeks
Withdrawals explained? All tests	No	No details of withdrawals given.

Weinans 2000

Clinical features and settings	High-risk referral for invasive testing.
Participants	63 participants: 8 cases and 55 controls matched for gestational and maternal age, maternal weight, duration of storage and smoking history The Netherlands - single hospital. October 1997 to May 1999. Pregnant women. 10-11 weeks' gestation.
Study design	Case-control study.
Target condition and reference standard(s)	Down's syndrome: 8 cases. Reference standard: CVS.
Index and comparator tests	Urinary hyperglycosylated hCG, (procedures previously described in Cole 1999a).

Weinans 2000 (*Continued*)

Follow-up	100% karyotyping.
Aim of study	To investigate the value of H-hCG measurements in very early pregnancy (prior to 12 weeks' gestation)
Notes	

Table of Methodological Quality

Item	Authors' judgement	Description
Representative spectrum? All tests	Yes	Selective testing of high-risk women as done in practice.
Acceptable reference standard? All tests	Yes	CVS.
Partial verification avoided? All tests	Yes	All women had a reference standard.
Differential verification avoided? All tests	Yes	All women had the same reference standard.
Incorporation avoided? All tests	Yes	Reference standard was independent of the index test.
Reference standard results blinded? All tests	Yes	Reference standard interpreted without knowledge of index test results
Index test results blinded? All tests	Yes	Index test interpreted without knowledge of reference standard results
Relevant clinical information? All tests	Yes	Information available as would be in standard clinical practice
Uninterpretable results reported? All tests	No	No details given for test failures/uninterpretable measurements
Withdrawals explained? All tests	No	No details of withdrawals given.

AFP: alpha-fetoprotein
ßhCG: beta human chorionic gonadotrophin
CVS: chorionic villus sampling
hCG: human chorionic gonadotrophin
ITA: invasive trophoblast antigen
NT**:** nuchal translucency
PAPP-A: Pregnancy-associated plasma protein A

SD: standard deviation
uE3: unconjugated oestriol

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Abbas 1995	Unable to extract useful data.
Abdul-Hamid 2004	No Down's syndrome pregnancies.
Abraha 1999	Unable to extract useful data.
Adekunle 1999	Unable to extract useful information.
Aitken 1993	Unable to extract useful data.
Aitken 1996a	Fewer than 80% of pregnancies had gestational age confirmed by USS
Aitken 1996b	Fewer than 80% of pregnancies had gestational age confirmed by USS
Akbas 2001	Less than 5 Down's syndrome pregnancies.
Antona 1998	Likely fewer than 80% of pregnancies dated by USS.
Antsaklis 1999	Women screened at greater than 24 weeks' gestation.
Ashwood 1987	Unable to extract useful data.
Asrani 2005	Review article.
Audibert 2001b	Data were not relevant to this review - this study was not looking at urine tests for Down's syndrome screening
Axt-Fleidner 2006	Unable to extract useful data.
Azuma 2002	Unable to extract useful data.
Baghagho 2004	Unable to obtain paper.
Bahado-Singh 1995	USS markers greater than 14 weeks' gestation.
Bahado-Singh 1996	USS markers greater than 14 weeks' gestation.
Bahado-Singh 1999b	USS markers greater than 14 weeks' gestation.
Bahado-Singh 2002	USS markers greater than 14 weeks' gestation.

(*Continued*)

Bahado-Singh 2003	Review article.
Bar-Hava 2001	No Down's pregnancies in study population.
Barkai 1996	No Down's pregnancies in study population.
Barnabei 1995	No Down's pregnancies in study population.
Bartels 1988	Unable to extract useful data.
Bartels 1993	No Down's pregnancies in study population.
Barth 1991	Second trimester ultrasound study.
Baviera 2004	Unclear method of confirmation of gestational age.
Bazzett 1998	Male versus female fetuses.
Bellver 2005	No Down's syndrome pregnancies in study.
Benn 1995	Less than 80% follow-up.
Benn 1996	Less than 80% follow-up.
Benn 1997	No Down's pregnancies in study population.
Benn 1998	Less than 80% follow-up.
Benn 2001	Statistical modelling (computer simulation).
Benn 2002	Modelled data.
Benn 2003a	Less than 80% of pregnancies dated by USS.
Benn 2003b	Editorial.
Benn 2005a	No Down's pregnancies included.
Benn 2005b	Mathematical model.
Berry 1995	Less than 80% of pregnancies USS dated.
Berry 1997	Less than 80% of pregnancies USS dated.
Bersinger 1994	Gestational age not USS estimated.
Bersinger 2000	Unable to extract useful data.

(*Continued*)

Bersinger 2001	No Down's syndrome pregnancies in study population.
Bersinger 2003	Unable to extract useful data.
Bersinger 2004	No Down's syndrome pregnancies in study population.
Bersinger 2005	No Down's syndrome pregnancies in study population.
Biggio 2004	Cost-effectiveness analysis.
Bindra 2002	Review article.
Blundell 1999	Unable to extract useful data.
Boots 1989	Population risk factor calculations.
Borruto 2002	Unable to extract useful data.
Boue 1990	Review article.
Bradley 1994	Screen-negative population gestations not confirmed by ultrasound
Braithwaite 1996	Review article.
Brambati 1995	USS screening inclusive of women greater than 14 weeks' gestation
Brambati 1996	Review article.
Brizot 1995a	Unable to extract useful data.
Brizot 1995b	Unable to extract useful data.
Brizzi 1989b	Second trimester ultrasound.
Brock 1990	Unable to extract useful data.
Campogrande 2001	Unable to extract useful data.
Canick 1988	Unable to extract useful data.
Canick 1995b	Unable to extract useful data.
Canini 2002	No Down's syndrome pregnancies in study population.
Cans 1998	Second trimester ultrasound.
Carreras 1991	Second trimester ultrasound.
Chen 1999	Review article.

(*Continued*)

Chen 2002	No Down's syndrome pregnancies in study population.
Chen 2004	Less than 5 Down's cases in study population.
Chen 2005	Unable to extract useful data.
Cheng 1993	Likely that fewer than 80% of gestational age confirmed by USS
Cheng 1999	Case series. No Down's syndrome pregnancies in study population
Cheng 2004a	No Down's syndrome pregnancies in study population.
Cheng 2004b	No Down's syndrome pregnancies in study population.
Chitayat 2002	Less than 5 Down's cases in study population.
Christiansen 2002	Unable to extract useful data.
Christiansen 2007	Unable to extract useful data.
Chung 2000	Less than 5 Down's syndrome pregnancies in study population.
CNGOF 1996	Unable to obtain translation.
Cole 1996	Review article.
Comas 2001	USS at greater than 14 weeks.
Comas 2002a	USS at greater than 14 weeks.
Comas 2002b	USS at greater than 14 weeks.
Comstock 2006	Unable to extract useful data.
Conde-Agudelo 1998	Review article.
Crossley 1991	Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1993	Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1996	No Down's syndrome pregnancies in study population.
Crossley 2002a	Adjustment factors for smokers.
Cuckle 1984	Gestational age not confirmed by USS.
Cuckle 1987a	Gestational age not confirmed by USS.

(*Continued*)

Cuckle 1987b	No gestational age limits given.
Cuckle 1990	Paper presenting adjustment factors.
Cuckle 1996	Data modelled on 4 meta-analysed studies.
Cuckle 1999b	Unable to extract useful data.
Cuckle 1999c	Review article.
Cullen 1990	Abnormal scans only in study population.
Cusick 2004	Less than 5 Down's syndrome pregnancies in study population.
D'Ottavio 1997	Second trimester USS.
Dancoine 2001	No Down's syndrome pregnancies in study population.
De Biasio 2000	Unable to extract useful information.
De Biasio, 1999	Unable to ascertain whether overlapping populations between several papers - attempted to contact author with no response
De Biasio, 2001	Unable to ascertain whether overlapping populations between several papers - attempted to contact author with no response
De Graaf 1991	Unable to extract useful data.
De Graaf 1999	Modelled data.
DeVore 2001	Second trimester ultrasound.
Dickerson 1994	Comment.
Dimaio 1987	Gestational age by USS only in screen-positive population.
Doran 1986	Ultrasound confirmation of gestational age performed in screen-positive women only
Drugan 1996a	Second trimester ultrasound.
Drugan 1996b	Unable to extract useful data.
Drysdale 2002	Fewer than 5 Down's syndrome pregnancies in population.
Ebell 1999	Review article.
Economides 1998	Unable to extract useful data.

(*Continued*)

Erickson 2004	No Down's syndrome pregnancies in population.
Evans 1996	No Down's syndrome pregnancies in population.
Falcon 2005	Unable to extract useful data.
Falcon 2006	Unable to extract useful data.
Ford 1998	Audit.
Frishman 1997	No Down's syndrome pregnancies in population.
Fukada 2000	Unable to extract useful data.
Ghidini 1998	Comparison of male versus female fetuses.
Goldie 1995	Fewer than 80% of study population had gestational age confirmed by USS
Gonçalves 2004	Greater than 14 weeks USS screening.
Goodburn 1994	Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Grozdea 2002	Unable to extract useful data.
Gyselaers 2004a	Less than 80% follow-up.
Gyselaers 2004b	Less than 80% follow-up.
Gyselaers 2006a	Unaffected pregnancies only.
Gyselaers 2006b	Unable to extract useful data.
Hackshaw 1995	No Down's syndrome pregnancies in population.
Hackshaw 2001	No Down's syndrome pregnancies in population
Haddow 1992	Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Hafner 1995	Less than 5 Down's pregnancies in study population.
Hallahan 1998	Gestational age greater than 24 weeks.
Harrison 2006	Less than 80% of pregnancies had gestational age confirmed by USS
Harry 2006	Editorial.
Hayashi 1995	Unable to extract useful data.

(*Continued*)

Hayashi 1996	Less than 5 Down's pregnancies in study population.
Heikkila 1997	Fewer than 80% of pregnancies had gestational age confirmed by USS
Heinonen 1996	No Down's syndrome pregnancies in population.
Herman 2000	No Down's syndrome pregnancies in study population.
Herman 2003	Correlation between markers, not evaluation of screening tests
Herrou 1992	Unable to extract useful data.
Hershey 1985	Gestation unclear.
Hershey 1986	Gestation based on LMP.
Hewitt 1993	Unable to extract useful data.
Hogdall 1992	Unclear method of determination of gestational age. Unable to extract useful data
Hong Kong Practitioner 2001	CME.
Howe 2000	Second trimester USS.
Hsiao 1991	Unable to obtain translation.
Hsieh 1999	No Down's syndrome pregnancies in study population.
Hsu 1997b	Adjustment factors.
Hsu 1998a	No Down's syndrome pregnancies in study population.
Hsu 1999b	No Down's pregnancies.
Huang 2003	No Down's syndrome pregnancies in study population.
Huggon 2004	Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003	No Down's syndrome pregnancies in population.
Hui 2005	No Down's syndrome pregnancies in population.
Hultén 2004	Editorial/commentary.
Hung 2003	Modelling.
Hurley 1993	Unable to extract useful data.

(*Continued*)

Huttly 2004	No Down's syndrome pregnancies in population.
Hwa 2004	Less than 5 Down's pregnancies in population.
Iles 1996	Review.
Ind 1994	Unable to extract useful data.
Jean-Pierre 2005	Review article.
Johnson 1991	Gestatiojnal age estimated by USS in fewer than 80% of cases
Johnson 1993	Normal pregnancies only.
Jorgensen 1999	Gestation greater than 14 weeks for USS.
Josefsson 1998	No Down's syndrome pregnancies in study population.
Jou 2001	Less than 5 Down's syndrome pregnancies in study population.
Kagan 2006	Screen-positive pregnancies only.
Kautzmann 1995	Fewer than 80% pregnancies had gestational age estimated by USS
Keith 1992	Summary article.
Kelekci 2004	Less than 5 Down's syndrome pregnancies in population.
Kellner 1995a	Less than 5 Down's syndrome pregnancies in population.
Kellner 1995b	Less than 80% follow-up. Unable to ascertain proportion of population with gestational age confirmed by USS
Kellner 1997	Assumption of normal karyotype without reference standard in significant proportion of control pregnancies
Knight 1990	Review article.
Knight 2001	Validation of a specific assay.
Knight 2005	Less than 80% of pregnancies had gestational age confirmed by USS
Koos 2006	Review article.
Kornman 1996	Less than 5 Down's syndrome pregnancies in population.
Kornman 1997	Unable to extract useful information.

(*Continued*)

Kramer 1998	No Down's syndrome pregnancies in study population.
Krantz 1996	Modelled data.
Krantz 2005	Adjustment factor.
Kulch 1993	No Down's cases in population.
Lai 1998	Modelled population.
Lai 2003	No Down's syndrome pregnancies in study population.
Laigaard 2006a	Unable to extract useful data.
Laigaard 2006b	Simulation.
Lam 1997	Unable to extract useful data.
Lam 1998	Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999a	No Down's syndrome pregnancies in population.
Lam 1999b	Unable to extract useful data.
Lam 2000	Study of women's decisions about screening.
Lam 2001	Male versus female fetuses.
Lambert-Messerlian 1996	Fewer than 80% of pregnancies USS dated.
Lambert-Messerlian 1998	Unable to extract useful data.
Lehavi 2005	Down's syndrome pregnancies only.
Leung 2006	Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993	Appears to be a review article (French).
Li 1998	Unable to obtain translation.
Li 1999	Unable to obtain translation.
Liao 1997	Unable to obtain translation.
Liao 2001	Unable to extract useful data.
Lim 2002	Second trimester ultrasound.

(*Continued*)

Lippman 1987	Editorial.
Liu 2003	Unable to obtain translation.
Lustig 1988	Gestational age by LMP only.
MacDonald 1991	Fewer than 80% of gestational ages estimated by USS.
Macintosh 1994	Unable to extract useful data.
Macintosh 1997	Unable to extract useful data.
Macri 1994	Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996	Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998	Review article.
Malone 2003	Review article.
Mangione 2001	Abnormal screening results only.
Maymon 2001a	No Down's syndrome pregnancies in study population.
Maymon 2001b	No normal test results included therefore unable to extract meaningful data
Maymon 2002	No Down's syndrome pregnancies in study population.
Maymon 2004	No Down's syndrome pregnancies in study population.
Maymon 2005	Modelled data.
McDuffie 1996	USS dating on screen-positive women only.
Meier 2002	Observed versus expected cases of Down's syndrome in a population
Merkatz 1984	Gestational age not confirmed by USS.
Merz 2005	Editorial.
Metzenbauer 2001	Normal pregnancies only.
Metzenbauer 2002	Unable to extract useful data.
Mikic 1999	No Down's syndrome pregnancies in study population.
Miller 1991	Unable to extract useful data.

(*Continued*)

Milunsky 1989	Fewer than 80% gestational age estimated by USS.
Milunsky 1996	Fewer than 80% gestational age estimated by USS.
Minobe 2002	Gestational age greater than specified limits.
Miyamura 1999	Unable to extract useful data.
Moghadam 1998	Unable to extract useful data.
Monni 2000	Less than 5 Down's syndrome pregnancies.
Monni 2002	Review article.
Mooney 1994	Greater than 24 weeks' gestation.
Muller 1994	No Down's syndrome pregnancies in study population.
Muller 1996b	Unable to extract useful data.
Muller 1999	Unable to extract useful data.
Muller 2002a	Getstional age greater than 24 weeks.
Muller 2002b	Unable to extract meaningful data - unable to separate double and triple test data
Muller 2003	No Down's syndrome pregnancies in study population.
Murta 2002	Unable to extract useful data.
Musone 2000	Unable to extract useful data.
Musto 1986	Fewer than 80% USS dated.
Myrick 1990	Unable to extract useful data.
Neveux 1996a	No Down's syndrome pregnancies in population.
Neveux 1996b	Unable to extract useful data.
Ng 2004	Unable to extract useful data.
Nicolaides 1992	Study of outcomes of abnormal NT results.
Nicolaides 2000	Review article.
Nicolaides 2004	Review article.

(*Continued*)

Nicolaides 2005a	Unable to obtain translation - appears to be a review article
Nicolaides 2005b	Unable to obtain translation - appears to be a review article
Nicolaides 2005c	Unable to obtain translation - appears to be a review article
Nicolaides 2005d	Unable to obtain translation - appears to be a review article
Nicolaides 2005e	Unable to obtain translation - appears to be a review article
Nicolaides 2005f	Review article.
Niemimaa 2001	No Down's pregnancies in study population.
Niemimaa 2002	No Down's syndrome pregnancies in population.
Niemimaa 2003	No Down's syndrome pregnancies in population.
Noble 1997	Unable to extract useful data.
Norgaard-Pedersen 1990	Less than 80% of gestational ages confirmed by USS.
Norton 1992	Unable to extract useful data.
O'Brien 1997a	No Down's syndrome pregnancies in population.
O'Brien 1997b	No Down's syndrome pregnancies in population.
Odibo 2004	Gestational age greater than 14 weeks in USS population.
Ognibene 1999	Unable to extract useful data.
Olajide 1989	Unable to extract useful data.
Onda 1996	Unable to extract useful data.
Onda 1998	Unable to extract useful data.
Onda 2000	Less than 80% follow-up.
Orlandi 2002	No Down's syndrome pregnancies in study population.
Palka 1998	Twin data used in calculation of the median.
Palomaki 1989	Fewer than 80% USS dated.
Palomaki 1993	No Down's syndrome pregnancies in population.

(*Continued*)

Palomaki 1994	No Down's syndrome pregnancies in population.
Palomaki 1996	Meta-analysis.
Palomaki 2005	Unable to extract meaningful data.
Panburana 2001	Less than 5 Down's syndrome pregnancies in population.
Pandya 1994	Study of outcomes of abnormal NT results.
Pandya 1995	Review article.
Paul 2001	Unable to extract useful data.
Peralta 2005	Unable to extract useful data.
Perenc 1998	No Down's syndrome pregnancies in study population.
Perheentupa 2002	No Down's syndrome pregnancies in population.
Perona 1998	Smokers versus non smokers.
Petervari 2000	Unable to extract useful data.
Petrocik 1989	Likely fewer than 80% USS dated.
Phillips 1992	Gestational age confirmed by USS in less than 80% of population
Phillips 1993	Gestational age confirmed by USS in less than 80% of population
Pinette 2003	Women screened prior to recruitment.
Platt 2004	Unable to extract useful data.
Podobnik 1995	Abnormal results only.
Prefumo 2002	Comparison of prevalence and prediction.
Prefumo 2004	Comparison of a marker in women of different ethnic origins.
Price 1998	Unable to extract useful data.
Páez 2004	Unable to obtain translation.
Raty 2000	No Down's syndrome pregnancies in population.
Rembouskos 2004	Unable to extract useful data.

(*Continued*)

Ren 1992	Review article.
Renier 1998	Method of ascertainment of gestational age unclear. Twin gestations included in general population
Resta 1990	Second trimester USS.
Reynders 1997	Fewer than 5 Down's cases.
Reynolds 1989	Explanation of mathematical techniques.
Reynolds 1999	Unable to extract useful data.
Ribbert 1996	No Down's syndrome pregnancies in study population.
Rice 2005	Down's syndrome pregnancies excluded from study.
Rich 1991	Unable to extract useful data.
Roberts 1995	No Down's syndrome pregnancies in study population.
Robertson 1991	Editorial.
Rode 2003	No Down's pregnancies.
Ronge 2006	Editorial - summary of FASTER trial results.
Rose 1995	Review article.
Ross 1997	Review article.
Rotmensch 1996	Unable to extract useful data.
Rotmensch 1999	No Down's syndrome pregnancies in study population.
Rozenberg 2006	USS greater than 14 weeks' gestation.
Rudnicka 2002	No Down's syndrome pregnancies in population.
Ryall 1992	Unable to determine method of confirmation of gestational age
Ryall 2001	High-risk results only included (i.e. no screen-negative group for comparison)
Räty 2002	No Down's pregnancies in population.
Sabriá 2002	Unable to ascertain how numbers calculated and from which populations
Sacchini 2003	Unable to extract useful data.

(*Continued*)

Saller 1997	Down's syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001	No Down's syndrome pregnancies in population.
Salonen 1997	Fewer than 80% had gestational age estimated by USS.
Saltvedt 2005	Gestation greater than 14 weeks for nuchal scanning.
Saridogan 1996	Down's syndrome and Edward's syndrome affected pregnancies only
Savoldelli 1993	Unable to extract useful data.
Schiott 2006	Unable to extract useful data.
Schuchter 1998	No Down's pregnancies in study population.
Scott 1995	Less than 5 Down's syndrome pregnancies in study population.
Seeds 1990	Review article.
Seki 1995	No Down's syndrome pregnancies in study population.
Shenhav 2003	No Down's syndrome pregnancies.
Shintaku 1989	Unable to extract useful data.
Shulman 2003	No Down's syndrome pregnancies in population.
Simon-Bouy 1999	Review article.
Simpson 1986	Gestational age confirmed by USS in less than 80% of population
Smith 1990	Analysis of screen-positive results.
Smith 1996	Review/meta-analysis.
Smith 1999	Unable to extract useful data.
Smith-Bindman 2001	Meta-analysis of second trimester ultrasound markers.
Smith-Bindman 2003	Population study, not examining DTA.
Snijders 1995	Study of prevalence, not screening.
Snijders 1999	Study of prevalence, not screening.
Soergel 2006	Less than 80% follow-up.

(*Continued*)

Sokol 1998	Observation of Down's prevalence stratified by age.
Sonek 2003	Editorial.
Spencer 1985	Fewer than 80% USS dated.
Spencer 1991a	Likely fewer than 80% USS dated.
Spencer 1991b	Unable to extract useful data.
Spencer 1992	Unable to extract useful data.
Spencer 1993a	Fewer than 80% USS dated.
Spencer 1993b	No Down's pregnancies in study population.
Spencer 1993c	Unable to extract useful data.
Spencer 1993d	Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1993e	Unable to extract useful data.
Spencer 1995	No Down's pregnancies in population.
Spencer 1996a	Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1997	Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a	No Down's pregnancies in population.
Spencer 1998b	Unable to extract useful data.
Spencer 1999a	Review.
Spencer 1999b	Statistical methods paper.
Spencer 2000a	Examination of median shifts rather than an evaluation of screening
Spencer 2000b	No Down's syndrome pregnancies in population.
Spencer 2000c	No Down's syndrome pregnancies in population.
Spencer 2000d	No Down's cases.
Spencer 2000e	Male versus female fetuses.

(*Continued*)

Spencer 2000f	No Down's cases in population.
Spencer 2000g	No Down's pregnancies in population.
Spencer 2000h	No Down's pregnancies in population.
Spencer 2000i	Comparsison of fetal sex.
Spencer 2001	No Down's syndrome pregnancies in population.
Spencer 2001a	Unable to extract useful data.
Spencer 2001b	Unable to extract useful data.
Spencer 2001c	Unable to extract useful data.
Spencer 2001d	No Down's syndrome pregnancies in population.
Spencer 2002a	No Down's pregnancies.
Spencer 2002b	Risk validation study.
Spencer 2002c	No Down's syndrome pregnancies in population.
Spencer 2002d	Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a	No Down's pregnancies in population.
Spencer 2003b	No Down's pregnancies in population.
Spencer 2003c	Calculation of weight correction factor.
Spencer 2003d	Fewer than 5 Down's syndrome pregnancies.
Spencer 2004	Calculation of smoking correction factor.
Spencer 2005a	No Down's pregnancies.
Spencer 2005b	No Down's pregnancies.
Spencer 2005c	Comparison of 2 different assays - not actual screening evaluation
Spong 1999	Comparison of male and female fetuses.
Stevens 1998	Literature review.
Stoll 1992	Review article.

(*Continued*)

Su 2002a	Unable to extract useful data.
Suchet 1995	Review article.
Suchy 1990	Unable to ascertain method of confirmation of gestational age
Summers 2003a	Fewer than 80% had gestational age estimated by USS.
Summers 2003b	No Down's syndrome pregnancies in study population.
Suntharasaj 2005	Examination of inter-observer variation in NT scanning.
Sutton 2004	Unable to extract useful data.
Suzuki 1998	Unable to extract useful data.
Tabor 1987	Geststional age not confirmed by USS.
Tanski 1999	Information on screen-positive pregnancies only.
Thilaganathan 1998	No Down's syndrome pregnancies in study population.
Thilaganathan 1999	Editorial.
Tislaric 2002	No Down's syndrome pregnancies in population.
Torok 1997	Unable to extract useful data.
Tsai 2001	Less than 5 Down's syndrome pregnancies in study population.
Valerio 1996	Fewer than 80% pregnancies had gestational age estimated by USS
Van Blerk 1992	Unable to extract useful data.
Van Heesch, 2006	No Down's syndrome pregnancies in study population. Software comparison study
Van Lith 1991	Unable to extract useful data.
Van Lith 1993	Unable to extract useful data.
Van Lith 1994	Unable to extract useful data.
Veress 1986	Unable to extract useful data.
Veress 1988	Unable to extract useful data.
Vintzileos 2003	Second trimester USS.

(*Continued*)

Wald 1988a	Less than 80% had gestational age confirmed by ultrasound.
Wald 1988b	Gestational age not confirmed by USS.
Wald 1991	No Down's pregnancies in study.
Wald 1992a	Less than 80% had gestational age confirmed by ultrasound.
Wald 1992b	No Down's pregnancies in study.
Wald 1992c	No Down's pregnancies in study.
Wald 1993	Fewer than 80% had gestational age estimated by USS
Wald 1994a	No Down's syndrome pregnancies in population.
Wald 1994b	Review article.
Wald 1996a	No Down's pregnancies.
Wald 1996b	Fewer than 80% had gestational age estimated by USS
Wald 1996d	No Down's syndrome pregnancies in population.
Wald 1996e	Gestational age greater than 24 weeks.
Wald 1997	Data modelled on 3 separate populations of women.
Wald 1998	Unable to extract useful data.
Wald 1999a	Unable to extract useful data.
Wald 1999b	Gestational age not confirmed by USS.
Wald 1999c	No Down's syndrome pregnancies.
Wald 1999d	Modelled on several studies, some of which have no USS dating
Wald 2003b	No cases.
Wald 2003c	Less than 80% had gestational age confirmed by USS.
Wald 2006	Modelled on SURRUS data.
Wallace 1994	Unable to extract useful data.
Wallace 1997	No Down's syndrome pregnancies in study population.

(*Continued*)

Ward 2005	Review article.
Watt 1996a	No Downs syndrome pregnancies in study population.
Watt 1996b	No Down's syndrome pregnancies in study population.
Weinans 2001	Unable to extract useful data.
Weinans 2004	Study of women's views on screening.
Welborn 1994	Abnormal results only (cystic hygroma).
Wenstrom 1993	Less than 80% of pregnancies had gestational age confirmed by USS
Wenstrom 1995a	Adjustment factors.
Wenstrom 1995b	Less than 80% of pregnancies had gestational age confirmed by USS
Whitlow 1998a	Unable to extract useful data.
Whitlow 1998b	Unable to extract useful data.
Whitlow 1999	Unable to extract useful data.
Williamson 1994	Fewer than 80% had gestational age estimated by USS.
Wilson 2000	Review.
Wojdemann 2001	No Down's syndrome pregnancies in study population.
Wong 2003	Less than 5 Down's syndrome pregnancies in population.
Wright 2006	Mathematical model.
Yagel 1998	Second trimester USS.
Yamamoto 2001a	Unable to extract useful data.
Yamamoto 2001b	Method of determination of gestational age unclear.
Yamamoto 2001c	Unable to extract useful data.
Yaron 2001	Male versus female fetuses.
Ye 1995	Unable to obtain translation.
Yoshida 2000	Fewer than 80% pregnancies had gestational age estimated by USS

(*Continued*)

Zeitune 1991	Only aneuploid pregnancies included in study.
Zelop 2005	No Down's cases in population.
Zhao 1998	Unable to obtain translation.
Zoppi 2003	Inappropriate study design.

DATA

Presented below are all the data for all of the tests entered into the review.

Tests. Data tables by test

Test	No. of studies	No. of participants
1 Betacore, 1st trimester urine test, 5% FPR	1	516
2 Betacore, 2nd trimester urine test, 5% FPR	6	9613
3 Betacore, 2nd trimester urine test, cutpoint mixed	7	10124
4 Gonadotropin, 2nd trimester urine test, risk 1:100	1	105
5 Gonadotropin, 2nd trimester urine test, risk 1:384	1	105
6 Gonadotropin, 2nd trimester urine test, 95% percentile	1	105
7 ITA, 1st trimester urine test, 5% FPR	2	579
8 ITA, 2nd trimester urine test, 3.74MoM	1	2051
9 ITA, 2nd trimester urine test, 5% FPR	3	2748
10 Total hCG, 1st trimester urine test, 5% FPR	1	516
11 Total hCG, 2nd trimester urine test, 5% FPR	1	390
12 Free ßhCG, 1st trimester urine test, 5% FPR	1	516
13 Free ßhCG, 2nd trimester urine test, 5% FPR	3	1517
14 Oestriol, 2nd trimester urine test, 5% FPR	2	1472
15 Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR	2	1649
16 Betacore and oestriol, 2nd trimester 5% FPR	1	315
17 AFP and ITA, 2nd trimester urine test, 3% FPR	1	524
18 AFP and ITA, 2nd trimester urine test, 5% FPR	1	524
19 AFP and ITA, 2nd trimester urine test,10% FPR	1	524
20 AFP and ITA, 2nd trimester urine test, 15% FPR	1	524

21 AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR	1	524
22 AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR	1	524
23 AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR	1	524
24 AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR	1	524
25 Age, betacore, 2nd trimester urine test, 1% FPR	2	2083
26 Age, betacore, 2nd trimester urine test, 3% FPR	2	2083
27 Age, betacore, 2nd trimester urine test, 5% FPR	5	3419
28 Age, betacore, 2nd trimester urine test, 10% FPR	1	926
29 Age, betacore, 2nd trimester urine test, 15% FPR	1	953
30 Age, betacore, 2nd trimester urine test, 20% FPR	1	926
31 Age, ITA, 2nd trimester urine test, 5% FPR	1	1016
32 Age, oestriol, 2nd trimester urine test, 5% FPR	1	474
33 Age, free ßhCG, 2nd trimester urine test, 5% FPR	2	879
34 Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR	1	1157
35 Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR	1	1157
36 Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR	3	2088
37 Age, free ßhCG to oestriol ratio, 2nd trimester urine test, 5% FPR	1	474
38 Age, oestriol and free ßhCG, 2nd trimester, 5% FPR	1	474
39 Age, betacore to free ßhCG ratio, 2nd trimester, 5% FPR	1	474
40 Age, betacore and oestriol, 2nd trimester 1% FPR	1	1157
41 Age, betacore and oestriol, 2nd trimester, 3% FPR	1	1157
42 Age, betacore and oestriol, 2nd trimester, 5% FPR	2	1631
43 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10	1	356

44 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20	1	356
45 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30	1	356
46 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58	1	356
47 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270	1	356
48 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526	1	356

Test 1. Betacore, 1st trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 1 Betacore, 1st trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Wald 2003	9	22	77	408	0.10 [0.05, 0.19]	0.95 [0.92, 0.97]		



Test 2. Betacore, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 2 Betacore, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1999b	15	54	8	1080	0.65 [0.43, 0.84]	0.95 [0.94, 0.96]
Cuckle 1995b	19	15	5	276	0.79 [0.58, 0.93]	0.95 [0.92, 0.97]
Cuckle 1999a	9	329	30	6256	0.23 [0.11, 0.39]	0.95 [0.94, 0.96]
Isozaki 1997	8	35	5	674	0.62 [0.32, 0.86]	0.95 [0.93, 0.97]
Spencer 1996	6	19	23	357	0.21 [0.08, 0.40]	0.95 [0.92, 0.97]
Wald 2003	9	16	56	309	0.14 [0.07, 0.25]	0.95 [0.92, 0.97]



Test 3. Betacore, 2nd trimester urine test, cutpoint mixed.

Review: Urine tests for Down's syndrome screening

Test: 3 Betacore, 2nd trimester urine test, cutpoint mixed

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1998	11	16	7	477	0.61 [0.36, 0.83]	0.97 [0.95, 0.98]
Cole 1999b	15	54	8	1080	0.65 [0.43, 0.84]	0.95 [0.94, 0.96]
Cuckle 1995b	19	15	5	276	0.79 [0.58, 0.93]	0.95 [0.92, 0.97]
Cuckle 1999a	9	329	30	6256	0.23 [0.11, 0.39]	0.95 [0.94, 0.96]
Isozaki 1997	8	35	5	674	0.62 [0.32, 0.86]	0.95 [0.93, 0.97]
Spencer 1996	6	19	23	357	0.21 [0.08, 0.40]	0.95 [0.92, 0.97]
Wald 2003	9	16	56	309	0.14 [0.07, 0.25]	0.95 [0.92, 0.97]



Test 4. Gonadotropin, 2nd trimester urine test, risk 1:100.

Review: Urine tests for Down's syndrome screening

Test: 4 Gonadotropin, 2nd trimester urine test, risk 1:100

Study	TP	FP	FN	TN	Sensitivity	Specificity
Canick 1995	11	2	3	89	0.79 [0.49, 0.95]	0.98 [0.92, 1.00]



Test 5. Gonadotropin, 2nd trimester urine test, risk 1:384.

Review: Urine tests for Down's syndrome screening

Test: 5 Gonadotropin, 2nd trimester urine test, risk 1:384

Study	TP	FP	FN	TN	Sensitivity	Specificity
Canick 1995	13	5	1	86	0.93 [0.66, 1.00]	0.95 [0.88, 0.98]



Test 6. Gonadotropin, 2nd trimester urine test, 95% percentile.

Review: Urine tests for Down's syndrome screening

Test: 6 Gonadotropin, 2nd trimester urine test, 95% percentile

Study	TP	FP	FN	TN	Sensitivity	Specificity
Canick 1995	12	5	2	86	0.86 [0.57, 0.98]	0.95 [0.88, 0.98]



Test 7. ITA, 1st trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 7 ITA, 1st trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Wald 2003	5	22	81	408	0.06 [0.02, 0.13]	0.95 [0.92, 0.97]
Weinans 2000	3	3	5	52	0.38 [0.09, 0.76]	0.95 [0.85, 0.99]



Test 8. ITA, 2nd trimester urine test, 3.74MoM.

Review: Urine tests for Down's syndrome screening

Test: 8 ITA, 2nd trimester urine test, 3.74MoM

Study	TP	FP	FN	TN	Sensitivity	Specificity
Palomaki 2004a	15	101	13	1922	0.54 [0.34, 0.72]	0.95 [0.94, 0.96]



Test 9. ITA, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 9 ITA, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cuckle 1999	17	13	21	256	0.45 [0.29, 0.62]	0.95 [0.92, 0.97]
Palomaki 2004a	13	49	15	1974	0.46 [0.28, 0.66]	0.98 [0.97, 0.98]
Wald 2003	26	16	39	309	0.40 [0.28, 0.53]	0.95 [0.92, 0.97]



Test 10. Total hCG, 1st trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 10 Total hCG, 1st trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Wald 2003	15	22	71	408	0.17 [0.10, 0.27]	0.95 [0.92, 0.97]



Test 11. Total hCG, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 11 Total hCG, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Wald 2003	20	16	45	309	0.31 [0.20, 0.43]	0.95 [0.92, 0.97]



Test 12. Free ßhCG, 1st trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 12 Free hCG, 1st trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Wald 2003	4	22	82	408	0.05 [0.01, 0.11]	0.95 [0.92, 0.97]



Test 13. Free ßhCG, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 13 Free hCG, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1997a	7	35	6	674	0.54 [0.25, 0.81]	0.95 [0.93, 0.97]
Spencer 1996	12	19	17	357	0.41 [0.24, 0.61]	0.95 [0.92, 0.97]
Wald 2003	8	16	57	309	0.12 [0.05, 0.23]	0.95 [0.92, 0.97]



Test 14. Oestriol, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 14 Oestriol, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1999b	3	54	20	1080	0.13 [0.03, 0.34]	0.95 [0.94, 0.96]
Cuckle 1995b	8	15	16	276	0.33 [0.16, 0.55]	0.95 [0.92, 0.97]



Test 15. Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 15 Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1997b	9	24	3	456	0.75 [0.43, 0.95]	0.95 [0.93, 0.97]
Cole 1999b	17	54	6	1080	0.74 [0.52, 0.90]	0.95 [0.94, 0.96]



Test 16. Betacore and oestriol, 2nd trimester 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 16 Betacore and oestriol, 2nd trimester 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cuckle 1995b	20	15	4	276	0.83 [0.63, 0.95]	0.95 [0.92, 0.97]



Test 17. AFP and ITA, 2nd trimester urine test, 3% FPR.

Review: Urine tests for Down's syndrome screening

Test: 17 AFP and ITA, 2nd trimester urine test, 3% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	16	15	8	485	0.67 [0.45, 0.84]	0.97 [0.95, 0.98]



Test 18. AFP and ITA, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 18 AFP and ITA, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	19	25	5	475	0.79 [0.58, 0.93]	0.95 [0.93, 0.97]



Test 19. AFP and ITA, 2nd trimester urine test,10% FPR.

Review: Urine tests for Down's syndrome screening

Test: 19 AFP and ITA, 2nd trimester urine test,10% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	21	50	3	450	0.88 [0.68, 0.97]	0.90 [0.87, 0.92]



Test 20. AFP and ITA, 2nd trimester urine test, 15% FPR.

Review: Urine tests for Down's syndrome screening

Test: 20 AFP and ITA, 2nd trimester urine test, 15% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	22	75	2	425	0.92 [0.73, 0.99]	0.85 [0.82, 0.88]



Test 21. AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR.

Review: Urine tests for Down's syndrome screening

Test: 21 AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	18	15	6	485	0.75 [0.53, 0.90]	0.97 [0.95, 0.98]



Test 22. AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 22 AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	19	25	5	475	0.79 [0.58, 0.93]	0.95 [0.93, 0.97]



Test 23. AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR.

Review: Urine tests for Down's syndrome screening

Test: 23 AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	22	50	2	450	0.92 [0.73, 0.99]	0.90 [0.87, 0.92]



Test 24. AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR.

Review: Urine tests for Down's syndrome screening

Test: 24 AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000a	22	75	2	425	0.92 [0.73, 0.99]	0.85 [0.82, 0.88]



Test 25. Age, betacore, 2nd trimester urine test, 1% FPR.

Review: Urine tests for Down's syndrome screening

Test: 25 Age, betacore, 2nd trimester urine test, 1% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999a	6	9	15	896	0.29 [0.11, 0.52]	0.99 [0.98, 1.00]
Cole 1999b	7	11	16	1123	0.30 [0.13, 0.53]	0.99 [0.98, 1.00]



Test 26. Age, betacore, 2nd trimester urine test, 3% FPR.

Review: Urine tests for Down's syndrome screening

Test: 26 Age, betacore, 2nd trimester urine test, 3% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999a	11	27	10	878	0.52 [0.30, 0.74]	0.97 [0.96, 0.98]
Cole 1999b	11	34	12	1100	0.48 [0.27, 0.69]	0.97 [0.96, 0.98]



Test 27. Age, betacore, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 27 Age, betacore, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999	10	22	3	422	0.77 [0.46, 0.95]	0.95 [0.93, 0.97]
Bahado-Singh 1999a	13	30	8	875	0.62 [0.38, 0.82]	0.97 [0.95, 0.98]
Cole 1999b	15	54	8	1080	0.65 [0.43, 0.84]	0.95 [0.94, 0.96]
Hsu 1999	34	20	35	385	0.49 [0.37, 0.62]	0.95 [0.92, 0.97]
Spencer 1996	12	19	17	357	0.41 [0.24, 0.61]	0.95 [0.92, 0.97]



Test 28. Age, betacore, 2nd trimester urine test, 10% FPR.

Review: Urine tests for Down's syndrome screening

Test: 28 Age, betacore, 2nd trimester urine test, 10% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999a	16	91	5	814	0.76 [0.53, 0.92]	0.90 [0.88, 0.92]



Test 29. Age, betacore, 2nd trimester urine test, 15% FPR.

Review: Urine tests for Down's syndrome screening

Test: 29 Age, betacore, 2nd trimester urine test, 15% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999a	16	136	5	796	0.76 [0.53, 0.92]	0.85 [0.83, 0.88]



Test 30. Age, betacore, 2nd trimester urine test, 20% FPR.

Review: Urine tests for Down's syndrome screening

Test: 30 Age, betacore, 2nd trimester urine test, 20% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999a	18	181	3	724	0.86 [0.64, 0.97]	0.80 [0.77, 0.83]



Test 31. Age, ITA, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 31 Age, ITA, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 2000	16	50	7	943	0.70 [0.47, 0.87]	0.95 [0.93, 0.96]



Test 32. Age, oestriol, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 32 Age, oestriol, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Hsu 1999	34	20	35	385	0.49 [0.37, 0.62]	0.95 [0.92, 0.97]



Test 33. Age, free ßhCG, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 33 Age, free hCG, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Hsu 1999	39	20	30	385	0.57 [0.44, 0.68]	0.95 [0.92, 0.97]
Spencer 1996	17	19	12	357	0.59 [0.39, 0.76]	0.95 [0.92, 0.97]



Test 34. Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR.

Review: Urine tests for Down's syndrome screening

Test: 34 Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1999b	5	11	18	1123	0.22 [0.07, 0.44]	0.99 [0.98, 1.00]



Test 35. Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR.

Review: Urine tests for Down's syndrome screening

Test: 35 Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1999b	13	34	10	1100	0.57 [0.34, 0.77]	0.97 [0.96, 0.98]



Test 36. Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 36 Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Bahado-Singh 1999	11	22	2	422	0.85 [0.55, 0.98]	0.95 [0.93, 0.97]
Cole 1999b	18	54	5	1080	0.78 [0.56, 0.93]	0.95 [0.94, 0.96]
Hsu 1999	40	20	29	385	0.58 [0.45, 0.70]	0.95 [0.92, 0.97]



Test 37. Age, free ßhCG to oestriol ratio, 2nd trimester urine test, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 37 Age, free hCG to oestriol ratio, 2nd trimester urine test, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Hsu 1999	44	20	25	385	0.64 [0.51, 0.75]	0.95 [0.92, 0.97]



Test 38. Age, oestriol and free ßhCG, 2nd trimester, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 38 Age, oestriol and free hCG, 2nd trimester, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Hsu 1999	47	20	22	385	0.68 [0.56, 0.79]	0.95 [0.92, 0.97]		

Test 39. Age, betacore to free ßhCG ratio, 2nd trimester, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 39 Age, betacore to free hCG ratio, 2nd trimester, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Hsu 1999	46	20	23	385	0.67 [0.54, 0.78]	0.95 [0.92, 0.97]		

Test 40. Age, betacore and oestriol, 2nd trimester 1% FPR.

Review: Urine tests for Down's syndrome screening

Test: 40 Age, betacore and oestriol, 2nd trimester 1% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Cole 1999b	9	11	14	1123	0.39 [0.20, 0.61]	0.99 [0.98, 1.00]		

Test 41. Age, betacore and oestriol, 2nd trimester, 3% FPR.

Review: Urine tests for Down's syndrome screening

Test: 41 Age, betacore and oestriol, 2nd trimester, 3% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1999b	17	34	6	1100	0.74 [0.52, 0.90]	0.97 [0.96, 0.98]



Test 42. Age, betacore and oestriol, 2nd trimester, 5% FPR.

Review: Urine tests for Down's syndrome screening

Test: 42 Age, betacore and oestriol, 2nd trimester, 5% FPR

Study	TP	FP	FN	TN	Sensitivity	Specificity
Cole 1999b	19	54	4	1080	0.83 [0.61, 0.95]	0.95 [0.94, 0.96]
Hsu 1999	47	20	22	385	0.68 [0.56, 0.79]	0.95 [0.92, 0.97]



Test 43. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10.

Review: Urine tests for Down's syndrome screening

Test: 43 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Bahado-Singh 1998b	4	4	6	342	0.40 [0.12, 0.74]	0.99 [0.97, 1.00]		



Test 44. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20.

Review: Urine tests for Down's syndrome screening

Test: 44 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Bahado-Singh 1998b	5	6	5	340	0.50 [0.19, 0.81]	0.98 [0.96, 0.99]		



Test 45. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30.

Review: Urine tests for Down's syndrome screening

Test: 45 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Bahado-Singh 1998b	8	11	2	335	0.80 [0.44, 0.97]	0.97 [0.94, 0.98]		



Test 46. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58.

Review: Urine tests for Down's syndrome screening

Test: 46 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Bahado-Singh 1998b	9	16	1	330	0.90 [0.55, 1.00]	0.95 [0.93, 0.97]		



Test 47. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270.

Review: Urine tests for Down's syndrome screening

Test: 47 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270

Study	TP	FP	FN	TN	Sensitivity	Specificity	Sensitivity	Specificity
Bahado-Singh 1998b	9	63	1	283	0.90 [0.55, 1.00]	0.82 [0.77, 0.86]		



Test 48. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526.

Review: Urine tests for Down's syndrome screening

Test: 48 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526



ADDITIONAL TABLES

Table 1. Direct comparisons of the diagnostic accuracy of five urine tests in combination with maternal age

Ratio of DORs (95% CI); P values (studies)	Second trimester AFP and ß-core fragment to oestriol ratio, risk 1:58	Second trimester ß-core fragment and oestriol, 5% FPR	Second trimester ITA, 5% FPR	Second trimester ß-core fragment to oestriol ratio, 5% FPR
Second trimester ß-core fragment and oestriol, 5% FPR	-			
Second trimester ITA, 5% FPR	-	-		
Second trimester ß-core fragment to oestriol ratio, 5% FPR	-	1.5 (0.7 to 3.0); P = 0.27 (*K* = 2)		
Second trimester ß-core fragment, 5% FPR	-	2.2 (1.1 to 4.5); P = 0.02 (*K* = 2)	-	1.5 (0.8 to 2.8); P = 0.21 (*K* = 3)

Direct comparisons were made using only data from studies that compared each pair of tests in the same population. Ratio of diagnostic odds ratios (DOR)s were computed by division of the DOR for the test in the column by the DOR for the test in the row. If the ratio of DORs is greater than one, then the diagnostic accuracy of the test in the column is higher than that of the test in the row; if the ratio is less than one, the diagnostic accuracy of the test in the row is higher than that of the test in the column.

AFP: alpha-fetoprotein; **CI:** confidence interval; **DORs:** diagnostic odds ratio; **FPR:** false positive rate; **ITA:** invasive trophoblast antigen

Table 2. Indirect comparisons of the diagnostic accuracy of five urine tests in combination with maternal age

Ratio of DOR (95% CI) ; P value			Second trimester AFP and ß-core fragment to oestriol ratio, risk 1:58	Second trimester ß-core fragment and oestriol, 5% FPR	Second trimester ITA, 5% FPR	Second trimester ß-core fragment to oestriol ratio, 5% FPR
		Studies	1	2	1	3
	Studies	**DOR (95% CI)**	186 (22, 1560)	50 (30 to 84)	43 (17 to 110)	38 (24 to 59)
Second trimester ß-core fragment and oestriol, 5% FPR	2	50 (30 to 84)	3.7 (0.4 to 33.0); P = 0.24			
Second trimester ITA, 5% FPR	1	43 (17 to 110)	4.3 (0.4 to 44.0); P = 0.22	1.2 (0.4 to 3.4); P = 0.78		
Second trimester ß-core fragment to oestriol ratio, 5% FPR	3	38 (24 to 59)	4.9 (0.6 to 43.4); P = 0.15	1.3 (0.7 to 2.6); P = 0.41	1.1 (0.4 to 3.2); P = 0.80	
Second trimester ß-core fragment, 5% FPR	5	25 (18 to 36)	7.3 (0.8 to 63.1); P = 0.07	2.0 (1.1 to 3.7); P = 0.03	1.7 (0.6 to 4.6); P = 0.30	1.5 (0.8 to 2.6); P = 0.18

Indirect comparisons were made using all available data. Ratio of diagnostic odds ratios (DOR)s were computed by division of the DOR for the test in the column by the DOR for the test in the row. If the ratio of DORs is greater than one, then the diagnostic accuracy of the test in the column is higher than that of the test in the row; if the ratio is less than one, the diagnostic accuracy of the test in the row is higher than that of the test in the column.

AFP: alpha-fetoprotein; **CI:** confidence interval; **DORs:** diagnostic odds ratio; **FPR:** false positive rate; **ITA:** invasive trophoblast antigen

APPENDICES

Appendix 1. Search strategy

Database: Ovid MEDLINE

---

1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 specific$.mp.
38 diagnos$.ti,ab.
39 "reproducibility of results".mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.

48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
****
EMBASE via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER OR MARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
40. REFERENCE ADJ VALUE$

41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ '21'
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCY OR PREGNANT OR TRIMESTER$ OR MATERNAL OR FETUS OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 Or 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
****

CINAHL via OVID

---

1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 "area under curve".mp.
31 exp false negative reactions/ or exp false positive reactions/
32 (false positive$ or false negative$).mp.

33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 specific$.mp.
36 diagnos$.ti,ab.
37 "reproducibility of results".mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
****

Search terms and instructions for Biosis

The following search terms were entered separately in standard search box (select 'Titles/subject/abstract' from the drop-down box on the right of the search box).

1. "reference standard*"
2. "reference value*"
3. "reproducibility of results"
4. diagnos*
5. sensitiv*
6. specific*
7. "likelihood ratio*"
8. "false negative*
9. "false positive"
10. "area under curve"
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. "ductus venosus"
19. "nasal bone"
20. "tricuspid regurgitation"
21. "chorion* vill* sampling"
22. amniocentesis
23. ultrasound
24. inhibin*
25. "unconjugaed oestriol"
26. "unconjugated estriol"
27. afp
28. "alpha fetoprotein*"
29. alphafetoprotein*
30. " bhcg"
31. "human chorionic gonadotrophin"
32. "papp a"

33. "pregnancy associated plasma protein"
34. "nuchal translucency"
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. "trisomy 21"
44. mosaicism
45. "down* syndrome"

The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: "trisomy 21") or (al: (mosaicism))) or (al: "down* syndrome"))) and ((((((((((((((((((((((((((((((((al: "reference standard*") or (al: "reference value*")) or (al: "reproducibility of results")) or (al: (diagnos*))) or (al: (specific*))) or (al: (sensitiv*))) or (al: "likelihood ratio*")) or (al: "false negative*")) or (al: "false positive*")) or (al: "area under curve")) or (al: (auc))) or (al: (roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: "ductus venosus")) or (al: "tricuspid regurgitation")) or (al: "nasal bone")) or (al: "chorion* vill* sampling")) or (al: (amniocentesis))) or (al: (ultrasound))) or (al: (inhibin*))) or (al: "unconjugated oestriol")) or (al: "unconjugated estriol")) or (al: (afp))) or (al: "alpha feto protein*")) or (al: "alpha fetoprotein*")) or (al: "b hcg")) or (al: "human chorionic gonadotropin")) or (al: "papp a")) or (al: "pregnancy associated plasma protein")) or (al: "nuchal translucency")))) and ((((((((((al: (foetal)) or (al: (fetal))) or (al: (foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))

CONTRIBUTIONS OF AUTHORS

KA undertook the searches, applied eligibility criteria, extracted and entered data and wrote the first and second draft of the review.

ZA applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the final draft of the review.

JD supervised and planned the review, checked data extraction, supervised statistical analyses and wrote the second draft of the review.

JP applied eligibility criteria, provided senior clinical input, oversaw the review process, and approved the final draft of the review.

BG checked data extraction and undertook statistical analyses.

MP applied eligibility criteria, extracted and entered data for the updated literature search, and entered characteristics of studies information.

SW applied eligibility criteria, extracted and entered data for the updated literature search, and entered characteristics of studies information

YT undertook statistical analyses and wrote parts of the first draft of the review.

DECLARATIONS OF INTEREST

S Kate Alldred: none known

Zarko Alfirevic: none known

Jonathan J Deeks: none known

James P Neilson: none known

Boliang Guo: none known

Mary Pennant: none known

Susanna Wisniewski: none known

Yemisi Takwoingi: none known

SOURCES OF SUPPORT

Internal sources

- University of Birmingham, Other.

Funding of research time for BG, MP, SW, YT and JD

External sources

- NIHR Health Technology Assessment Programme, UK, Other.

Project grant

- NIHR Health Technology Assessment Programme, UK, Other.

Funding for the Cochrane Reviews of Diagnostic Test Accuracy Support Unit, based at the University of Birmingham (JD).

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies. Where such information was found, it was difficult to extract meaningful data to allow for comparison between studies because data were not reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects of tests; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in a karyotypically normal pregnancy and following confirmation of Down's syndrome or following detection of other chromosomal abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.

The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high. We excluded studies that identified fewer than five Down's syndrome pregnancies in their study population. We excluded studies that had less than 80% follow- up of participants.

In addition, the analytical strategy was informed by the volume of tests and studies included, so that we focused on key tests and test combinations by a) only meta-analysing tests that were included in four or more studies, or b) showed more than 70% sensitivity with at least a 95% specificity. In addition, a requirement that a minimum of 10 studies for a single test was required before subgroup analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.

NOTES

This review belongs to a suite of planned systematic diagnostic test reviews examining antenatal screening for Down's syndrome which include four other titles: *First trimester serum tests for Down's syndrome screening*; *Second trimester serum tests for Down's syndrome screening* (Alldred 2012); *First trimester serum and ultrasound tests for Down's syndrome screening*; and *First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening*. The plans for these reviews were described in a generic protocol (Alldred 2010) published in the Cochrane Library in 2010. The project as a whole has been much larger than initially anticipated, both in terms of size and statistical complexity. The initial search was completed in 2007 and an updated search in August 2011. After identifying studies appropriate for inclusion, a significant amount of time has been devoted to data management and analysis.

The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new urine tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to tests included in this review. Whilst not fulfilling the usual Cochrane up-to-date criteria, this review is published because it provides historical context in what is a rapidly-changing field, and because it is unlikely to ever be repeated.